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CHAPTER 1: INTRODUCTION
CHAPTER 1: INTRODUCTION
The motoneuron
In vertebrates, the term motoneuron (motor neuron) classically applies to neurons located in the 
central nervous system (CNS) which project their axons outside the CNS and directly or indirectly 
control  muscles.  Motoneurons  can  be  divided  into  somatic  motoneurons  and  visceral 
motoneurons.
Alpha motoneurons  innervate  extrafusal  muscle  fibers  (typically  referred  to  simply  as  muscle 
fibers) located throughout the muscle. They posses large-caliber, heavily myelinated axons that 
conduct action potentials rapidly. Gamma motoneurons innervate intrafusal muscle fibers found 
within the muscle spindle and posses slender, lightly myelinated axons that conduct less rapidly.
In addition to voluntary skeletal muscle contraction, alpha motoneurons also contribute to muscle 
tone,  the  continuous  force  generated  by  noncontracting  muscle  to  oppose  stretching.  When a 
muscle is stretched, sensory neurons within the muscle spindle detect the degree of stretch and 
send a signal to the CNS. The CNS activates alpha motoneurons in the spinal cord which cause 
extrafusal muscle fibers to contract and thereby resist further stretching. This process is also called 
the stretch reflex. Gamma motoneurons regulate the sensitivity of the spindle to muscle stretching. 
With activation of gamma neurons, intrafusal muscle fibers contract so that only a small stretch is 
required to activate spindle sensory neurons and the stretch reflex.
Lower  motoneurons  are  located  in  the  ventral  horns  in  the  spinal  cord  whereas  upper 
motoneurons are located in the motor cortex in the brain (Fig.1 and 2). Usually upper motoneurons 
synapse lower motoneurons in the spinal cord and then lower motoneurons contact voluntary 
muscles at the neuromuscuar junction.
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Fig 1. Motoneuron organization in the central nervous system
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The neuromuscular junction
A neuromuscular junction (NMJ) is the synapse or junction of the axon terminal of a motoneuron 
with  the  motor  end  plate,  the  highly-excitable  region  of  muscle  fiber plasma  membrane 
responsible for initiation of  action potentials across the muscle's surface, ultimately causing the 
muscle  to  contract  (Fig.  3).  The  signal  passes  through  the  neuromusclar  junction  via  the 
neurotransmitter acetylcholine. 
Upon the arrival of an action potential at the axon terminal, voltage dependent calcium channels 
open and Ca2+ ions flow from the extracellular fluid into the motor neuron's cytosol. This triggers 
excitation-contraction  coupling,  a  biochemical  cascade  that  causes  neurotransmitter-containing 
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Fig 2. Spinal cord anatomy and organization
Fig 3. Schematic representation of the neuromuscular junction: 1.Presynaptic terminal. 2.Sarcolemma. 
3.Synaptic vescicles. 4.Nicotinic acetylcholine receptor. 5.Mitochondrion 
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vesicles to fuse to the motor neuron's cell membrane and release acetylcholine into the  synaptic 
cleft. Acetylcholine crosses the synaptic cleft and binds to the nicotinic acetylcholine receptors that 
dot  the  motor  end  plate.  The  receptors  are  ligand-gated  ion  channels,  and  when  bound  by 
acetylcholine, they open, allowing sodium and potassium ions to flow in and out of the muscle's 
cytosol,  respectively.  Because of  the differences  in electrochemical  gradients  across  the plasma 
membrane, more sodium moves in than potassium out, producing a local depolarization of the 
motor end plate known as an end plate potential (EPP). This depolarization spreads across the 
surface  of  the  muscle  fiber  into  transverse  tubules  eliciting  the  release  of  calcium  from  the 
sarcoplasmic  reticulum,  thus  initiating  muscle  contraction.   The  action  of  acetylcholine  is 
terminated when the enzyme acetylcholinesterase degrades the neurotransmitter.
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic Lateral Sclerosis (ALS), also known as motoneuron disease or Lou Gherigh's disease, 
is  a fatal  neurodegenerative disease  that primary affects  upper and lower motoneurons in the 
central nervous system. Interestingly, only alpha-motoneurons appear to be affected during the 
disease (Conradi et al., 1993). It was first described by the French biologist Jean-Martin Charcooth 
in 1869. The word amyotrophic is Greek in origin. A means no or negative, myo refers to muscle 
and trophic means nourishment, meaning "no-muscle-nourishment.” Lateral identifies the areas of 
the spinal cord where portions of the nerve cells that signal and control the muscles are located. As 
this area degenerates it leads to scarring or hardening (sclerosis) in the region. The degeneration of 
the  motoneurons  leads  first  to  muscle  denervation  and  eventually  to  muscle  atrophy. 
Motoneuronal degeneration is distal, that is from the synapse to the cell body, so there is a dying 
back process (Fischer et al., 2004). 
Epidemiology of ALS
Rough average world prevalence and incidence of the disease are of 4-6 and 1-2 cases per 100,000 
(Kahana et al., 1976; Murros et al., 1983; Murray et al., 1987; Traynor et al., 1999; Beghi et al., 2007) 
individuals respectively whereas the age of onset is usually after the fourth decade, but there are 
also early age onset variants. The worldwide prevalence of ALS seems to be approximately the 
same but from some statistical studies, some populations seemed to have a higher prevalence than 
others  (UK  8/100,000;  in  Italy  6/100,000;  in  Mexico  2/100,000).  It  seemed  as  if  the  Mexican 
population had some kind of resistance or protective factor against ALS  (Olivares et al.,  1972). 
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However  these  results  were  not  successfully  confirmed  in  following  studies,  suggesting  that 
probably the results were biased because of an inadequate pool of individuals studied  (Kurtzke 
1982; Otero-Siliceo et al., 1997). 
ALS incidence seems to be higher than the rest of the world in the Kii Peninsula (Japan) and the 
island of Guam in the pacific (Reed et al., 1975a, 1975b; Kurtzke et al., 1982) Some risk factors seem 
to have been identified. In the island of Guam, the Chamorro population, a native population, 
seems to develop an ALS-similar disorder (Reed et al., 1975a, 1975b; Brody et al., 1995), the ALS-
Parkinson's Disease complex (ALS-PD).  It has been found that these populations include cycad 
nuts in their diets. Steryl glycosides have been identified in cycad nut flour and they seems to exert 
an excitotoxic mechanism in culture and mice (Ly et al., 2007).
A possible association between ALS and sport has been proposed. Football players, especially in 
Italy, seem to have a higher incidence of ALS, when compared to the mean population (Belli et al., 
2005; Chio et al., 2005). It is not yet understood what could cause ALS in football players. Whether 
it is due to a genetic predisposition, environmental risk factors or substances that football players 
are administered during their sport career is not yet understood. 
Other studies have proposed exposure to lead and pesticides as risk factors (Qureshi et al., 2006, 
Kamel et al., 2005). On the other hand risk factors like cigarette smoke have given controversial 
results. In one study cigarette smoke was found to be not a risk factor for developing ALS (Fang et 
al., 2006) but in another one it was (Veldink et al. 2005a). Another proposed risk factor would be 
constant stress applied to motoneurons, that is from excessive exercise. Again, controversial results 
were obtained regarding physical activity as a risk factor. In one study, high physical activity was 
associated with an earlier age of onset (Veldink et al., 2005a) . In another study however, sport 
practice  was  not  associated  (Valenti  et  al.,  2005).  Care  should be  taken  when risk factors  are 
involved,  because  risk  factors  can  behave  differently  in  various  populations  and  the  studies 
described before were performed in different populations. 
Requierements for the diagnosis of ALS
Because  symptoms of  ALS can  be  similar  to  those  of  a  wide  variety  of  other,  more treatable 
diseases  or  disorders,  appropriate  tests  must  be  conducted to  exclude  the  possibility  of  other 
conditions. Infectious diseases such as human immunodeficiency virus (HIV) infection (Verma et 
al.,  2006;  MacGowan  et  al.,  2001),  human  T-cell  leukemia  virus  (HTLV)  (Silva  et  al.,  2005; 
Matsuzaki et al., 2000), Lyme disease (Hansel et al., 1995), syphilis (Malin et al., 1986) and tick-
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borne  encephalitis  (Müller  et  al.,  1975)  viruses  can  in  some  cases  cause  ALS-like  symptoms. 
Neurological  disorders  such  as  multiple  sclerosis,  post-polio  syndrome,  multifocal  motor 
neuropathy, and spinal muscular atrophy can also mimic certain facets of the disease and should 
be considered by physicians attempting to make a diagnosis. 
The diagnosis of Amyotrophic Lateral Sclerosis (ALS) is based on El Escorial criteria (Fig. 4)  and 
requires the presence of:
1. Evidence of  lower motor neuron (LMN) degeneration by clinical, electrophysiological or 
neuropathologic examination.
2. Evidence of upper motor neuron (UMN) degeneration by clinical examination.
3. Progressive spread of symptoms or signs within a region or to other regions, as determined 
by history or examination.
Together with the absence of:
1. Electrophysiological  and  pathological  evidence  of  other  disease  processes that  might 
explain the signs of LMN and/or UMN degeneration. 
2. Neuroimaging evidence of other disease processes that might explain the observed clinical 
and electrophysiological signs.
Recently,  through  proteomic  studies,   three  proteins  were  found  in  significantly  lower 
concentration  in  the  cerebral  spinal  fluid  of  patients  with  ALS  than  in  healthy  individuals 
5
Fig 4. From Subcommittee  on Motor Neuron Diseases of World Federation of Neurology Research Group 
on Neuromuscular Diseases, El Escorial "Clinical Limits of ALS" Workshop Contributors (1994). El Escorial 
World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis, Journal of the 
Neurological Sciences 124 : 96-107.
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(Pasinetti et al, 2006). These proteins were identified as a 13.4kDa protein (cystatin C), a 4.8kDa 
protein (a  proteolytic  fragment of  the neuroendocrine specific  protein VGF) and an additional 
7.6kDa protein that could not be identified because of low-abundance.. Evaluating the levels of 
these three proteins proved 95% accurate for diagnosing ALS. Elevated angiogenin serum levels 
(Cronin et al. 2006)  have also been linked to ALS diagnosis but they need further validation.  
Other reports show increased NOGO-A levels and decreased NOGO-C levels  in ALS diagnosed 
patients from muscle biopsies and post-mortem samples (Dupuis et al, 2002) NOGO-A is a potent 
inhibitor of neurite outgrowth in the central nervous system (Chen et al. 2000). It gives rise also to 
isoforms B , C, D and E through alternative splicing and is not normally expressed in muscle.  Why 
NOGO-A is expressed in muscle from ALS patients is not understood but it can serve as another 
diagnosis  biomarker  that  can  be  evaluated  from a  muscle  biopsy.  With  current  methods,  the 
average time from onset of symptoms to diagnosis is around 12 months. Since once the disease has 
been diagnosed, there is a life expectancy of six to twelve months, a fast diagnosis would allow 
patients to receive relief from symptoms at an earlier stage. 
About 75% of patients experience limb onset ALS. In some of these cases, symptoms initially affect 
one of the legs, and patients experience awkwardness when walking or running or they notice that 
they are tripping or stumbling more often. Other limb onset patients first see the effects of the 
disease  on  a  hand  or  arm  as  they  experience  difficulty  with  simple  tasks  requiring  manual 
dexterity such as buttoning a shirt, writing, or turning a key in a lock.  About 25% of cases are 
bulbar onset ALS. These patients first notice difficulty speaking clearly. Speech becomes garbled 
and slurred. Nasality and loss of volume are frequently the first symptoms. Difficulty swallowing, 
and loss of tongue mobility follow. Eventually total loss of speech and ability to protect the airway 
when swallowing are experienced.
Regardless of the part of the body first  affected by the disease,  muscle weakness and atrophy 
spread to other parts of the body as the disease progresses. Patients have increasing problems with 
moving,  swallowing  (dysphagia),  and  speaking  or  forming  words  (dysarthria).  Symptoms  of 
upper  motor  neuron  involvement  include  tight  and stiff  muscles  (spasticity)  and exaggerated 
reflexes  (hyperreflexia)  including  an  overactive  gag  reflex.  Symptoms  of  lower  motor  neuron 
degeneration  include  muscle  weakness  and  atrophy,  muscle  cramps,  and  fleeting  twitches  of 
muscles that can be seen under the skin (fasciculations). Around 15–45% of patients experience 
pseudobulbar effect, also known as "emotional lability", which consists of uncontrollable laughter 
or crying. 
The disease usually does not affect cognitive abilities and patients are aware of their progressive 
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loss of function and may become anxious and depressed though. A small percentage of patients go 
on  to  develop  frontotemporal  dementia  characterized  by  profound  personality  changes 
(Valdmanis  et  al.,  2007;  Yokota  et  al.,  2006).   A larger  proportion  of  patients  experience  mild 
problems with word-generation, attention, or decision-making. Cognitive function may be affected 
as  part  of  the  disease  process  or  could  be  related  to  poor  breathing  at  night  (nocturnal 
hypoventilation). Because of diaphragm and intercostal muscle atrophy, most people with ALS die 
of respiratory failure or pneumonia, not the disease itself. 
Unfortunately no cure has been developed so far.  The only drug that has been approved  for 
human use is riluzole, which seems to extend survival by two months (Bensimon et al., 1994; 1996; 
Miller et al. 2007). Patients can benefit from supportive care therapy that aims to relieve symptoms 
and increase quality  of  life.  In the end stage of  the disease,  patients  are forced to live with a 
respirator to support ventilation. 
Anatomic-pathologic-morphologic overview
From the anatomic-pathologic-morphologic point of view, protein aggregates (Bruijn et al., 1997, 
1998; Gurney et al., 1994; Watanabe et al., 2001; Wong et al., 1995), neurofibrillary tangles ((Hirano 
et al., 1984; Mendonça et al., 2005; Mizusawa et al., 1989; Rouleau et al., 1996; Sobue et al., 1990; 
Wong et  al.,  2000),  and SOD1 and/or ubiquitin immunoreactive inclusions  (Deng et  al.,  2006; 
Furukawa et al., 2006; Johnston et al., 2000; Jonsson et al., 2004, 2006; Wang et al., 2003, 2005)  have 
been reported in post-mortem samples of ALS patients and animal models (Fig. 5).
Protein aggregation is common a common feature of other neurodegenerative diseases such as 
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Fig. 5. Immunohistochemical features of 
pathology in ALS. (A) Ventral horn motor neuron 
immunoreactive to phosphorylated NF; (B) 
Neuroaxonal spheroids immunoreactive for 
neurofilament; (C) Degenerating motor neurons 
can be  identified by ubiquitin immunoreactivity, 
e ither as skeins (white  arrow) or as dense  
aggregates (black arrow); (D) Motor neurons are  
also immunoreactive  to nitrotyrosine; (E) ALS 
motor neurons demonstrate diffuse  perikaryal 
staining of α-internexin (black arrow); (F) 
Another diffuse perikaryal immunoreactivity for 
peripherin in a neuron containing an ubiquitin-
immunoreactive Lewy-like body (white arrow) 
together with intense neuroaxonal spheroid 
immunostaining (black arrow); (G) Microglial 
activation observed as lipid-laden phagocytic 
microglia in degenerating corticospinal tracts
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Alzheimer's disease (Kosik et al., 1984), Huntignton's disease (DiFiglia et al., 1997) and Kennedy's 
disease (Merry et al., 1998).The role of these protein aggregates in ALS is not understood. 
A strong gliosis is also observed in the late stage of the disease in the spinal cord of animal models 
and ALS human patients (Kushner et al., 1991; Nagy  et al., 1994; Schiffer et al., 1996;  Howland  et 
al.  2002).  This gliosis  could result  from the activation from glial cells  attempting to repair the 
damaged motoneuron sites by creating scars (Kalderon et al., 1990).
Fragmented  Golgi  apparati  have  been  reported  both  in  asymptomatic  transgenic  ALS  mice 
(Mourelatos  et al.,  1996) and ALS patients (Gonatas  et al.,  1992; Fujita et al.,  2000) as well as 
swollen and vacuolized (Fig. 6) mitochondria (Afifi et al. 1966; Xu et al., 2004). Muscle biopsies 
from transgenic animal models and human patients also reveal abnormalities such as elevated 
amyloid-precursor protein levels (Koistinen et. al, 2006). No other tissues/organs seem to develop 
any kind of abnormalities. 
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Fig. 6. Largely swollen (A, B) or 
vacuolated (C, D, E) mitochondria are 
prominent features of the anterior 
horn motor neurones (axons and 
somata) of presymptomatic G93A 
mice . Some of the vacuolar changes 
seen presymptomatically include 
dilatation of matrix and cristae (C), 
partial vacuolisation (D) and complete 
vacuolisation and disorganisation in 
the inner compartment
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Genetics of ALS
When we speak about ALS, we are actually speaking about a heterogeneous group of motoneuron 
degenerative disorders. Both sporadic and hereditary cases have been reported. Sporadic cases are 
those considered when no other family member is affected by the disease, these account for about 
90% of total cases. Hereditary cases on the other hand account for about 10% of total cases. Several 
loci have been associated to the disease from genetic studies and the causative genes for few of 
these loci have been reported:
 Disease Protein Locus Transmission References
Typical ALS
ALS1 (SOD1) cytoplasmic 
superoxide 
dismutase
21q22.1 AD/AR Rosen et al.,1993
ALS3 ? 18q21 AD Hand et. al, 2002
ALS6 ? 16q12 AD Abalkhail et al., 2003; Ruddy et 
al., 2003; Sapp et al., 2003
ALS7 ? 20p13 AD Sapp et al. 2003
ALS with dementia
ALS-FTD ? 9q21-22 AD Hosler et al. 2000; Ostojic et al. 
2003
ALS-FTDP MAPT 17q21.1 AD Clark et al., 1998; Hutton et al., 
1998
Atypical ALS
ALS8 VAPB 20q13.3 AD Nishimura et al. 2004
Progressive lower 
motoneuron disease
DCTN1 2p13 AD Puls et. al. 2003
Other MNDs sometimes 
referred as ALS
ALS2 ALSin 2q33 AR Hentati et al. 1994; Hadano et 
al. 2001; Yamanaka et al. 2006
ALS4 SETX 9q34 AD Chance et al. 1998; Chen et al. 
2004
ALS5 ? 15q15.1-
q21.1
AR Hentati et al. 1998
Mitochondrial genes
ALS-M COX1 mtDNA Maternal Comi G.P., 1998
ALS-M IARS2 mtDNA Maternal Borthwick G.M., 2006
Players in Amyotrophic Lateral Sclerosis
Cytosolic superoxide dismutase (SOD1) 
Superoxide  ions  are  normally  produced  in  the  cell  as  a  byproduct  of  metabolism  (including 
mitochondria  as  a  by-product  of  oxidative  phosphorylation).  Superoxide  ions  like  other  free 
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radicals,  if  not  scavenged,  can  damage  the  cellular  DNA,  cell  membranes  and  other  cellular 
organelles.  Cytosolic superoxide dismutase (SOD1) is an enzyme  in charge of scavenging free 
superoxide ions and transforming them into peroxide (McCord and Fridovich, 1969) through the 
following reaction:
2O2- + 2H+ -> H2O2 + O2
Peroxide is then transformed into water by catalase according to the following reaction:
2H2O2 + O2 -> 2H2O + 2O2
SOD1's biologically active form is actually a dimer  (Fig. 7) and has a catalytic core formed by a 
copper and a zinc atom. The catalytically active atom is copper, whereas the zinc atom seems to 
have a structural role. (Carrico and Deutsch, 1970; Keele et al., 1971; Richardson et al., 1972; Hartz 
and Deutsch, 1972). Disulphide bonds are crucial in keeping the dimeric structure (Keele et al., 
1971; Hartz and Deutsch, 1972; Arnesano et al., 2004). 
Fig. 7. SOD1 structure. Protein Data Bank entry 1SPD (1 copper and 1 zinc atom are outlined in each monomer)
SOD1 was shown to be the first proven cause of ALS when mutated, as described by Rosen (Rosen 
et al., 1993), through a post-mortem genetic, pathological and biochemical study on ALS patients. 
SOD1 mutations (ALS1) are responsible for 20% of all hereditary cases. Over 114 mutations in the 
human  SOD1  gene  have  been  reported  and  can  be  viewed  on  the  ALSOD  database 
(www.alsod.org). These mutations are spread all over the protein sequence including the metal 
binding  residues  (four  histidines  coordinate  the  copper  atom).  It  is  surprising  that  so  many 
mutations can be found in such a small protein, consisting of 153 aminoacids. Most mutations are 
aminoacidic substitutions while others are insertions and truncations.  Whilst most mutations are 
dominant, the D90A mutation shows to be recessive in Scandinavian populations (Robberecht et 
al., 1996). In fact in other world populations, the same D90A mutation is transmitted in a dominant 
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fashion. Therefore the environment or other factors must play a crucial role in developing the 
disease.
Recently,  it  has  been  reported  that  mutant  cytosolic  SOD1  can  also  be  secreted  with 
chromogramins in vescicles by motoneurons that can activate microglia  (Urushitani et al., 2006). 
Activated microglia could then release factors that are toxic for motoneurons.
Two other superoxide dismutases are known: a mitochondrial manganese superoxide dismutase 
(SOD2) and an extracellular superoxide dismutase (SOD3) but they have not been associated with 
ALS.
Tau and ApoE
Tau  is  a  protein  involved  in  neurofilament  assembly  and  organization  and  therefore  also 
contributes  to  cytoskeletal  stability.  Another  protein,  ApoE,  binds  and  protects  Tau  from 
hyperphosphorylation. In Alzheimer's Disease, tau might be hyperphosphorylated when bound 
by  the  ε4  polymorphism  which  seems  to  bind  tau  less  tightly  (Thaker   et  al.,  2003) 
Hyperphosphorylated tau would then form aggregates with other proteins and would no longer 
bind to neurofilaments. Neurofilaments lacking tau binding would become disorganized and form 
tangles inside the cell. It is interesting to note that in transgenic ALS models, increased ApoE  ε4 
levels have been reported which could suggest a link with ALS (Haasdijk et al., 2002) 
VAPB
Vesicle-associated membrane protein-associated protein B  is a type IV 33 kD membrane protein 
found in plasma and intracellular vesicle membranes and can associate with microtubules.  It has 
been implicated in endoplasmic reticulum to Golgi transport, while other functions in membrane 
transport have been postulated, in particular its role in axonal transport of membrane components 
(from previous evidence Skehel et al., 2000). A P56S mutation was identified in Brazilian families 
of  Portuguese  origin  (Nishimura  et  al.,  2004).  The  phenotype  is  characterised  by  slowly 
progressive lower motor neuron symptoms in all  patients,  accompanied,  in most instances,  by 
postural  tremor,  cramps  and  fasciculations,  representing  an  atypical  ALS.  One  fourth  of  the 
affected individuals in each family displayed a late-onset type of Spinal Muscular Atrophy (SMA), 
whilst a small proportion of patients developed symptoms of classic ALS (Nishimura et al., 2004)
11
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Dynactin
Motoneurons are particular cells because they can have very long axons, (up to one meter when 
we talk about lower motoneurons that contact leg muscles from the spinal cord). Therefore the 
motoneuronal cytoskeleton must be very well organized so that trophic factors can be transported 
to the cell body, vescicles can be secreted, and cellular organelles can be transported all along the 
axon, especially mitochondria. The dynein-dynactin complex is one of the most important cargo 
complexes in motoneurons and is part of the major retrograde transport motor. Mutations in the 
p150 subunit of dynactin, a component of the dynein complex, have been reported and cause a 
lower  motoneuron  disorder  (Puls  et  al.  2003).  Since  this  complex  is  only  expressed  by 
motoneurons,  in this case we can talk about pure ALS, because only motoneurons express the 
mutant protein. For all other cases, most mutant proteins that cause ALS seem to be ubiquitary or 
at least to be expressed by several cell types. 
ALSin
ALSin is  a  184kD protein associated with a  recessive form of  ALS (ALS2),  first  reported in a 
Tunisian family (Yang et al.  2001).  Linkage analyses associated this variant to the ALS2 locus. 
Bioinformatic analyses identified three domains in this protein conserved in other GEF proteins: 
RCC1-like (chromatin condensation), RhoGEF and VPS9 (protein vacuolar traffic). All these GEF 
members interact with Ras GTPases and RhoGEF has been shown to interact with the cytoskeleton. 
An  additional  domain,  a  pleckstrin-like  domain,  has  been  identified  in  ALSin.  Pleckstrin  is  a 
protein involved in signal transduction and cytoskeletal remodelling. Alsin seems to interact with 
mutant (Kanekura et al. 2004) but not wild-type SOD1 through its RhoGEF domain, which could 
suggest a link between the two types of ALS. It is therefore possible that ALSin interacts with the 
motoneuronal cytoskeleton. However,  because a transgenic mouse model that expresses ALSin 
mutations, develops a disease very similar to spinal muscular atrophy (SMA) (Yamanaka et al. 
2006), the ALSin model should rather be used to study SMA rather than ALS.
Senataxin
Senataxin  is  a  303 kDa protein  with  a  DNA/RNA helicase  domain  with  homology to  human 
RENT1 and IGHMBP2 — two genes that encode proteins involved in RNA processing (Chen et al. 
2004, 2006). Affected individuals present missense mutations and develop ALS-like symptoms.
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Mitochondrial genes
Defects in two mitochondrial genes cause motor neuron disorders with clinical features that are 
suggestive of ALS.. A 5 bp deletion in the mitochondrial gene cyclooxygenase 1 (COX1) results in 
early adult onset of corticospinal motor neuron loss (Comi  et al. 1998). By contrast, a 4272T->C 
mutation  in  mitochondrial  transfer  RNA  (isoleucine)  causes  a  late  onset,  slowly  progressive, 
predominantly lower motor neuron disease (Borthwick  et al., 2006)
More players in ALS?
Other genes seem to cause sporadic cases of the disease or could potentially be involved in ALS 
pathogenesis but no genetic association studies have reported  any  hereditary cases:
 Gene Protein Localization
NF-H neurofilament heavy chain 22q12.2
NF-L neurofilament light chain 8q21
ANG angiogenin 14q11.1
PRPH Peripherin 12q12-13
EAAT2 (GLT-1) glial glutamate transporter 11p12-13
AMPA kainic glutamate transporter 5p33
ApoE Apolipoprotein E 19q13.2
CNTF Ciliary neurotrophic factor 11q12.2
VEGF Vascular endothelial growth factor 6p12
Proteasome complex Several subunits Several chromosomes
Chaperones Several proteins Several chromosomes
SMN Survival motoneuron 14q13
NAIP Neuronal apoptosis inhibiroty protein 5q13.1
Neurofilaments, peripherin and interleukin-6
Neurofilaments are constituted of 3 different kinds of chains: heavy (NF-H), intermediate (NF-M) 
and light (NF-L). They were among the first genes suspected of causing ALS, since neurofilament 
accumulations are a common hallmark of both familial and sporadic ALS cases (Hirano et al. 1984) 
and are also present in transgenic mice that overexpress mutant SOD1 (Gurney et al., 1994; Bruijn 
et al. 1997). Transgenic mice that overexpress NF-H and NF-L subunits develop an age-dependent 
motoneuron disorder (Cote et al. 1993; Cleveland et al. 1996). Despite this evidence, exhaustive 
screening of the NF genes in patients has not found any mutation linked to the disease (Garcia et al 
2006) eventhough dominant point mutations in NF-L have been linked to Charcot-Marie-Tooth 
disease (De Jonghe et al.  2001; Jordanova et al.  2003), a milder motoneuron disorder. NF-H in-
frame insertions or deletions within the normal 44-45 KSP (lysine-serine-proline) repeats in the tail 
domain have been reported in about 1% of sporadic cases (Figlewicz et al., 1994; Tomkins et al., 
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1998; Al-Chalabi et al., 1999). 
Another  player  that  could  involve  motoneurons  in  ALS  is  peripherin.  Peripherin  is  another 
neuronal  intermediate  filament  protein.  A frameshift  mutation that  disrupts correct  peripherin 
assembly has been reported in one sporadic ALS case (Gros-Louis et al., 2004). Transgenic mice 
that overexpress peripherin develop an ALS-like phenotype such as motoneuronal degeneration, 
muscle atrophy and fibrillary tangle accumulation inside motoneurons (Beaulieu et al. 1999). A 
peripherin  neurotoxic  splice  variant  has  been  reported  in  ALS  mice  (Robertson  et  al.,  2003). 
Peripherin levels  could be increased due to the action of inflammatory cytokines such as IL-6 
(Sterneck et al., 1996; Beaulieu et al., 2002). It has been reported that IL-6 levels seem to increase 
with aging in healthy subjects (Wei et al., 1992) and mice (Ye et al., 1999). Therefore IL-6 could be 
another risk factor for ALS. It seems that mutations in neurofilament chains do not directly cause 
the disease but could be considered as risk factors that increase the chance of developing ALS. 
Angiogenin
This protein has one known function to be an intranuclear RNAse (Shapiro et al., 1986; Palmer et 
al., 1986) that can aid RNA synthesis, at least from what reported in endothelial cells (Xu et al., 
2002). Angiogenin, as its name suggests is involved angiogenesis but it is also expressed in the 
central nervous system, including motoneurons. Seven missense mutations were identified in 15 
familial ALS patients and in 11 sporadic ALS patients (Greenway et al., 2006). Most mutations are 
located in the catalytic core of the protein and one of them in the nuclear localization signal, which 
suggest  these  mutations  lead  to  a  loss-of-function,  resulting  in  ALS.  However  angiogenin 
mutations have only been found in Scottish and Irish populations but no other populations in the 
world, therefore ALS cases due to angiogenin mutations seem to be very rare and restricted to 
certain populations and thus contribute very little to hereditary cases.
CNTF
Ciliary Neurotrophic Factor is a neurotrophin that activates survival signals in neurons. Decreased 
levels of CNTF have been observed in ALS patients in cortico-spinal tract neurons (Ono et al., 
1999),  while  a  knock-out  animal  model  for  CNTF  develops  a  progressive  motoneuron 
degeneration  (Masu  et  al.,  1993).  Noteworthy,  CNTF  has  shown  to  be  neuroprotective  in 
transgenic  Huntington  Disease  models  where  polyglutammine  rich  huntingtin  aggregates 
(Emerich et al., 1997a, 1997b).
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VEGF
Vascular Endothelial Growth Factor is a 41kD growth factor which for a long time was believed to 
be involved strictly in angiogenesis but recently it has been reported that VEGF itself can act as a 
survival growth factor on several neuronal populations, including motoneurons (Oosthuyse et al., 
2001;  Van Den Bosch et al.,  2004) It  has been reported that VEGF activates a survival  cascade 
where IP3-Kinase and Akt are involved (Li et al., 2003). Interestingly, it was discovered by chance 
in a transgenic mouse model, when the hypoxia responsive element (HRE) was removed from the 
VEGF promoter, as part of a study on VEGF regulation and hypoxia, that the animals developed 
an  ALS-like  phenotype  (Oosthuyse  et  al.,  2001).  The  animals   suffered  from  motoneuronal 
degeneration, muscular atrophy and neurofibrillary tangle accumulation.  Screening of the VEGF 
gene promoter and the HRE element found no link between HRE variants and disease in humans 
(Gros-Louis et al., 2003) but two haplotypes in other regions of the promoter showed an increased 
risk of  developing ALS in some populations (Lambrechts  et  al.,  2003;   Fernández-Santiago R., 
2006).
Proteasome complex and ubiquitin
Ubiquitin is an 8kD protein that is bound to lysine residues on proteins that need to be degraded. 
The tagged proteins are then transported into the proteasome complex and they are degraded. In 
cell culture experiments, when the proteasome is inhibited, protein aggregates can be observed in 
the cells (Wyttenbach et al., 2000). Moreover, selective motoneuron death in organotypic cultures 
has been reported when the proteasome system is inhibited (Tsuji et al., 2005).  It is hypothesized 
that protein aggregates could choke the proteasome machinery contributing to the apoptotic signal 
in the cell.  Increased expression levels of the proteasome and ubiquitin have been reported in ALS 
patients when compared to controls (Mendonca et al., 2006). 
Chaperones
Heat-shock  proteins  or  chaperones  are  proteins  that  are  responsible  for  the  correct  folding of 
proteins once they have been synthesized. When chaperones act on a neo-synthesized protein, the 
protein is forced to acquire its correct 3-D conformation. In cellular models of neurodegenerative 
diseases  where  protein aggregation is  known (such as  spinal  bulbar  muscular  atrophy,  spinal 
cerebellar  ataxia,  Alexander's  disease  and Huntington's  disease),  protein aggregates  that  show 
heat-shock protein immunoreactivity have been reported (Wyttenbach et al., 2000; Der Perng et al., 
2006;  Mitsui  et  al.  2002)  suggesting that  these  proteins  either  attempt to correct  the  abnormal 
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folding of aggregated proteins or that  chaperones get  trapped and are sequestered from other 
important pathways in the cell. As it is known, some heat-shock proteins seem to posses an anti-
apoptotic function as well  (Brar et al.,  1999;  Wagstaff  et  al.,  1999).  In a transgenic ALS mouse 
model, treatment with  arimoclomol increased survival by some days. Arimoclomol induces the 
phosphorylation-mediated  activation  of  the  HSP  inducing  factor  HSF-1,  thereby  leading  to 
increased levels of Hsp70 and Hsp90 in spinal cords (Kieran et al., 2004).
SMN and NAIP
Survival  Motoneuron (SMN) is  a  34kD protein and belongs to  the  family of  Gemins,  a  set  of 
proteins  involved  in  RNA splicing.  SMN is  actually  present  as  two copies  on chromosome 5 
(SMN1, SMN2), however the only functional protein seems to be SMN1. SMN2 undergoes one 
exon skipping because of one nucleotide difference (Lorson et al., 1999; Monani et al., 1999). SMN1 
mutations are responsible for another motoneuron disease called Spinal Muscular Atrophy (SMA) 
which affects lower motoneurons at childhood (Lefebvre et al.,  1995; Rodrigues et al.,  1995). In 
another association study, SMN1 copy number has been proposed as a risk factor for sporadic ALS 
(Veldink et al., 2005; Corcia P., 2006).
Neuronal-apoptosis inhibitor protein (NAIP) is a protein that belongs to a family of antiapoptotic 
proteins. Mutations in this gene have been associated with SMA cases (Roy et al., 1995). In a study 
on an ALS transgenic mice, a modifier locus was mapped very close to the NAIP gene, suggesting 
that this gene or region could be involved in the penetrance of other causative genes of ALS (Kunst 
et al., 2000). Despite these findings, no modifier loci or genes have been found in humans, in fact, 
up to date, mutations in NAIP are considered to be SMA specific (Parboosingh et al., 1999).
Available ALS disease models
The first ALS transgenic model was developed by Gurney et al.  in 1994. This model carries 8-9 
tandem copies of the human SOD1 gene (cDNA) with a G93A mutation (haploid genome). These 
transgenic  mice  develop  a  progressive  muscular  atrophy  and  die  around  4-5  months  of  age. 
Nowadays,  several  transgenic  models  based on mutant  SOD1 have been developed including 
transgenic rats (Nagai et al., 2001) that also express mutant human SOD1 and also develop similar 
symptoms.  It is important to state that there are SOD1 models that carry a low copy number and a 
high  copy number of  the  human SOD1 gene in  tandem and that  the  number  of  gene  copies 
modifies disease onset and progression times before the animals die. 
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Mutation Transgene 
copy number 
(diploid)
Onset (days) Days before death 
(duration)
Reference
hG37R 42 120 ND Wong et al., 1995
hG85R 148 240 7-14 Brujin et al., 1997
hD90A 
heterozygous
1 130 600 Brannstrom et al., 2000
hDA90A 
homozygous
2 ND ND Brannstrom et al., 2000
hG93A 25 90 < 60 Dal Canto et al., 1997
hG93A 18 130 < 70 Gurney et al., 1994, Dal Canto 
et al., 1997
hG93A 10 290 > 110 Dal Canto et al., 1997
hG93R ND 230 10-13 Friedlander et al., 1997
hI113T ND 330 slow Kikugawa et al., 2000
mG86R 2 100 3 Ripps et al., 1995
h = human gene                m= mouse gene                ND= not documented
In  addition  to  the  transgenic  SOD1  model,  more  models  have  been  developed  to  study 
motoneuronal degeneration. 
● Wst  (wasted).  This  model  has  a  15.8kB  deletion  in  the  gene  that  codes  for  eEF1A-2 
(translation elongation factor 1A-2). The deletion removes the promoter and the first exon 
in  the  gene which block its  expression (Chambers  et  al.,  1998).   EF1A2 protein is  only 
expressed in differentiated cells from the central nervous system.  Homozygous wst-/wst- 
mice  die  about  four  weeks  after  birth  and  develop  motoneuronal  degeneration  and 
abnormal accumulation of perikaryal phosphorylated neurofilaments (NF-H) (Lutsep et al., 
1998). 
● Nmd  (neuromuscular  degeneration).  This  model  is  based  on  an  automosal  recessive 
mutation in the gene that codes for Ighmbp2 (mu 2 immunoglobulin – binding protein). 
This protein works as a transcription activator and as a DNA helicase as well (Cox et al., 
1998).  Nmd  mice  develop  a  progressive  paralysis  and  die  about  4  weeks  after  birth. 
Because this gene is ubiquitously expressed, it is not understood why only motoneurons 
are affected in this model.
● As stated earlier, deletion of the HRE from VEGF causes motoneuronal degeneration in 
mice (Oosthuyse et al., 2001), so this can also be considered as a motoneuron disease model. 
The transgenic  mouse SOD1 model  has been so far  the most  widely used.  The first  symptom 
transgenic mutant animals develop is slight twitching of the anterior limbs. Also, when mutant 
animals are held by the tail, they are not able to stretch their hindlimbs as a normal reflex when 
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compared to control littermates (Fig. 8) 
In the late phase of the disease, the hindlimbs paralyze as well as the anterior limbs (Fig.9). Death 
usually occurs by asphyxia due to diaphragm paralysis. 
Fig. 9. Phenotype of SOD1G93A mice  (A) at the end stage of the disease, compared to a non-transgenic (B) littermate. 
Notice splayed hind limbs (red arrow) and pronounced muscle wastage (white arrow) in transgenic animal. 
Transgenic SOD1 models have been further studied and manipulated in order to understand the 
mechanisms of disease in ALS. The different kind of experiments developed with murine SOD1 
models can be divided as shown below:
1. Experiments in which transgenic SOD1 mice were treated with different compounds to test 
for  disease  onset/progression  changes.  Eg:  antioxidants  (vitamin  E,  acetyl-cysteine), 
creatine, minocycline, COX2 inhibitors, caspase inhibitors, AMPA antagonists.
2. Experiments in which double transgenic mice were developed from transgenic SOD1 mice 
to test  for  the effect  of another overexpressed gene in SOD1 mice.  Eg: calcium binding 
proteins (parvalbumin), neurofilament subunits, growth factors such as HGF, bcl2, ICE D-.
3. Experiments in which gene therapy/delivery was applied to transgenic SOD1 mice to test 
for disease onset/progression changes. Eg: BDNF , GDNF (Wang et al., 2002), IGF-1 (Kaspar 
et al., 2003),  cardiotrophin-1 (Bordet et al., 2001), bcl-2 (Azzouz et al., 2000).
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Fig. 8.  Notice how the G93A animal is not able  to extend its legs when lifted by the tai (right)l. Non-transgenic and 
wild-type animals on the other hand are able  to extend their legs (left)
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Experiment SOD1 
mutation
Survival, no 
treatment 
(days)
Survival with 
treatment (days)
References
1%-2% Creatine administration G93A 143 ± 2 157 ± 3; 169 ± 5 Klivenyi et al., 1999
Ferric porphyrin administration G93A 129 ± 2 136 ± 2 Wu et al., 2003
zVAD-fmk (wide spectrum 
caspase inhibitor) 
administration
G93A 103 ± 3 124 ± 7 Li et al., 2000
NBQX (AMPA antagonist) G93A 129.9 ± 3.6 143.3 ± 2.8 Van Damme et al.., 2003
Minocyclin administration G93A 126 ± 3 139 ± 2 Zhu et al., 2002
Nimesulide administration G93A 108 ± 120 ± Pompl et al., 2003
NF-H  and NF-L overexpression G37R 285 ± 84 474 ± 195 Kong et al., 2000
HGF overexpression G93A 147 ± 2 175 ± 6 Sun et al., 2002
Parvalbumin overexpression G93A 132 ± 2 146 ±  5 Beers et al., 2001
Interleukin converting enzyme 
(dominant negative) expression
G93R 249  ± 4 270  ±  7 Friedlander et al., 1997
Bcl-2 overexpression G93A 240 ±  2 275 ±  4 Kostic et al., 1997
Understanding ALS pathogenesis
Even though SOD1 has been proved as one of the genetic caused of ALS, the disease  mechanisms 
are  still  not  well  understood.  Several  mechanisms  have been proposed to  try  to  explain  ALS 
pathogenesis: Oxidative stress,  Protein aggregation, Axonal transport disruption, Excitotoxicity, 
Mitochondrial dysfunction and Inflammatory response.
Oxidative stress
In  the  beginning,  researchers  thought  that  SOD1  mutations  led  to  disease  because  of  loss  of 
function (Deng et al., 1993). This implied that the free radical scavenging function of SOD1 was lost 
and therefore free radicals would damage the cell and lead to degeneration. Despite these first 
suspicions, it was later proved that several mutant types of SOD1 retain catalytic activity (Borchelt 
et al., 1994).  Surprisingly, a knock-out mouse model where the endogenous SOD1 gene had been 
removed, had a normal lifespan and developed normally (Reaume et al., 1996). Also, when wild-
type hSOD1 was expressed in transgenic mice that expressed mutant hSOD1 as well, the disease 
was exacerbated instead of slowed down (Jaarsma et al., 2000), suggesting that the concomitant 
presence of normal catalytic activity had no effect on disease course. At this point, it was thought 
that mutant SOD1 developed a toxic gain of function. As explained earlier, SOD1 is responsible for 
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the conversion of superoxide ions to peroxide and then peroxide is converted into water an oxygen 
by catalase.   The oxidative stress hypothesis suggests that the catalytic core in SOD1 develops an 
aberrant chemistry and could even perform the reverse chemical reaction by producing more free 
radicals  such as  peroxynitrite  (Beckman et  al.,  1993)  that  can harm the cell  (Hall  et  al.,  1998). 
Otherwise, mutant residues could bind less tightly the zinc atom and it could be lost. Since the zinc 
atom could be structurally needed for correct copper atom orientation, this could also contribute to 
abnormal catalytic activity of the copper atom.  Copper Chaperone for SOD1 (CCS) is a chaperone 
that loads copper into the catalytic core of SOD1 (Culotta et al., 1997). Subramaniam et al. (2002) 
demonstrated that CCS null transgenic mutant hSOD1 mice, which express a catalytically-inactive 
mutant enzyme (no copper is  present in the enzyme),    still  develop ALS. This suggests   that 
oxidative stress is not the main cause of ALS, since copper is responsible for the catalytic reactions 
and is not anymore loaded into SOD1. Some scientists however, proposed that copper could still 
be loaded through alternative pathways because some activity was still observed in SOD1 from 
CCS null  mice,  which  indeed cannot  be  excluded (Beckman et  al.,  2002).  But  it  could also  be 
possible that when SOD1 is extracted from mouse tissue, copper from the tissues binds to SOD1 
and therefore creates an artifact. However, transgenic mice that express QUAD hSOD1 (hSOD1 in 
which the four copper-binding histidines are mutated) and therefore express copper-free hSOD1, 
still develop ALS (Wang et al., 2003).
Nonetheless,  antioxidant  therapy with  N-acetyl-L-cysteine  (Andreassen  et  al.,  2000)  and ferric 
porphyrin (Wu et al., 2003), proved effective to slightly increase survival of affected mice but had 
no effect on disease onset at all. It is therefore suspected that oxidative stress on its own is not the 
cause of the disease but could possibly contribute at some extent.
Protein aggregation
The term aggregate in ALS has actually a dual meaning:
● It  refers  to  ubiquitin  reactive  protein  inclusions,  neurofibrillary  tangles  and  hyaline 
inclusions, as described earlier.
● It  refers  to  SOD-1  immunoreactive  detergent-insoluble  species  that  can  be  detected  by 
biochemical methods from affected tissues (Wang et al., 2002, 2003). 
As we stated before, protein aggregates have been found in both sporadic ALS and familial ALS 
cases, including SOD1 induced fALS in human patients and transgenic mice  (Bruijn et al., 1997, 
1998; Gurney et al.,  1994;  Watanabe et al.,  2001; Wong et al.,  1995;  Shibata et.al.,  1996).  These 
observations led scientists to speculate that mutant SOD1 could directly form protein aggregates in 
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the cells or trigger their formation. In fact, cell culture experiments have shown that mutant SOD1 
tends to form aggregates (Johnston et al., 2000; Wang et al., 2003; ref). Metal-free (holo) SOD1 has 
been  shown  to  form  amyloid-like  filaments  when  grown  in  crystals  (Elam  et  al.,  2003).  . 
Experiments on non-neuronal cells where the proteasome system was inhibited showed  protein 
aggregate  accumulation  inside  the  cells  (Wyttenbach  et  al.,  2000;  Turner  et  al.,  2004).  Also 
apoptosis  induction in neuronal cells  was observed after  proteasome inhibition (Rideout et.al., 
2002). In fact one of the proposed disease mechanisms is that these protein aggregates  sequester 
essential proteins for cell survival such as heat shock proteins (Watanabe et al., 2001), choke the 
proteasome  system  and/or  disrupt  the  cytoskeletal  architecture.  This  would  lead  to  incorrect 
neurofilaments assembly and fibrillary tangle formation. The latter would block axonal transport 
and trophic factor transport to the cell body and ultimately lead to cell death. To support this view, 
a presymptomatic deficit of slow axonal transport has been reported in transgenic mutant hSOD1 
mice (Williamson and Cleveland, 1999, Zhang et al., 1997).
Another set of main characters in protein aggregation are chaperones. Chaperones or heat-shock 
proteins (HSPs)  are responsible for the correct folding of proteins to render them fully functional. 
During stress  conditions,  HSPs are activated (Morandi  et  al.,  1989;  Cox et  al.,  1993)  to correct 
protein structure of unfolded proteins (Chai et al., 1999).  HSPs such as hsp25 and hsp70 have been 
proposed to interact with SOD1 and mutant SOD1 could sequester them (Okado-Matsumoto and 
Fridovich,  2002).  Since some HSPs also have an antiapoptotic  role this could contribute to the 
apoptotic cascade in the cell.
However some experiments have shown that elevated wild-type hSOD1 overexpression causes 
some motoneuronal degeneration in transgenic mice (Jaarsma et al., 2000). Still, these mice appear 
healthy all throughout their lives and no wild-type hSOD1 aggregates have been reported.  Care 
should be taken because the overexpression level of hSOD1 in transgenic animals is far higher than 
physiological levels. It could be possible that if wild-type hSOD1 was expressed at physiological 
levels, probably no pathologic signs would develop in mice. Perhaps only the mutant protein is 
able to form aggregates.  It  has been reported that  some mutant proteins (A4V) are less stable 
(Hough et al., 2004) and only form aggregates in mutant SOD1 mice when wild-type hSOD1 is 
overexpressed as well (Deng et al.,  2006). This could stabilize the mutant protein by forming a 
heterodimer.   Having said so,  other  reports  show that  the degradation of  SOD1 itself  and its 
aggregates is proteasome mediated (Basso et al., 2006; Niwa et al., 2002; Urushitani et al., 2004; 
Urushitani et al., 2002), because these SOD1 aggregates are heavily ubiquitinated and a specific 
ubiquitin ligase, dorfin, that acts on mutant but not wild-type SOD1 has been discovered (Niwa et 
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al., 2002). While proteasome malfunction has been implicated in motor neuron death, it is not yet 
established whether it  is  a cause or consequence of aggregate formation.  Contradictory results 
have been reported. In mutant hSOD1 G93A mice which accumulate mutant protein to high levels, 
proteasome activity is downregulated in the lumbar spinal cord well before the development of 
symptoms (Kabashi et al., 2004), while in a different line of mice with lower accumulated levels of 
the  same  mutant,  increased  proteasome  activity  in  the  spinal  cord  has  been  reported  at 
symptomatic stages (Puttaparthi and Elliott, 2005).  
On the other hand, in spinal cord extracts  of presymptomatic ALS mice, an overall decrease of 
chaperone  activity  has  been  reported  which  persists  throughout  disease  course,  and  multiple 
recombinant SOD1 mutants inhibit chaperone function in vitro (Bruening et al., 1999; Tummala et 
al.,  2005).  SOD1  induced  protein  aggregates  could  also  provoke  organelle  dysfunction  by 
translocating inside or blocking their functions (see mitochondrial damage below).
A proposed mechanism of protein aggregate effect is summarized in Fig. 10.
It  is  interesting to point out that protein aggregates have also been reported in astrocytes and 
oligodendrocytes  in  ALS  mouse  models  (Stieber  et  al.,  2000).  The  direct  implication  of  these 
aggregates in these two cell populations is still  not understood. After having presented all this 
evidence, a clear idea of the role of protein aggregates in ALS pathogenesis is not known. Whether 
these  aggregates  are  harmful  or  not,  cause  or  consequence  of  the  disease,  still  needs  to  be 
determined. 
Axonal transport
Another characteristic  of ALS is the reduced activity of axonal transport, described both in ALS 
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Fig. 10. Proposed protein-aggregation mechanism in ALS
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patients and ALS mice (Sasaki et al., 1996, 2005). The transport of molecules and organelles is a 
fundamental  cellular  process  that  is  particularly  important  for  the  development,  function  and 
survival of neurons. This process is dictated by the highly polarized anatomy of neurons: axonal 
proteins are synthesized in the cell body and must be transported in an anterograde manner along 
the  axons  and  dendrites  to  reach  synapses,  whereas  substances  such  as  peripherally  located 
trophic factors must be transported centrally from the synaptic regions by retrograde transport. 
The  molecular  motors  for  anterograde  and  retrograde  transport  are  kinesin  and  the  dynein–
dynactin complex, respectively (Fig. 11). Transport is conventionally regarded as either slow or 
fast.  Presumably,  functional  and efficient  axonal  transport  is  particularly  important  for  motor 
neurons, which are among the largest and longest cells in the body.
Several findings indicate that defects in axonal transport might contribute to the demise of motor 
neurons in ALS. First, both slow and fast anterograde transport are slowed in transgenic G93A-
SOD1  and  G37R  ALS  mice  prior  to  disease  onset  (Zhang  et  al.,  1997;  Borchelt  et  al.,  1998; 
Williamson et al., 1999). Second, retrograde transport is also disrupted in ALS mice (Murakami et 
al.,  2001). Third,  although the  molecular basis  for this slowing is  not fully elaborated,  several 
authors  suggest  that  aggregations  of  neurofilaments  in  the  proximal  axons  (spheroids)  might 
physically compromise the transport apparatus (Sasaki et al., 1996), at least for anterograde traffic. 
Neurofilaments  have  also  been  incriminated  as  modulators  of  axonal  transport  because  they 
regulate axonal caliber (Rao et al., 2003). Diminution of retrograde transport in ALS mice has been 
attributed to the mislocalization and disruption of dynein function (Ligon et al., 2005). 
As noted above, mutations in the p150Glued subunit of dynactin elicit an unusual form of human 
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Fig. 11. Axonal transport schematic representation in motoneurons
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lower motor neuron disease. Finally, in mice, disruption of the dynein–dynactin complex by the 
forced expression of dynamitin, a sub unit of dynactin, also produces a late onset motoneuron 
disease (LaMonte et al., 2002). Interestingly, when  specific dynein mutations were introduced in 
transgenic mice expressing G93A mutant SOD1, an amelioration was observed (Kieran et al., 2005; 
Teuchert et al., 2006). This could derive from the fact that a toxic function performed by mutant 
SOD1 needs dynein-mediated transport along microtubules either in the axon or the cell body. All 
this  observations  suggest  that  axonal  transport  disruption  is  an  important  factor  in  ALS 
pathogenesis.
Excitotoxicity
Glutamate is one of the neurotransmitters used by neurons in the central nervous system. During 
glutamatergic  neurotransmission,  glutamate  released  from  the  presynaptic  neuron  activates 
ionotropic glutamate receptors present on the postsynaptic neuron. Activation of these glutamate 
receptors results in the influx of Na+ and Ca2+ ions into the cell, leading to depolarization and 
ultimately  to  the  generation  of  an  action  potential.   Once  glutamate  has  been  released  for 
transmission,  it  is  removed from the neuronal  synapse by a glial  glutamate transporter  (GLT-
1/EAAT2) expressed on the plasma membrane of astrocytes (Fig. 12).
Excitotoxicity is the neuronal degeneration caused by over-stimulation of the glutamate receptors 
(Olney et al., 1978). At first, the NMDA receptor was considered to be uniquely responsible for 
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Fig 12. Schematic representation of glutamate re lease  and uptake at a neuronal synapse
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excitotoxicity (Choi et al., 1998). More recently, it became apparent that the activation of AMPA 
receptors is at least as important (Prehn et al., 1995). The predominant mediator of neuronal injury 
is Ca2+ influx through NMDA receptors, Ca2+-permeable AMPA receptors or voltage-gated Ca2+ 
channels (Kim et al., 1987; Carriedo et al., 1996; Van Den Bosch et al., 2000). Excessive influx of 
Ca2+ ions can result in the activation of several enzymes, such as lipases, phospholipases, caspases 
(Takadera et al., 1997), endonucleases, protein phosphatases, protein kinase C, xanthine oxidase 
and NO synthase. As it is well known, caspases induce programmed cell death or apoptosis. This 
can happen if glutamate is not removed from the synaptic cleft. 
Two types of excitotoxicity can be defined: classical and slow excitotoxicity (Doble, 1999). Classical 
excitotoxicity  refers  to  neuronal  degeneration  that  occurs  after  an increase  of  the  extracellular 
glutamate concentration, while slow excitotoxicity is the death of a weakened postsynaptic neuron 
in the presence of normal synaptic glutamate levels. Acute elevations of glutamate are thought to 
induce neuronal damage in conditions such as stroke, status epilepticus and neurotrauma. More 
chronic  and  milder  elevations  of  glutamate  are  believed  to  underly  excitotoxicity  in 
neurodegenerative diseases.
Increased CSF glutamate levels have been reported in ALS patients when compared to controls 
(Rothstein et  al.,  1990;  Plaitakis et  al.,  1988;  Shaw et al.,  1995).  In addition,  from human post-
mortem tissue and transgenic models that express mutant SOD1, decreased levels of EAAT2 have 
been reported on astrocyte membranes as the disease progresses (Fray et al., 1998; Maragakis et al., 
2004;  Rothstein  et  al.,  1995).  It  has  also  been shown that  mutant  SOD1 interacts  with  EAAT2 
transcript splicing and therefore the resulting proteins are aberrant or non-functional (Lin et al., 
1998). Moreover, AMPA GluR2 subunit editing is reduced in the spinal cord motoneurons from 
sALS patients when compared to controls (Kawahara et al.,  2004; Takuma et al.,  1999),  but no 
AMPA editing difference was observed in G93A and H46R rat models (Kawahara et al., 2006). This 
AMPA GluR2 editing is important because the editing is responsible for reducing the permeability 
of the closed/inactive channel to calcium ions. The editing process changes the codon 586 from 
CAG into CGG, changing the aminoacide from a neutral glycine into a positively-charged arginine 
residue. Under normal conditions, the editing process is very efficient. When no correct editing is 
achieved, the permeability of the closed/inactive channel to calcium ions increases.  
As stated earlier some motoneuronal populations (Haenggeli et al., 2002)  are not affected in ALS. 
It has been shown that ocular, trochlear, abducens and Onuf's nucleus motoneurons express high 
amounts of calcium binding proteins such as calbindin and parvalbumin  (Alexianu et al., 1994; 
Celio  et  al.,  1990;  Ince et  al.  1993;  Reiner et  al.,  1995)  whereas ALS vulnerable  motoneurons 
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express lower amounts of calcium binding proteins (Laslo et al.,  2000). A high level of calcium 
binding proteins could definitely function as a calcium buffering system and thus protect from 
excitotoxic effects. Following these findings, double transgenic mice were developed. Transgenic 
mutant hSOD1 mice were bred with transgenic  mice that overexpress parvalbumin,  a  calcium 
binding protein.  The findings showed that  double transgenic  animals  had a slightly increased 
survival when compared to control littermates (Beers et al., 2001). 
Riluzole, the only drug approved for ALS therapy, has been shown to block glutamate release 
(Doble  et  al.,  1996).  This  could  explain  why  some  slight  effect  on  the  disease  is  observed. 
Ceftriaxone, a B-lactam antibiotic, increases EAAT2 activity and extends survival in G93A mice 
(Rothstein et al., 2005). All these evidences suggest that excitotoxicity contributes to ALS.
Mitochondrial damage
Ultrastructural  analysis shows that mitochondria start  swelling and degenerating at very early 
stages in asymptomatic mutant animals, but only in those animals that express dismutase active 
(G37R,  G93A)  mutant  proteins  (Higgins  et  al.,  2003;  Kong  and  Xu  1998;  Wong  et  al.  1995). 
Surprisingly, also mice that express wild-type hSOD1 develop vacuolated mitochondria but do not 
develop any disease  (Jaarsma et  al.,  2000,  2001).  It  has been reported that  in both mouse and 
patient samples, mutant SOD1 was purified from mitochondria-enriched fractions but only from 
affected tissues (Bergemalm et al.,  2006;  Deng et  al.,  2006;  Liu et al.,  2004)..  This suggests  that 
somehow SOD1 is able to translocate into these organelles. In fact, it has been proved by electron 
microscopy  that  SOD1  localizes  in  both  isolated  mitochondria  (Liu  et  al.,  2004)  and  in  situ 
motoneuronal mitochondria (Higgins et al. 2002; Sasaki et al., 2007). SOD1 mutants that provoke 
disease  at  the  lowest  accumulated  leves  (G85R,  G127X)  are  those  that  show  the  highest 
mitochondrial association (Liu et al,  2004).  Another interesting observation is that endogenous 
wild-type  SOD1   has  not  been  found  as  mitochondrially  associated  and  despite  the  mutant 
proteins are mitochondrially associated in the spinal cord, they have not been found in the liver 
(Liu et al., 2004).  It is not yet understood how SOD1 affects mitochondrial function but proteome 
differences between mutant and non-mutant mitochondria have been reported (Fukada et al., 2004; 
Kirby et al., 2005; Lukas et al., 2006).  Assuming that mutant SOD1 is preferentially imported into 
or  deposited  onto  mitochondria  in  affected  tissues,  some mechanisms have been proposed to 
explain its effects (Fig. 13):
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1. Electron transport  chain:  mutant SOD1 may interfere with the elements  of  the electron 
transport chain, thereby disrupting ATP-generating oxidative phosphorylation.
2. Calcium homeostais: mutant SOD1 may also disrupt mechanisms by which mitochondria 
buffer cytosolic calcium levels. 
3. Apoptotic  machinery:  mutant  SOD1  aggregates  may  interfere  with  components  of 
mitochondrial-dependent apoptotic machinery, such as Bcl-2, thereby triggering premature 
activation of an apoptotic cascade including cytochrome c release into the cytosol.
4. Mutant SOD1 may indirectly affect similar pathways linked to mitochondria by physically 
blocking the protein import machines, TOM and TIM. 
5. Oxidative  damage  incurred  by  various  mitochondrial  proteins  may  also  contribute  to 
overall mitochondrial dysfunction. 
All together, these mechanisms (or a combination) could disturb cellular homeostasis (within glial 
and/or motor neurons), ultimately triggering motor neuron death.
Further evidence that supports mitochondrial involvement in ALS, shows transgenic mutant mice 
treated  with  creatin,  showed  an  increased  survival  when  compared  to  untreated  littermates 
(Klivenyi et al., 1999). Creatin contributes to increasing the ATP pool in the cells by donating a 
readily available phosphate group in order to regenerate ATP from ADP. In another experiment, 
transgenic mice were treated with minocyclin, a third generation tetracycline. Minocycline was 
shown to inhibit  cytochrome c release from mitochondria which also reduced caspase 3 and 7 
activation. Treated transgenic mutant mice indeed showed a prolonged survival when compared 
to untreated littermates (Zhu et al., 2002).
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Fig. 13. Proposed mechanism for mitochondrial damage induced by mutant SOD1
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Inflammatory response 
It  has  been hypothesized that  external  factors  like  pathogens  could  contribute  to  motoneuron 
degeneration. This observation comes from findings that show that enteroviral RNA sequences 
were found in ALS post-mortem tissue samples (Berger et al.,  2000).  This suggests that a viral 
infection could be a contributing factor in ALS either directly by killing motoneurons or indirectly 
by  triggering  an  immune reaction  that  leads  to  degeneration  or  autoimmunity.  However,  the 
involvement of enteroviruses in ALS has long been discussed since contradictory results have been 
obtained  in  different  reports  (Nix  et  al.,  2004;  Cermelli  et  al.,  2003).  Nonetheless,  a  viral 
contribution cannot be completely outruled since the  Sindbis virus induced motoneuron disease 
model needs to be considered as well (Darman et al., 2004).
Another interesting aspect involving the immune system in ALS pathogenesis is that several auto-
antibodies have been found in the serum and CSF of ALS patients, such as anti-L-type Ca2+ channel 
(Kimura et al., 1994) expressed by motoneurons, anti-GM1 ganglioside (Li et al., 1991 and anti-
acetylcholinesterase  (Conradi  et  al.,  1994)  as  well  as  anti-NFL  and  anti-a-actinin  antibodies 
(Niebroj-Dobosz et al., 2006). These autoantibodies by binding to L-type calcium channels could 
constitutively activate them, leading to increased calcium influx and possible excitotoxicity (Smith 
et  al.,  1994).  In  addition,  when  cultured  motoneurons  were  treated  with  CSF  from  affected 
patients, the cultured motoneurons degenerated and died (Demestre et al., 2005), therefore, some 
soluble factor in the CSF appears to be toxic to cells.
We  must  remember  that  motoneurons  are  not  located  in  an  isolated  environment.  In  fact, 
motoneurons are surrounded by other kinds of cells such as microglia, astrocytes and Schwann 
cells. It is well established that microglial cells belong to a hematopoietic lineage and that these 
cells  are  immune  system  cells  in  the  central  nervous  system.  Astrocytes  as  stated  before,  are 
responsible for glutamate uptake and they also aid motoneuronal survival by secreting trophic 
factors.  Schwann cells are responsible for myelin ensheathing of motoneurons fundamental for 
speeding up impulse transmission.
The  reason  we  need  to  consider  motoneurons  as  non  isolated  cells  is  because  there  is  a 
neuroinflammatory interaction of microglia, neurons, and astrocytes. In the healthy CNS microglia 
present  a  ramified  morphology  (Fig.  14)  providing  immune  surveillance  in  the  neuronal 
environment (Raivich et al.,  2005). In response to primary stimuli from neurons and astrocytes 
(initiating  mechanism  unknown  in  ALS),  microglia  become  primed  (Fig.  14)  causing  pro-
inflammatory cytokine production and growth factor expression dowregulation (Perry et al., 2004). 
In  response  to  secondary  stimuli  microglia  become  fully  activated  amoeboid  cells  with  full 
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phagocytic  potential  (Fig.  14).  These  cells  produce  increased  quantities  of  pro-inflammatory 
cytokines, reactive nitrating intermediates (RNI), reactive oxygenating intermediates (ROI), and 
glutamate. Astrocytes, on the other hand, decrease their growth factor contribution and release 
glutamate and inflammatory mediators. Neurons residing in the inflammatory microenvironment 
degenerate via apoptotic mechanisms (Fig 14).
It has recently been shown that mutant SOD1 when secreted by affected motoneurons is a strong 
activator  of  microglia  (Urushutani  et  al.,  2006)  Microglial  activation  has  been  reported before 
motoneuron loss and disease progression in ALS (Henkel et al., 2006). Other inflammation markers 
have been reported:  COX-2 upregulation in the spinal cord of ALS patients has been reported 
(Yasojima et al., 2001; Yiangou et al., 2006). It is known that COX-2 is a marker of inflammation 
and is only induced under pathological circumstances. Another player, the chemokine fractalkine, 
has been  identified as a chemoattractant in signaling the microglial response by injured motor 
neurons (Zujovic et al.,  2000; Harrison et al.,  1998). It has been reported to promote microglial 
proliferation  in  vitro  (Hatori  et  al.,  2002)  and  its  receptor  is  expressed  on  both  neurons  and 
microglia (Meucci et al., 1998). In cell culture exporiments, fractalkine suppressed the production 
of nitric oxide (NO), IL-6 and TNF-α by activated microglia and suppressed neuronal cell death 
induced by microglia  activated with LPS and interferon-gamma (IFN-γ),  in  a  dose-dependent 
manner (Mizuno et al., 2003). Fractalkine is a chemokine that seems to have a role as an intrinsic 
inhibitor against microglia-induced neurotoxicity. Interestingly, when the fractalkine receptor is 
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Fig 14. Proposed interaction between microglia, astrocytes and motoneurons in ALS
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ablated in ALS mice, the disease is exacerbated (Re and Przedborski, 2006), therefore fractalkine 
seems to have a role in ALS pathogenesis as well.
In addition, increased dendritic-cell  populations have been found in the spinal cord of affected 
transgenic mice and also macrophage infiltrates  have been revealed in the spinal  cord of ALS 
patients (Henkel et al, 2006) suggesting an inflammatory response that goes actually  beyond  the 
CNS  players  of  inflammation  such  as  microglia.  Taken  together,  all  these  reports  show  that 
inflammation is an important aspect of ALS.
Apoptotic mechanisms in ALS
Apoptosis markers can be observed in terminal stage ALS patients and animal models (Guegan et 
al., 2003; Pasinelli et al., 1998, 2000; Vukosavic et al., 1999). Cultured neuronal cells either injected 
or transfected with mutant SOD1 cDNA die by apoptosis (Durham et al.,  1997; Pasinelli et al., 
1998).  Gradual  decrease  in  intra-mitochondrial  cytochrome-c  levels   has  been  associated  with 
disease  progression  (Bacman et  al.,  2006).  Bcl-2,  an  important  antiapoptotic  protein,  has  been 
reported to be bound and sequestered by mutant sod1 (Pasinelli et al., 2004). Activation of caspase 
1 in G85R and G37R mice  months before caspase-3 activation and disease onset has been reported 
(Pasinelli et al., 1998, 2000). Cytochrome-c translocation into the cytosol, and its interaction with 
APAF1  (apoptotic  peptidase  activating  factor  1)  and  dATP  binding  form  an  oligomeric 
apoptosome.  The  apoptosome  is  then  able  to  cleave  and  activate  procaspase-9  .  Caspase-9 
activation is followed by caspase-1 activation before caspase-3 and caspase-7 activation. Once the 
pro-apoptotic signal has been activated in motoneurons,  secondary events amplify this process 
such as microglial and T-cell  activation with the release of inflammatory cytokines and factors 
such as interleukin- 1β, TNF-α and COX-2 (Alexianu et al., 2001; Robertson et al., 2001; Almer et 
al., 2001). TNF-α has been shown to activate caspase-8 in the late stage of ALS in transgenic mice 
and cultured embryonic motoneurons have been shown to be sensitive to a Fas-induced apoptosis 
(Raoul et al., 2002, 2006). This evidence suggests that these inflamatory cytokines could mediate a 
motoneuron-specific apoptotic pathway in ALS.
From the previously presented evidence, we can conclude that ALS pathogenesis is very complex 
and may involve all of the proposed mechanisms (Fig. 15).
One of  the first  events  in ALS pathogenesis  seems to be the disruption of  the neuromuscular 
junction due to motoneuronal terminal retraction (Jokic et al., 2006). Also in the early phase of the 
disease, SOD1 mediated aggregates could disrupt neurofilament organization and mitochondrial 
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function. Moreover, secreted SOD1 (Urushitani et al.,  2006) would trigger microglial premature 
activation.  In  the  symptomatic  stage  of  the  disease,  activated  microglia  and astrocytes  would 
produce toxic and inflammatory factors harmful for the affected motoneuron. It has been reported 
that activated astrocytes produce NGF (Pehar et al., 2004) and that degenerating motoneurons in 
ALS express  the p75NTR receptor (Lowry et al., 2001). This receptor is not normally expressed in 
adult  motoneurons.  An  apoptotic  mechanism  mediated  by  the  binding  of  NGF to the  p75NTR 
receptor  has  been  reported  (Pehar  et  al.,  2004).  However,  it  has  also  been  reported  that 
motoneurons  produce  FGF-1  that  potently  activates  astrocytes  to  produce  and  secrete  NGF 
(Cassina  et  al.,  2005).  Still  in the  symptomatic  stage,  astrocytes  would present  lower  levels  of 
EAAT2 transporter (Fray et al., 1998; Maragakis et al., 2004; Rothstein et al., 1995) and aberrant 
EAAT2 products (Lin et al., 1998), contributing to excitotoxicity. Impaired axonal transport would 
also reduce trophic factor transport and organelle transport in the affected motoneuron.
Overloaded proteasomes would choke and protein aggregates would sequester other important 
proteins  in  the  cell  such  as  HSPs.  Damaged  mitochondria  would  not  perform  oxidative 
phosphorylation correctly, oxidative stress would increase and calcium buffering by mitochondria 
would  be  impaired,  because  of  SOD1  induced  dysfunction.  All  these  events  would  lead  to 
mitochondrial cytochrome-c release and caspase activation triggering motoneuronal apoptosis and 
ultimately to phagocytosis. Complete muscle atrophy would develop  and  glial scarring would be 
formed where the affected motoneuron used to be. 
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Fig. 15. Proposed ALS pathogenesis overview mechanism
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Sometimes neighbors matter 
Even though  SOD1-induced  degeneration  is  clearly  motoneuron-specific,  a  contribution  from 
surrounding cells is obvious. We must remember that SOD1 is ubiquitously expressed, therefore 
an important  question was raised:  in order to develop ALS,  must  mutant SOD1 be expressed 
ubiquitously or is it enough to express it only in motoneurons to develop disease?  When mutant 
SOD1 was expressed selectively either  in  motoneurons  or  in astrocytes,  mice did not  develop 
motoneuron disease  (Gong et al., 2000; Lino et al., 2002), suggesting that SOD1 toxicity requires 
mutant  damage  not  just  within  motoneurons  but  also  to  non-neuronal  cells.  This  was  also 
demonstrated by Clement et al.  (2003) who showed that in chimeric mice that are mixtures of 
normal and SOD1 mutant-expressing cells, toxicity to motoneurons is shown to require damage 
from mutant SOD1 acting within non-neuronal cells. Normal motoneurons surrounded by mutant 
SOD1-expressing  non-neuronal  cells  developed aspects  of  ALS  pathology.  Conversely,  mutant 
motoneurons could escape degeneration and death if surrounded by a relatively small minority of 
normal  non-neuronal  cells.  Therefore,  mutant  SOD1  induced  ALS  can  be  defined  as  non-cell 
autonomous or as a neighbourhood disease,  because only ubiquitous expression of the mutant 
protein can cause the disease.  
On the other hand, let  us consider ALS induced by dynactin mutations.  Dynactin is  a neuron 
specific protein and is not expressed by microglia and astrocytes. In this case, the mutant protein is 
expressed only by the affected cells. This suggets that dynactin induced ALS (Puls et al., 2003) is 
cell autonomous, meaning that some types of ALS can be cell autonomous but other types of ALS 
imply the contribution of different cells in order to develop disease. 
Therapy and clinical trials
As stated before, the only drug so far approved for human use is riluzole. Riluzole shows to inhibit 
glutamate release and modestly extends survival of ALS patients by 2 months (Doble et al., 1996). 
Unfortunately, up to date, no clinical trial has been successful on humans. Many compounds that 
showed  improvement  in  ALS  animal  models  such  as  creatine  (Klivenyi  et  al.,  1999),  proved 
ineffective in humans (Groeneveld et al., 2003). Growth factors such as IGF-1 (Borasio et al., 1998; 
Lai et al., 1997), BDNF (The BDNF Study Group, 1999) and CNTF (ALS CNTF Treatment Study 
Group, 1996)  showed little or no benefit. However, some ALS clinical trials should be redesigned. 
Some of the substances were administered systemically whereas a localized administration could 
show some benefit and reduce side-effects. Also some of the administered substances were not 
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able to pass through the blood brain barrier (BBB). The BBB could be skipped (Fig. 18) by directly 
infusing  the  desired  growth  factor  into  the  brain  (intracerebroventricular)  or  spinal  cord 
(intrathecal).  In fact, continuous intracerebroventricular infusion of IGF-1 showed slight benefit in 
ALS patients (Nagano et al., 2005). 
A possible target for clinical trials in humans could be RNA silencing of mutant SOD1. In order to 
do this, RNAi could be applied locally either by intracerebroventricular or intrathecal injection In 
fact,  SOD1  transgenic  mutant  mice  that  were  administered  mutSOD1  RNAi  using  modified 
lentiviral vectors directly in the spinal cord  (Raoul et al., 2005) showed a prolonged survival (Fig. 
16). 
A  less  invasive  strategy  is  intramuscular  injection  of  modified  viral  vectors   that  carry  the 
mutSOD1 RNAi. These are then anterogradly transported to the motoneuronal cell body (Ralph et 
al., 2005; Miller et al., 2005). These mice showed an increased survival as well.  Growth factors can 
also be delivered by using modified viral vectors. Survival in mutant G93A SOD1 expressing mice 
treated with viral  vectors  carrying IGF-1 (Kaspar et  al.,  2003)  and VEGF (Azzouz et  al.,  2004) 
coding sequences, was increased after intramuscular injection (Fig. 18) , therefore it could be worth 
applying the same to humans.
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Fig 16. Proposed ALS therapies and delivery methods
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Cell therapy in ALS
One of the most promising therapies in ALS is stem cell therapy. Stem cells are able to differentiate 
into  several  cell  types  (Fig.  19).  Especially  embryonic  stem cells  (ESCs)  have been induced to 
differentiate into spinal motoneurons (Harper et al., 2004) by the combined treatment with retinoic 
acid  which  induces  a  horizontal  neuralization   and  sonic  hedgehog  which  induces  a  ventral 
orientation in these cells. ESC-derived motoneurons have also been show to grow axons (Harper et 
al., 2004) and generate neuromuscular junctions in periphernal nerve injury rat models (Craff et al., 
2007). In another report, ESCs  showed to implant and grow processes in the injured animals and 
contributed  to  movement  recovery,  although  the  extent  of  recovery  cannot  be  determined 
(Desphande et al., 2006). Adult stem cells have also drawn attention because it has been reported 
that they can also differentiate into several cell lineages, including neural lineage progenitors (Kim 
et al., 2006). Because of ethical issues, adult stem cells would be easier to use.   Despite all these 
encouraging reports, ALS stem cell therapy still needs further development before it can lead to 
successful results in humans. In order to achieve successful ALS stem cell therapy, differentiated 
motoneurons must be able to grow axons along the spinal cord and synapse lower motoneurons 
(this  is  the  case  for  affected  upper  motoneurons).  For  affected  motoneurons,  the  implanted 
motoneurons must be able to grow axonal processes that can be as long as one meter (lower limb 
muscles) and also develop neuromuscular junctions with innervated muscles. 
Of course stell cell therapy must not only focus on motoneuronal degeneration, since as it has been 
shown  and  discussed  earlier,  microglia  and  astrocytes  also  play  a  fundamental  role  in  cell-
autonomous ALS. Whether oligodendrocytes are affected in ALS is not known yet.
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Fig. 17. Stem cell potential to differentiate into different ce ll types
CHAPTER 1: INTRODUCTION
Why neurochemistry studies?
Most ALS studies on animal models have focused on disease pathogenesis  and have aimed at 
finding strategies  to  increase  survival  and slow disease  onset  and progression.  However,  few 
reports have dealt with topics such as behavior, learning and memory in ALS mice. These aspects 
during disease course are also interesting to study because cognitive deficits and various degrees 
of dementia have been documented in ALS patients (Kew et al., 1993; Kato et al., 1994; Massman et 
al., 1996; Hanagasi et al.,  2002), and no attention has been so far paid to possible alterations of 
brain systems related to learning and memory. We therefore decided to study cholinergic systems 
in ALS transgenic mice during disease course.
On the other hand,  long-term dietary supplementation with creatine has  been proposed to be 
neuroprotective in both acute and chronic neurodegenerative diseases. Neuroprotective effects of 
creatine have been demonstrated in some animal models of neurotoxicity/excitotoxicity but not in 
others (Malcon et al., 2000; Matthews et al., 1998, 1999), in traumatic brain and spinal cord injury 
(Hausmann et  al.,  2002;  Sullivan et  al.,  2000)  and in ischemia  (Zhu et  al.,  2004).  Furthermore, 
attenuation of disease symptoms and increased lifespan through dietary creatine supplementation 
has been described in animal models  of  human neurodegenerative diseases  (Ellis  et  al.,  2004). 
Surprisingly, reports on dietary creatine supplementation in animal models of neurodegenerative 
injuries and diseases have not dealt, so far, with the derangement of neurochemical parameters 
related to degenerating neurons and with their  rescue through the dietary manipulation.  This 
information is very relevant, because specific alterations of neurochemical parameters are one of 
the most reliable markers to evaluate the extent of neural damage. Furthermore, this approach 
may  be  potentially  able  to  put  in  evidence  differential  responses  to  insults  and protection  of 
different neuronal populations present in the same brain region. 
Finally, polyamines are a family of several polycationic compounds found in virtually all the living 
organisms, from simple prokariotic to eukariotic cells. In mammals, they are produced in a highly 
regulated  biosynthetic  pathway  in  which  the  key  enzyme,  ornithine  decarboxylase  (ODC), 
converts the immediate precursor ornithine into the diamino compound putrescine that, in turn, 
gives rise to higher order derivatives, including spermidine and spermine, the two physiologically 
most important polyamines. The widespread distribution together with the highly regulated levels 
of cell polyamines are thought to reflect a prominent physiological role of these compounds. In 
recent years, many studies have demonstrated the involvement of polyamines in various cellular 
processes such as regulation of gene expression, cell proliferation and differentiation and tissue 
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regeneration (Pegg and McCann, 1982; Banan et al., 1998; Thomas and Thomas, 2001; Childs et al., 
2003;). In parallel with interest raised by the physiological roles of polyamines, a growing attention 
has been paid to the possible pathological involvement of these compounds. For instance, based on 
their  ability  to  promote  cell  proliferation,  polyamines  are  suspected  to  be  involved  in  tumor 
growth  (Gerner  and  Meyskens,  2004;  Gugliucci,  2004).  In  the  central  nervous  system  (CNS), 
polyamines, that have been localized to both neurons and glial cells (Bernstein and Muller, 1999), 
show characteristic profiles of regional and developmental abundance. 
For instance, ODC activity and putrescine levels are found at high levels during perinatal phases 
of neurogenesis and nerve cell differentiation (Slotkin and Bartolome, 1986). On the other hand, in 
the mature brain the ODC/polyamine system is regulated at very low levels, but the ODC activity 
and the parallel synthesis of polyamines can be rapidly induced by various traumatic insults and 
in neuropathological conditions (Paschen, 1992). Increase of polyamine levels has been described 
in focal cerebral ischemia in humans (Els et al., 2001) and in various animal models of transient 
and permanent  brain  ischemia  (Baskaya et  al.,  1997;  Adibhatla  et  al.,  2002;  Babu et  al.,  2003). 
Alterations of ODC/polyamines system have been also reported in post-mortem investigations on 
patients affected by Alzheimer’s and Parkinson’s diseases (Morrison and Kish, 1995; Morrison et 
al., 1998; Gomes-Trolin et al., 2002). In spite of relatively abundant data on ODC activation and 
polyamines accumulation in various neuropathological states, not much is known about cellular 
and molecular mechanisms affected by these changes. Since glutamate excitotoxicity is from a long 
time  considered  a  major  determinant  of  neurodegenerative  processes,  an  excessive  positive 
modulatory  effect  of  polyamines  on  NMDA  receptor  has  been  suggested  to  be  involved  in 
polyamine  neurotoxicity  (Contestabile  et  al.,  1994;  Sparapani  et  al.,  1997;  Williams,  1997). 
Moreover, abnormally elevated polyamine levels can induce activation of enzymes involved in the 
apoptotic  cascade  of  neuronal  death  (Poulin  et  al.,  1995;  Schipper  et  al.,  2000).  By  contrast, 
neuroprotective  roles  of  natural  polyamines  have  also  been  reported  by  several  investigators 
(Ferchmin  et  al.,  2000;  Harada  and  Sugimoto,  1997;  Clarkson  et  al.,  2004).  In  view  of  these 
controversial results, it seems important to explore systematically the temporo-spatial profiles of 
ODC/polyamine alterations in multiple animal models of neuropathological disorders in order to 
unmask coincidental and common features. Data about changes of ODC/polyamines system in rat 
CNS during aging have been reported in a previous paper and a marked increase in ODC activity 
and putrescine and spermidine accumulation in the spinal cord but not in brain areas of aged rats 
were reported (Virgili et al., 2001). This suggested that the spinal cord can be a sensitive target for 
neurodegeneration and a region where derangement of ODC/polyamine system is correlated with 
36
CHAPTER 1: INTRODUCTION
impairment of motor function (Virgili et  al.,  2001).  On this basis,  it  was deemed interesting to 
study alterations of this system in a pathological condition primarily involving degeneration of 
spinal cord motor neurons, such as amyotrophic lateral sclerosis (ALS). The only available report 
on this disease, revealed no significant alteration in polyamine levels in post-mortem studies in the 
spinal cord of patients deceased by ALS (Ekegren et al., 2004). Therefore we decided to perform a 
study on a mice model of ALS.
Why proteomics?
There are several compelling reasons to use proteomics and approach biological questions from 
the  protein  perspective  (Banks  et  al.,  2000;  Lopez  and  Melov,  2002;  Petricoin  et  al.,  2002; 
Schulenborg et al., 2006). The term proteome describes the ensemble of proteins expressed by a 
cell, tissue or the whole organism, and unlike the temporally constant genome, it is dependent on 
intra- and extra-cellular parameters, dynamics and variables. Proteins are the functional output of 
the cell and therefore they are expected to provide the most relevant information in the context of 
the biological system and specific networks they are involved in. Their expression and function 
can be modulated in many ways, from transcription to post-translation (e.g. alternative splicing of 
the pre-mRNA and post-translational modifications), leading to multiple protein products from a 
single gene that can not be predicted from analysis of nucleic acids alone. These modifications may 
affect the catalytic activity, association, stability, half-life or localisation of a specific protein in a 
disease  state  and  thus  their  detection  would  be  important  to  understand  underlying  disease 
mechanisms. 
The central  tool  for displaying the proteome is  two-dimensional  gel  electrophoresis  (O'Farrell, 
1975).  In 2D electrophoresis, proteins in a sample are first separated according to their isolectric 
point: isoelectric focusing (IEF), this is the first dimension. In the second dimension, poteins are 
separated according to their molecular weight. 
Proteins  are  amphoteric  molecules;  they  carry  either  positive,  negative,  or  zero  net  charge, 
depending on the pH of their surroundings.  The net charge of a protein is  the sum of all  the 
negative and positive charges of its amino acid side chains and amino- and carboxyl-termini. The 
isoelectric point (pI) is the specific pH at which the net charge of the protein is zero. Proteins are 
positively charged at pH values below their pI and negatively charged at pH values above their pI. 
The presence of a pH gradient is critical to the IEF technique. In a pH gradient and under the 
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influence of an electric field,  a protein will  move to the position in the gradient where its  net 
charge is zero. A protein with a net positive charge will migrate toward the cathode, becoming 
progressively less positively charged as it moves through the pH gradient until it reaches its pI. A 
protein  with  a  net  negative  charge  will  migrate  toward  the  anode,  becoming  less  negatively 
charged until  it  also  reaches  zero  net  charge.  If  a  protein should diffuse  away from its  pI,  it 
immediately gains charge and migrates back. This is the focusing effect of IEF, which concentrates 
proteins  at  their  pIs  and  allows  proteins  to  be  separated  on  the  basis  of  very  small  charge 
differences.
When comparing the proteome of healthy versus diseased tissue, distinct protein alterations can be 
detected. Several post-translational modifications that modify molecular weight of a protein to a 
minimal extent (such as phosphorylation) can be detected with 2D electrophoresis,  because the 
protein's  pI  changes.  Differentially  expressed proteins can be identified by mass spectrometry. 
Mass spectrometry is an analytical tool used for measuring the  molecular mass of a sample. For 
large samples such as biomolecules,  molecular masses can be measured to within an accuracy of 
0.01% of the total molecular mass of the sample i.e.  within a 4 Daltons (Da) or atomic mass units 
(amu)  error  for  a  sample  of  40,000  Da.  This  is  sufficient  to  allow minor  mass  changes  to  be 
detected, e.g.  the substitution of one amino acid for another, or a post-translational modification. 
In matrix assisted laser desoprtion ionization (MALDI) sample molecules are bombarded with a 
laser and become ionized. The type of a mass spectrometer most widely used with MALDI is the 
TOF (time-of-flight mass spectrometer),  mainly due to its large mass range.   The time-of-flight 
analyser separates ions according to their mass(m)-to-charge(z) (m/z) ratios by measuring the time 
it takes for ions to travel through a field free region known as the flight, or drift, tube. The heavier 
ions are slower than the lighter ones. Peptide mass fingerprinting is used with a MALDI-ToF mass 
spectrometer. In this case  the unknown protein of interest is cleaved into peptides by a  protease 
such  as  Trypsin.  The  collection  of  peptides  resulting  from  this  cleavage  comprise  a  unique 
identifier  of  the  unknown  protein.  The  absolute  masses  of  the  (still  unknown)  peptides  are 
accurately measured with a mass spectrometer such as MALDI-TOF 
Differentially expressed proteins then have to be validated and characterized in depth to elucidate 
their function and affected pathways. 
To date numerous proteomic studies have been performed in the field of neurodegeneration. In 
Parkinson’s  disease  (PD),  a  2D  gel  based  differential  proteome  study  reported  mitochondrial 
dysfunction and oxidative damage in ventral midbrain of parkin deficient mice. Parkin is an E3 
ubiquitin ligase, known to be impaired by mutations in an early onset form of familial PD. The 
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study resulted in the detection of 13 downregulated proteins in the parkin null mice,  eight of 
which  seemed  to  be  linked  to  mitochondrial  respiration  or  detoxification  of  byproducts  of 
mitochondrial respiration (Palacino et al.,  2004). In another proteomic study, Basso et al.  (2004) 
analysed protein extracts from human post-mortem substantia nigra of PD patients and identified 
several  differentially  expressed  proteins,  including  neurofilaments,  peroxiredoxin  II  and 
complexes III and IV of the respiratory chain. Calmodulin, cytochrome c and cytochrome c oxidase 
were among the proteins that were differentially expressed in dopamine depleted brain regions of 
brain tissue sections from a rat model of PD (Pierson et al., 2004). In Alzheimer’s disease, several 
proteomic studies have been also published over the last years. Cottrell et al. (2005) analysed 21 
proteins in human AD brain, which co-precipitated with the main component of neuritic plaques 
amyloid  precursor  protein  (APP),  by  2D  gel  electrophoresis  and  identified  them  by  mass 
spectrometry.  In  addition to  six  known interactors  of  APP,  they identified  15  new interacting 
partners including proteins involved in axonal transport (dynein, myosin, dynamin), cytoskeletal 
and  structural  proteins  (actin,  tubulin,  GFAP,  spectrin,  neurofilaments),  as  well  as  chaperone 
proteins (αB-crystallin, HSP90, HSC71, cyclophilin A). Oxidative modification of proteins, due to 
oxidative stress and free radical formation, is an early event of neurodegenerative diseases and can 
be detected using oxyblot prior to their separation by 2D-PAGE. In this case the carbonyl group, 
introduced  to  lysine,  arginine,  proline  or  threonine  residues  by  oxidative  processes,  can  be 
derivatized  to  2,4-dinitrophenylhydrazone  using  2,4-dinitrophenylhydrazine  and  eventually 
detected  using  a  specific  antibody.  This  method  has  been  used  extensively  by  the  group  of 
Butterfield who reported several differentially oxidized proteins in the hippocampus but not in the 
cerebellum of AD patients compared to matched controls (Castegna et al.,  2002;  Sultana et  al., 
2006).  Excessively  oxidized  proteins  included  α-enolase,  triose  phosphate  isomerase  (TPI), 
dihydropyrimidinase-related  protein-2  (DRP-2),  creatine  kinase  and  HSC71.  Proteomic 
technologies have also been used to screen body fluids, such as cerebrospinal fluid (CSF), serum 
and plasma, with the aim to identify specific disease biomarkers for early diagnosis. Two reviews 
by Davidsson and Sjogren (2005, 2006) summarize results from proteomic studies of differential 
protein patterns in neurodegenerative diseases with focus on AD. 
In the field of ALS, a few proteomic studies have also been designed in order to identify new 
potential  marker  proteins  involved  in  the  pathogenesis  of  motor  neuron  degeneration.  As 
described earlier, a recent CSF proteomic study reported the identification of three protein species 
(a 4.8-kDa VGF peptide, cystatin C and a 6.7-kDa cationic protein species) that were significantly 
lower in concentration in the CSF from patients with ALS compared to normal controls as well as 
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patients with purely motor peripheral neuropathy (Pasinetti et al., 2006). The combination of the 
three protein species correctly identified patients with ALS with 95% accuracy, 91% sensitivity and 
97% specificity from the controls, during the early timepoint of the disease. Decreased cystatin C 
was identified in the CSF of ALS patients, in another study, along with transthyretin and carboxy-
terminal fragment of neuroendocrine protein 7B2 (Ranganathan et al. 2005). In addition, Ekegren et 
al. (2006) identified several differentially expressed proteins in post-mortem spinal cords from ALS 
patients compared to control subjects, including GFAP, haemoglobin α and β chain, myelin basic 
protein, thioredoxin, α-enolase and choline acetyltransferase. Using a motor neuron-like cell line, 
Fukada et al.  (2004) identified 45 mitochondrial proteins that are altered in the presence of the 
G93A-SOD1 mutation. Nine and 36 protein spots displayed elevated and suppressed abundance 
respectively in SOD1G93A-expressing cells. Half of the differentially expressed proteins were found 
to be involved in various metabolic pathways, mainly the mitochondrial respiratory chain, while 
the remaining included proteins involved in membrane transport, antioxidant proteins, and heat 
shock molecular  chaperones  among others.  A proteomic  analysis  of  protein  expression  in  the 
SOD1G93A mouse model was also undertaken to identify differences in protein expression in the 
spinal cords of end-stage mice (Lukas et  al.,  2006).  Protein profiling was done on soluble and 
particulate fractions of spinal cord extracts, using 2D liquid chromatography coupled to tandem 
mass  spectrometry,  and  revealed  that  changes  in  mitochondria-associated  proteins  were 
particularly prevalent, suggesting that part of the “gain of function” of mutant SOD1 is to target 
specific mitochondrial proteins.  Recently, in another project, Massignan et al. (2007) performed a 
proteomic analysis of spinal cord extracts from asymptomatic (9 week-old) wild-type and mutant 
SOD1 expressing transgenic mice. The analysis was performed by using 2D gel electrophoresis. 
The group found that 10 proteins were significantly over-represented and 5 proteins were under-
represented in SOD1  mutant mice when compared to wild-tpye animals. The identified proteins 
belonged to several biological processes such as mitochondrial metabolism, glycolitic metabolism 
and protein degradation among others.
We thought that 2D-PAGE could be a useful technique in separating hundreds of proteins present 
in insoluble protein fractions extracted from spinal cords of SOD1G93A expressing  mice with a high 
resolution, helping identifying the components of this fraction. The present proteomics project is 
the continuation of a proteomic analysis perfomed on insoluble protein fractions from end-stage 
(16 week-old) animals (unpublished).
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Animals
Transgenic  mice  overexpressing  a  mutated  form  of  human SOD1  gene,  an  animal  model  for 
familial ALS, were used. The mutation consists of a glycine 93 to alanine (G93A) substitution and 
is located in exon 4 of the gene (Gurney et al., 1994). Mice carrying the mutated gene, designated 
B6SJL-TgN  (SOD1G93A)  1GUR  and  mice  overexpressing  the  wild-type  SOD1  human  gene, 
designated B6SJL-TgN (SOD1G93A) 2GUR),  were obtained from Jackson laboratories.  The colony 
was established and maintained by crossbreeding male transgenic mice with B6EiC3Sn females. To 
assess the genotypes of transgenic offspring, DNA was extracted from the tail of 30-40  day-old 
mice and amplified by using a PCR assay with specific primers for wild-type mouse IL-2 (Horak, 
Ivan 1991) : 
forward 5'-   CTA ggC CAC AgA ATT gAA AgA TCT   -3'  
reverse 5'-   gTA ggT ggA AAT TCT AgC ATC ATC C   -3' 
and for exon 4 of human SOD1 (Brown, Robert Jr 1993 exon 4 set b) : 
forward 5'-   CAT CAg CCC TAA TCC ATC TgA   -3', 
reverse 5'-   CgC gAC TAA CAA TCA AAg TgA   -3'  
as shown by the image below:
The experiments were designed to compare results from three groups of mice: G93A carrying a 
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high copy number of copies of the human mutated gene, wild-type transgenic mice carrying an 
equivalent number of copies of the human wild-type gene and non transgenic littermates. 
Male Wistar rats form Harlan Italy were also used where specified.
Neurochemistry studies
Forebrain cholinergic system alterations  in SOD1 mutant transgenic mice
Initial neurochemical experiments considered males and females as separate groups but, after data 
analysis, we found no significant differences related to sex and thus data from both groups were 
pooled. In survival experiments, only females were included in the experimental groups to avoid 
sex-related  variability,  as  it  is  known from the  literature  that  mean lifespan  of  G93A females 
exceeds by few days that of males. Experiments of choline supplementation were performed by 
treating pregnant females with 35 mM choline chloride (Sigma, St. Louis) added to the drinking 
water (sweetened with 0.5% saccharine) from gestational day 11 to birth. The daily average choline 
intake was 7 mmol choline/(kg day), including choline added to the water and choline present in 
the standard food diet,  which amounted to 1.5  mmol choline/(kg day).  In addition,  groups of 
choline-treated  or   untreated  progeny  of  G93A  mice  were  supplemented  with  25  mM  acetyl 
carnitine hydrochloride (ALCAR, Sigma, St. Louis), starting from 40 days of age and continuing 
until death. Average intake was 3.5 mmol/(kg day). Experiments were  conducted according to the 
Italian  law  on  the  use  of  animals  for  experimental  purposes,  which  conforms  to  European 
Community rules and were authorized by a local bioethical committee. Veterinary surveillance on 
animal health and comfort was ensured by a University Veterinary committee. 
Neurochemical assays
At 55, 110 and 125 days of age, animals were killed by decapitation and various brain samples 
were dissected,  immediately  frozen on dry ice  and stored at  -80°C until  used.  On the day of 
experiment, collected tissue was homogenized in ice-cold solution containing 50 mM Tris–HCl, pH 
7.4, and 0.5% Triton-X 100. The homogenate was used to determine protein content and to perform 
enzyme activity  assays.  Choline  acetyltransferase  (ChAT)  and glutamate  decarboxylase  (GAD) 
activity were determined according to established radiochemical methods (Fonnum, 1975; Fonnum 
et al., 1977). Acetylcholinesterase (AchE) and glutamine synthetase (GS) activity were quantified 
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using colorimetric methods (Ellman et al., 1961; Patel et al., 1983). All chemicals were purchased 
from Sigma (St.  Louis,  MO),  except  for  radiochemical  substrates  originated from Perkin-Elmer 
([acetyl-1-14C]-labeled  coenzyme  A;  Boston,  USA)  and  from  GE  Healthcare  ([14C]-labeled 
glutamate; Buckinghamshire, UK), respectively.
Assay for nucleosomal DNA fragmentation 
Oligonucleosomal  DNA  fragmentation,  a  characteristic  feature  of  apoptotic  cell  death,  was 
determined  by  binding  of  a  monoclonal  antibody  to  internucleosomal  proteins  using  a 
commercially available kit (Cell Death Detection ELISA Plus, Roche, Indianapolis,  IN). Lumbar 
spinal  cord  and  cortex  from  110-day-old  G93A  mice  and  non-transgenic  littermates  were 
homogenized in the provided lysis buffer and centrifuged. The supernatant was used to quantify 
the index of apoptosis following the manufacturer’s instructions.
Immunohistochemical procedures 
Mice were anesthetized and perfused with 4% paraformaldehyde in 100 mM phosphate buffer, pH 
7.4. Cervical and lumbar spinal cord segments and brains were dissected and postfixed overnight 
in the same fixative. After washing, samples were immersed in 15% sucrose for 24 h and sectioned 
at 40 mm thickness with a freezing microtome.
For immunohistochemistry, all washing  and incubation steps were performed on a flatbed shaker 
at room temperature, unless specified. Sections were first washed with PBS 0.1% Triton X-100 for 
15 minutes. Following this step, endogenous peroxidases were blocked by incubating the sections 
for 30 minutes in 0.3% (v/v) H2O2 diluted in methanol. The sections were then washed 3 times for 
10 minutes with PBS 0.1% (v/v) Triton X-100. Aspecific binding sites were blocked by incubating 
the sections with PBS-T 0.1% Triton X-100 plus BSA 2% (w/v, Sigma) and 1.5% (v/v) normal rabbit 
serum (Sigma). Primary antibody incubation (1:100 dilution) was performed at 4°C overnight in 
PBS 0.1% Triton plus BSA 1% and normal rabbit serum. A goat anti-ChAT polyclonal antibody 
(Chemicon) was used to label ChAT reactive cells. The next days the sections were washed 3 times 
for 5 minutes and then incubated for 1 hour with a biotinylated mouse anti-goat (Sigma) secondary 
antibody (1:500 dilution) in PBS 0.1% Triton X-100 plus BSA 1% and 1.5% normal rabbit serum 
(v/v). After this incubation, the sections were washed 3 times for 5 minutes in PBS. The sections 
were then incubated for 1 hour with ABC reagent (Vectastain). ABC reagent was prepared at least 
30 minutes before the incubation as specified by the manufacturer.  Following this incubation, the 
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sections were washed 3 times for 5 minutes in PBS and aftwerwards with 50mM pH 7.6 Tris-HCl. 
Immunoreactivity  was  revealed  through  DAB  staining  following  the  manufacturer's  protocol 
(Vectastain). DAB staining was blocked by washing the sections with double-distilled water when 
the required staining was achieved. 
Sections were mounted on gelatin-coated glass slides and left to dry overnight. The following day 
the mounted sections were dehydrated by incubating  the glass slides for at least 1 minute in 95% 
ethanol, then 100% ethanol, a second incubation in 100% ethanol and a last incubation in xylene. 
Sections were coverslipped in permount mounting medium and left to dry.
Statistics
Experimental  data  were  subjected  to  statistical  analysis  by  using  Student’s  t-test  or,  when 
appropriate, analysis of variance (one-way ANOVA) followed by post hoc comparison through 
Bonferroni’s test.
Differential neuroprotecion by creatine supplementation
Male Wistar rats form Harlan Italy were divided into two groups at 40 days of age. The first group 
was fed ad libitum with standard diet. The second group received the same diet supplemented 
with 2% creatine. Rats underwent surgical operation at 70 days of age and were then allowed to 
survive for additional 30 days, continuing to be fed with the normal or the supplemented diet 
during all these periods. 
For surgery, rats were anesthetized with ether, fixed to a David Kopf stereotaxic instrument and 
holes were drilled in the skull at the appropriate stereotaxic coordinates. Two different models of 
excitotoxic  neurodegeneration  were  adopted  to  test  possible  neuroprotection  from  creatine 
supplementation. In the first model, rats received unilateral injections of the neurotoxin, ibotenic 
acid (IBO, 7 Ag/1 Al saline), into the left striatum at the following coordinates (Paxinos et al., 1982): 
1 mm in front of bregma, 3 mm lateral, 5 mm below the dura. This treatment results in widespread 
degeneration of  striatal  neurons and in particular of  the  cholinergic  and GABAergic  neuronal 
population present in this brain region (Ciani et al., 2001). In the second model, IBO (5  Ag/1  Al 
saline)  was  unilaterally  injected  in  the  area  of  the  nucleus  basalis  magnocellularis,  where 
cholinergic  neurons  providing  most  of  the  cholinergic  input  to  the  neocortex  are  localized 
(Mesulam et al., 1983; Woolf et al., 1991), at the following coordinates: 1 mm behind bregma, 2.7 
mm lateral,  7.8  mm below the  dura.  The  excitotoxic  lesion  of  these  neurons  results  in  fall  of 
cholinergic  parameters  in  cortical  areas  as  a  consequence  of  the  degeneration  of  cholinergic 
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terminals  (Casamenti  et  al.,  1998;  Contestabile  et  al.,  2004).  Injections  were  performed  slowly 
(about 3 min followed by 2 min during which the needle was left in place), using a 10 Al Hamilton 
syringe operated by a micrometric device. In both cases, the contralateral (right) side of the brain 
received an equivalent injection of saline and served as control for the excitotoxic lesion. After 30 
days of recovery, rats were killed by decapitation, the brains were rapidly removed and sliced 
with a Sorvall tissue chopper. Samples of the striata (for striatum-injected animals) obtained from 
two consecutive slices comprised between levels bregma 1.2 and bregma 0.2 (Paxinos et al., 1982), 
or the fronto-parietal cortex (for nucleus basalis magnocellularis-injected animals) obtained from 
three slices comprised between levels bregma 1.2 and bregma 1.3 (Paxinos et al., 1982), from the 
two brain sides were separately microdissected under the stereomicroscope, frozen in dry ice and 
stored at -80°C until assayed. This procedure, which has been used for many years in our lab 
(Ciani  et  al.,  2001;  Contestabile  et  al.,  2004;  Crochemore  et  al.,  2005),  allows  reproducible 
dissections of equivalent samples from different animals without compromising reliability of the 
neurochemical  determinations indicated below. Samples were homogenized in 0.32 M sucrose, 
added with 0.5% Triton X-100 (final concentration) and the whole homogenate was used to assay 
the activity of the cholinergic marker, choline acetyltransferase (ChAT) (Fonnum et al., 1975) and 
of the GABAergic marker, glutamate decarboxylase (GAD) (Fonnum et al., 1977), as well as sample 
protein content  (Lowry et  al.,  1951).  ChAT activity  was  assayed by incubating aliquots  of  the 
homogenates  containing  known amount  of  protein,  for  10–30  min  at  37°C in  the  presence  of 
choline (8 mM) and  14  CacetylCoA (0.2 mM, NEN, specific activity 51.6 mCi/mmol) and adding 
eserine  (0.1  mM)  to  block  acetylcholinesterase.  The  labeled  acetylcholine  formed  through  the 
enzymatic reaction was extracted by Kalignost (0.5% in acetonitrile), brought to the organic phase 
of a scintillation cocktail (Instafluor, Packard), counted and expressed as Amol formed/unit protein 
weight. GAD activity was assayed by incubating aliquots of the same samples for 1 h at 37°C in the 
presence  of  14C-glutamate  (21.6  mM,  NEN,  specific  activity  45  mCi/mmol),  trapping  the  CO2 
evolved by the enzymatic reaction with hyamine hydroxyde, counting and expressing the activity 
as  Amol  of  CO2 formed/unit  protein  weight.  We  knew  from  previous  experiments  that  glial 
proliferation consequent to the lesion does not alter the protein content of the affected regions 
(Virgili et al., 1992). 
Starting  from  40  days  of  age,  wild  type  and  G93A  transgenic  mice  were  divided  in  groups, 
composed of approximately the same number of males and females, which received standard diet 
or diet supplemented with 2% creatine. When 110 days old, an age at which disease symptoms are 
manifested in G93A mice and cholinergic deficit is evident not only in the degenerating segments 
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of the spinal cord, but also in some forebrain regions (Crochemore et al., 2005), wild type mice and 
part of the G93A ones were killed by decapitation. 
Samples from the lumbar spinal cord, the hippocampus,  the olfactory cortex and the striatum 
(Franklin et al., 1997) were rapidly collected in parallel by two experienced operators and stored in 
the deep freezer for subsequent determination of ChAT activity.
The remaining G93A mice were used to assess survival and were therefore maintained under the 
different diets until euthanized when they reached the final stage of the disease, characterized by 
complete limb paralysis and inability to move and feed. 
Statistical  analysis  was  carried  on  through  Student’s  t  test  or  analysis  of  variance  (one  way 
ANOVA) followed by post-hoc Bonferroni’s test. The number of animals used for each experiment 
is indicated in figure legends. Experiments were performed in accordance with the Italian and 
European Community law on the use of animals for experimental purposes and were approved by 
the University of Bologna bioethical committee. Throughout the study, animals were kept under 
veterinary surveillance for their comfort and health.
ODC/polyamine system alterations in ALS-G93A mice
For the study of the polyamine system in ALS G93A mice, animals from each group, taken at pre-
symptomatic  (55  days  of  age)  and  at  symptomatic  (125  days  of  age)  stages,  were  killed  by 
decapitation and the selected regions from brain and spinal  cord were immediately dissected, 
frozen in dry ice and stored at°80°C until used.  
ODC activity
To extract the enzymatic protein, tissue from the different samples was homogenized in ice-cold 50 
mMTris–HCl (pH 7.5), containing 0.1 mMEDTA, 5 mM dithiothreitol and 0.04 mM pyridoxal-5-
phosphate, by a motor-driven homogenizer equipped with a Teflon pestle (1200 rpm, 12 strokes). 
The homogenate was centrifuged at 18,000  g  for 20 min and aliquots of the supernatants were 
transferred to small tubes where they were assayed essentially according to a previous described 
procedure (Baudry et al., 1986). Briefly, samples were incubated (for 1 h at 37 8C) with a reaction 
mixture  containing [14C]ornithine  as  a substrate  (NEN, specific  activity  40–60 mCi/mmol,  final 
concentration 0.05 mM). At the end of the decarboxylation reaction, the [14C] CO2 released was 
trapped using hyamine hydroxide and measured by liquid scintillation spectrometry.  Enzyme 
activity was expressed as CO2 released/unit of protein content in the supernatant (Lowry et al., 
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1951).
Determination of polyamines
The determination of the three polyamines, putrescine, spermidine and spermine, was performed 
by  HPLC  after  pre-column  derivatization  with  dansyl  chloride.  The  tissue  samples  from  the 
various CNS regions were homogenized in 5–10 volumes of 0.3N HClO4 (1000 rpm, 14 strokes) 
and the homogenate was centrifuged at 14,000  g  for 15 min. The pellet was dissolved in 0.5N 
NaOH and subsequently utilized for protein content determination by the method of Lowry et al. 
(1951). To obtain the dansylation of polyamines, 300  ml of a standard mixture (containing 1.25 
nmoles of putrescine and 10 nmoles of spermidine and spermine) and 300 ml of the supernatant 
from  every  sample  were  added  to  20  ml  of  100  mM  1,8-diaminooctane,  used  as  an  internal 
standard, 20 ml of 3N KOH and 180 ml of 1.5 M Na2CO3 (pH 10.5). After adding 0.8 ml of a dansyl 
chloride solution (8 mg dissolved in 1 ml acetone), the reaction mixture was allowed to stay in the 
dark overnight. At the end of the incubation, 200 ml of 0.3N KOH were added and the dansylated 
polyamines  were  extracted  in  1  ml  of  diethyl  ether  under  vigorous  shaking  conditions.  The 
samples were then gently centrifuged and 900 ml of the diethyl ether phase were transferred, dried 
under vacuum and resuspended in 400 ml of methanol. Twenty ml of this sample were injected 
into a twin pumps HPLC apparatus equipped with a reverse phase C18 column (4.6 mm 150 mm, 
5  mm ODS) and with a fluorimetric detector set at an excitation wavelength of 340 nm and an 
emission wavelength of 510 nm. Polyamines were eluted at a flow rate of 1.2 ml/min with a mobile 
phase resulting by mixing two solutions: eluent A (50% water, 30% acetonitrile and 20% methanol) 
and eluent B (60% acetonitrile and 40% methanol). The elution was performed by a linear gradient 
changing from 50 to 100% B in 16 min.
Statistical analysis
To assess  the  significance of  the differences  between the experimental  groups all  results  were 
subjected  to  one  way analysis  of  variance  (ANOVA)  followed by Bonferroni  post  test  only  if 
overall p < 0.05.
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Proteomics studies
Insoluble protein fraction extraction
For the proteomic study of insoluble protein complexes, male animals from each group were taken 
at an early pre-symptomatic (6 weeks of age) and an early symptomatic (11 weeks of age). Males 
were taken to exclude possible gender variability.
The animals were anesthetized with 70mg/kg of pentobarbitone and perfused with PBS containing 
4U/ml of heparin at a constant flow of 25ml/min using a pump in order to wash out blood that 
could otherwise interfere with the 2D PAGE analysis. The spinal cords were then quickly dissected 
and snap frozen in liquind nitrogen and then stored at 80°C until needed. 
6 spinal cords from 6-week and 6 spinal cords from 11-week old transgenic mutant animals and 
control littermates were used for bidimensional electrophoresis. The insoluble protein fraction was 
extracted using a modified Wang protocol (Wang et al., 2002) in order to make it compatible with 
subsequent bidimensional electrophoresis.  The spinal cords were weighed and all buffers were 
added  in  a  1:10  proportion  according  to  tissue  weight.  Briefly,  the  spinal  cords  were  firstly 
homogenized in  TEN-1 (100mM Tris  pH 8.0,  25mM EDTA pH 8.0,  400mM NaCl)  and TEN-2 
(100mM Tris pH 8.0 , 25 mM EDTA pH 8.0, 400mM NaCl, 1% NP-40, 2X sigma protease inhibitor 
cocktail) buffers and then sonicated with a probe sonicator (70W; TEKMAR, Cincinnati, OH, USA) 
in ice at 40% intensity for 3 cycles of 30 seconds. An aliquot of this first fraction was stored for 
further western blotting analyses and stored at -80°C. The samples were centrifuged in an Optima 
(Beckman) preparative ultracentrifuge at 100,000xg, 4°C for 10 minutes. The supernatant (S1) was 
then stored and 1:10 volumes of TEN-3 (100mM Tris pH 8.0, 1% NP-40) were added to the pellet 
(P1) and then the samples were sonicated in ice at 40% intensity for 3 cycles of 30 seconds in ice 
and centrifuged at 100,000xg, 4°C for 10 min.  The supernatant (S2) was stored and 1:10 volumes of 
TEN-4 (100mM Tris pH 8.0, 1% NP-40, 0.25% SDS, 0.5% sodium deoxycholate) buffer were added 
to  the  pellet  (P2)  and the  samples  were  sonicated (no ice)  at  40% intensity  for  3  cycles  of  30 
seconds. The samples were then centrifuged at 100,000xg, 4°C for 10 min. The supernatant was 
stored (S3) and the remaining pellet was washed again with another 1:10 volumes of TEN-4 buffer 
and centrifuged at 100,000xg, 4°C for 10 minutes. The supernatant was completely removed and 
the  remaining  pellet  (P3)  was  solubilzed  using  2D-PAGE  rehydration  buffer  (8M  urea,  0.5% 
CHAPS) and sonicated at 40% intensity for 3 cycles of 10 seconds to prevent overheating of the 
samples that could lead to protein carbamylation and create artifacts.  The samples were left to 
48
CHAPTER 2: MATERIAL AND METHODS
solubilize in a spinning wheel overnight and the next day spun at 13,000 rpm for 10 min to remove 
any insoluble material. 
Protein content assay
A Non-Interfering Protein Assay (NIPA, G-Biosciences St. Louis MO, USA) was used to assay all 
samples. The manufacturer's protocol was used for all samples.
2D-electrophoresis
Strip rehydration
50ug of P3 fraction were made up to 350ul with rehydration buffer and DTT, pharmalytes and 
bromophenol blue were added  (8M urea, 0.5% (w/v) CHAPS, 0.8% (v/v) pH 3-10 GE Healthcare 
Pharmalytes, 18mM DTT, 0.002% (w/v) bromophenol blue (Sigma). The samples were loaded into 
a  rehydration strip  tray and 18cm pH3-10  non-linear  IPG strips  (GE Healthcare)  were  loaded 
facing the samples and let to rehydrate for at least 10 hours (overnight). 
First dimension
The next day, the first dimension was run using a Multiphor II (GE Healthcare) at 50uA per strip 
using the following steps:
Step Voltage Time (minutes)
1 100 V 60
2 150 V 60
3 300 V 60
4 600 V 30
5 1200 V 30
6 1800 V 30
7 2400 V 30
8 3000 V 30
9 3500V up to 80kV Total
The first  two steps were run at a low voltage in order to eliminate ions from salts  that could 
otherwise interfere with the focusing step. The electrode wicks were changed after the two one-
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hour initial steps and by the end of the day. Once the first dimension was finished, the strips were 
stored at -80°C until needed for the second dimension.
Strip equilibration
Before  the  second  dimension,  the  strips  needed  to  be  equilibrated.  The  equilibration  was 
performed by incubating the strips in equilibration buffer (6M urea, 75mM Tris-HCl ph 8.8, 29.3% 
(v/v) glycerol, 2% (w/v) SDS, 0.002% (w/v)  bromophenol blue) first in 1% DTT for 15 minutes and 
then in 2.5% iodoacetamide for 15 minutes.  Following the equilibration, the strips were briefly 
washed in Laemli SDS electrophoresis buffer (25mM Tris base, 192mM glycine, 0.1% SDS).
Second dimension
During the second dimension, proteins migrate along the strip and once they reach their isolectric 
point, that is the pH where they are not anymore charged, they stop migrating. The equilibrated 
strips were loaded onto 12% acrylamide gels by gently pushing them down against the top part of 
the gel making sure not to trap any air bubbles between the gel and the IPG strip. 2ul of  RPN800 
rainbow protein marker (GE Healthcare) were loaded onto filter paper and loaded next to the IPG 
strips.  The IPG strips were overlaid with agarose sealing solution (0.5% (w/v) agarose,  0.002% 
(w/v) bromophenol blue in Laemli SDS electrophoresis buffer) in order to keep them on top of the 
gels all throughout the second dimension. The second dimension was performed in an Ettan Dalt 
six  (GE  Healthcare)  tank  using  the  following  protocol  keeping  the  buffer  tank  temperature 
constant at 20°C  all throughout the second dimension:
30 min at 2W per gel
5-6 h at 15 W gel until the blue dye front reached the bottom of the gel.
Silver staining
All  solutions were prepared as  described in the table  below. After  the second dimension was 
completed, the gels were taken out from the glass plates and places in glass trays with enough 
fixing solution  and stored overnight at 4°C.
The next day, the fixing solution was removed and enough sensitizing solution was added to the 
gels and incubated on a shaker for 30 minutes at RT. Glutaraldehyde was added just before the 
sensitizing solution was added to the gels. The gels were then washed 3 times for 5 minutes with 
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double-distilled water and then the gels were incubated with the silver solution  for 20 minutes at 
RT.  Formaldehyde  was  added  fresh  to  the  silver  solution  prior  to  incubating  with  the  gels. 
Following this incubation, the gels were  quickly washed 2 times for 1 minute with double distilled 
water and then the developing solution was added to the gels. Formaldehyde was added fresh to 
the developing solution before the gels were incubated. The best incubation time according to spot 
number and background intensity  was determined empirically.  All   gels were incubated for 7 
minutes in order to increase reproducibility of the spots visualized on the gels and to avoid high 
background. In order to stop the silver staining reaction, the developing solution was removed and 
the gels were incubated with stop solution  for at least 10 minutes. The gels were then washed 3 
times for 5 minutes with double distilled water and stored in sealed plastic  bags with double 
distilled water at 4°C until required for image scanning for computer analysis.
Silver stain fixing solution
40% (v/v) ethanol, 10% (v/v) acetic acid
Final concentration 
Ethanol, absolute 40%
Acetic acid, glacial 10%
Sensitizing solution
30% (v/v) ethanol, 6.8% (w/v) sodium acetate, 0.2% (w/v) 
sodium thiosulphate, 0.125% (v/v) glutaraldehyde
Final concentration 
Ethanol, absolute 30%
Sodium acetate, anhydrous (FW 82.03) 6.8%
Sodium thiosulphate, pentahydrate (FW 248.18) 0.2%
25% glutaraldehyde 0.125%
Silver solution
0.25% (w/v) silver nitrate, 0.015% (v/v) formaldehyde
Final concentration 
Silver nitrate (FW 169.87) 0.25%
37% formaldehyde 0.015%
Developing solution
2.5% (w/v) sodium carbonate, 0.0074% (v/v) formaldehyde
Final concentration 
Sodium carbonate, anhydrous (FW 105.99) 2.5%
37% formaldehyde 0.0074%
Stop solution
1.5% (w/v) Na2EDTA
Final concentration 
Na2EDTA (ethylenediaminetetraacetic acid, disodium salt) (FW 
372.24) 
1.5%
Computer analysis
Phoretix  2D  evolution  v2005  (now  Progenesys  PG600,  Non-linear  dynamics)  was  used  for 
computer analysis following these guideline steps:
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1. Spot detection. All intensity signals above the gel background are considered to be spots by 
the program. Care should be taken as some detected spots can actually be false positives 
due to impurities or gel handling. Therefore detected spots should also be checked one by 
one by the user.
2. Gel matching. The detected spots are then matched between all the gels. Manual matching 
of spot patterns that can be recognized by eye can help by setting some spot matches as 
seeds that can further aid the program to finish automatic matching.
3. Gel warping. Once gel matching has been done, gel images can be warped or overlapped 
on each other to increase positive matches. Manual warping by introducing some manual 
anchors  according  to  visible  spot  patterns  can  aid  automatic  warping.  After  warping, 
matching should be performed once again and this process is repeated until the percentage 
of positive matches is high enough to proceed with analysis. At least 80% of positive spot 
matching was used for this project.
4. Background subtraction. The background value from each gel is subtracted from each spot 
value.
5. Spot normalization. In order to be able to compare similar spots from different gels, the 
spot intensity values need to be normalized by creating an absolute ratio when compared 
with the total spot intensity from each gel.
6. The normalized spot  intensity  values  can then be  used for  statistical  analysis.  For  this 
project, 6 gels for each disease stage and animal type were used (6+6+6 animals 6 weeks, 
6+6+6 animals 11 weeks). 
7. Image production. 2D images can be directly created by selecting a specific area with the 
cursor from the visualized image and then copied onto the clipboard. 3D images can be 
created using the same specific selected area and then using the 3D visualization option. 
Protein spot peaks can be reduced or increased with this function and the images can be 
rotated as well.
Statistical analysis of 2D gel derived data
Comparative quantitative analysis is performed by resolving the ratio for a single protein spot 
between experimental groups. That is, the mean normalized volume of a spot in the Experimental 
group is divided by that for the same spot in the Control group. This enables the detection of spots 
of increased or decreased expression in the Experimental group. Comparisons were made between 
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all experimental groups, i.e. G93A vs hSOD, G93A vs non-transgenic and hSOD vs non-transgenic. 
Firstly,  an F-Test  was performed, to determine whether the variances in the experimental  and 
control groups were significantly different, using a two-tailed probability calculation, where p was 
set at 0.05. F-Test could not obviously return any value for spots that were present in less than two 
gels. The F-Test result was then used in a ‘nested’ Student’s T-Test. Based on the F-Test result two 
versions of the Student’s T-Test were performed (assuming either equal or non-equal variance) for 
the means of each spot, and a statistically significant result was reported after setting the P value at 
0.05. A list of spots with at least a 2-fold change in normalized expression between G93A and 
hSOD as well as G93A and non-transgenic was produced.
Preparative gels
For preparative gels 400ug of protein were loaded per 18cm pH 3-10NL IPG strip (GE Healthcare). 
The first dimension protocol was similar to the analytical gel protocol but required more time to 
achieve 80kV. The second dimension protocol was also similar to the analytical gel protocol and 
required more time as well because of increased protein load. The silver staining protocol was 
performed  the  same  way  as  for  analytical  gels  except  that  for  the  sensitizing  step  where 
glutaraldehyde  was  omitted  and  the  silver  staining  step  where  formaldehyde  was  omitted. 
Formaldehyde was kept in the developing solution instead.
Mass spectrometry
Spots of interest were excised using the One Touch Plus (Web Scientific; Crewe, UK) spot picking 
pipettes from MS compatible preparatory gels (see 2.7.3). Two sizes of pipettes and tips were used 
to remove either 1.5mm or 3.0mm diameter spots from 2D gels. A new tip was used for every spot, 
eliminating cross contamination from one sample to the next. Spot excision was performed in clean 
environment and eppendorf tubes were rinsed with ddH2O in order to minimise contaminating 
proteins such as keratin entering the protein identification workflow at this stage.
In-gel trypsinolysis was performed using an Investigator Progest (Genomic Solutions, Huntington, 
UK) robotic  digestion system (Westbrook  et  al.,  2001).  Tandem electrospray mass spectra were 
recorded  using  Q-Tof  hybrid  quadrupole/orthogonal  acceleration  time-of-flight  spectrometer 
(Waters, Manchester, UK) interfaced to a Waters CapLC capillary chromatograph. Samples were 
dissolved in 0.1% aqueous formic acid, injected into a Pepmap C18 column (300 μm x 0.5 cm; LC 
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Packings, Amsterdam, The Netherlands), and eluted into the electrospray with an acetonitrile/0.1% 
formic acid gradient (5-70% acetonitrile over 20 min).
Data-dependent MS/MS acquisitions were performed on precursors with charge states of 2, 3, or 4 
over  a  survey mass  range of  540-1200.  Known trypsin autolysis  products  and keratin-derived 
precursor  ions  were  automatically  excluded.  Proteins  were  identified  by  correlation  of 
uninterpreted tandem mass spectra to entries in SwissProt/TREMBL, using ProteinLynx Global 
Server (Wait  et al.,  2002). One missed cleavage per peptide was allowed, and the fragment ion 
tolerance was set to 100 ppm. Carbamidomethylation of cysteine was assumed, but other potential 
modifications were not considered in the first pass search. All matching spectra were reviewed 
manually, and in cases in which the score reported by ProteinLynx Global Server was less than 
100,  additional  searches  were  performed  against  the  NCBI  non-redundant  data  base  using 
MASCOT,  which  utilises  a  robust  probabilistic  scoring  algorithm  (Perkins  et  al.,  1999).  Mass 
spectrometry  was  performed by Prof.  Wait’s  group at  the  Kennedy Institute  of  Reumatology, 
Imperial College London.
Western blotting
10ug of protein extract per lane were loaded and separated in 10% acrylamide gels using Laemli 
SDS running buffer [25mM Tris base, 192mM glycine, 0.1% (w/v) SDS] in Mini-Protean 3 cells (Bio-
Rad) initially at 1W per gel until the samples entered the separation gel and then the power was 
set to 2W per gel until the blue dye front reached the bottom of the gel. 5ul of rainbow marker (GE 
healthcare, RPN800) were loaded per gel. The proteins from the gel were then transferred onto 
nitrocellulose membranes (Hybond-ECL, GE Healthcare ) in Mini trans-blot 3 cells (Bio-Rad) using 
transfer buffer (50mM Tris, 200mM glycine) at a constant current of 400mA for 2 hours. Large 
format gels destined for western blotting were run as described before in the second dimension 
section and were subjected to a semi-dry transfer at a constant current of 400mA for 2 hours in a 
Multiphor  II  unit  (GE  Healthcare).  Following  the  transfer,  Ponceaus-S  staining  [0.1%  (w/v) 
Ponceaus-S, 10% (v/v) acetic acid] was performed in order to check for transfer efficiency. The 
membranes were then first washed in ddH20,  then in TBS (2mM Tris pH 7.6, 1.37 M NaCl) for 5 
minutes and blocked with 5% (w/v) milk (BioRad) and TBS-Tween 20 0.1% (v/v)  (Sigma). After 
blocking, the primary antibodies were diluted in 3% milk TBS-T 0.1% and the membranes were 
incubated overnight at 4°C. The antibody used was sheep anti-SOD1 (1:3000, Calbiochem)  and 
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then  the  secondary  antibody  was  diluted  in  milk  3%  TBS-T  0.1%  and  the  membranes  were 
incubated  for  1  hour  at  RT.  The  secondary  antibody  used  was  donkey  anti-goat  (1:3000, 
Chemicon). Following the secondary antibody incubation, the membranes were washed 3 times for 
5 minutes with TBS-T 0.1% and then 1 time for 5 minutes in TBS. In the dark room, the membranes 
were incubated with ECL detection reagents (Chemicon),  wrapped with Saran wrap and X-ray 
film (GE Healthcare) was exposed to the membranes for the required times.
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Forebrain cholinergic system alterations in SOD1 mutant mice
Brain regional  neurochemistry at  different  stages  of  disease  progression assays were based on 
samples taken from G93A mice, wild-type transgenic mice and non-transgenic littermates at a pre-
symptomatic (55 days of age), a symptomatic (110 days of age) and an advanced symptomatic (125 
days of age) stages. In agreement with reports from the literature, motor behavior of G93A mice 
was normal at  55 days,  while  posterior  limb motility was clearly  affected at  110 days.  Severe 
paralysis of the posterior limbs and incipient paralysis of the anterior ones was evident at 125 
days.  Mean lifespan of  G93A mice (1365 days)  was  evaluated in  a group of  female  animals, 
euthanized at the terminal stage of the disease, which is characterized by complete limb paralysis 
and inability to eat and drink. Brain cholinergic systems were initially studied in various brain 
areas of the three groups of mice at 55 and 125 days of age by measuring ChAT catalytic activity. 
At 125 days of age, ChAT activity was significantly decreased in the hippocampus (22, 18%), the 
olfactory–entorhinal  cortex  (18,  20%)  and  the  fronto-parietal  cortex  (13,9%)  of  G93A  mice 
compared  to  wild-type  transgenic  mice  and  non-transgenic  littermates,  respectively  (Fig.  1A). 
These differences were clearly related to the disease progression, as they were not present at the 
pre-symptomatic stage (Fig. 1A). In other brain regions, such as the striatum and the cerebellum, 
no significant alterations of ChAT activity were measured (Fig. 1B). Neurochemical alterations of 
the forebrain cholinergic systems were already present at an earlier symptomatic stage (110 days of 
age) and showed a trend towards aggravation with age. This is demonstrated in Fig. 1C, where the 
percent decrease of ChAT activity in the various brain regions of G93A mice is plotted against the 
value of wild-type transgenic mice at the different ages examined. In the same brain regions, no 
significant alterations of the cholinergic–cholinoceptive marker, AchE, were measured (Table 1). 
Furthermore, the GABAergic system appeared completely unaffected in the hippocampus and the 
olfactory–entorhinal cortex regions showing the largest decrease of cholinergic activity (Table 1). 
Forebrain regions, in which cholinergic neurons projecting to the cortex and the hippocampus are 
localized, were examined by ChAT immunocytochemistry at 125 days of age. Compared to non-
transgenic  littermates,  in  G93A  mice  cholinergic  neurons  were  less  abundant  in  the  medial 
septum–ventral diagonal band (Fig. 2A and B) and appeared to some extent reduced in number 
also in the nucleus basalissubstantia innominata area (Fig. 2C and D). The striatum, possessing a 
well-characterized population of cholinergic interneurons, did not show any regressive alterations 
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of ChAT immunoreactive neurons (Fig. 2E and F). 
Neurochemical correlates of motor neuron degeneration in the spinal cord and brainstem
Assays of cholinergic activity at the main sites of motor neuron degeneration, the lumbar and the 
cervical  spinal cord as well  as the brain stem, revealed decreases in ChAT catalytic activity in 
G93A mice at a  symptomatic stage (125 days of age), while no changes were observed at 55 days 
of age (Fig. 3A). The reduction found in G93A mice reached 22–29% in the cervical spinal cord, 35–
39%  in  the  lumbar  spinal  cord  and  17–15%  in  the  brain  stem  when  compared  to  wild-type 
transgenic mice and non-transgenic littermates, respectively. In addition, AChE enzymatic activity 
was significantly decreased in both the spinal cord segments of 125-day-old G93A mice (Fig. 3B). A 
marker  for  GABAergic  neurons  (GAD)  was  unaffected  in  the  spinal  cord  of  G93A  mice,  as 
compared to wild-type transgenic animals.  When compared to non-transgenic littermates,  both 
types of transgenic mice showed a significant decrease of GAD enzymatic activity at the cervical 
spinal cord level (Fig. 3C). Immunocytochemistry of cervical and lumbar spinal cord segments at 
125 days of  age showed that  most  large ChAT immunoreactive motor  neurons present  in the 
ventral  horn  of  non-transgenic  littermates,  had  disappeared  in  G93A  animals  (Fig.  4).  At  the 
neurochemical level, a significant decrease of ChAT activity was already detectable in the spinal 
cord and the brain stem of G93A mice at 110 days of age (Fig. 5). Other assays (AChE and GAD) 
carried on at 110 days of age, gave results similar to those reported above for the 125 days stage. In 
particular, AChE activity was already significantly decreased in both the cervical and the lumbar 
spinal cord of G93A mice while GAD activity showed no differences (data not shown). As these 
data indicated that a substantial loss of spinal motor neurons was already occurring in G93A mice 
at 110 days of age, we used this stage to obtain an evaluation of presumably apoptotic cell death, 
an aspect of human ALS and of mutated SOD1 animal models that has raised controversies in 
recent literature (reviewed in Guegan and Przedborski, 2003). By using a sensitive assay to detect 
the amount  of  nucleosomal  DNA fragmented in an apoptotic  like  way in  tissue  homogenates 
(White and Barone, 2001;Monti and Contestabile, 2003),  we found significantly higher levels of 
DNA fragmentation in the lumbar spinal cord of G93A mice compared to wild-type transgenic 
animals,  while  no significant  differences  were detected in homogenates  from a cortical  region 
taken from the same animals (Fig. 6). 
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Fetal choline supplementation and postnatal ALCAR  treatment
In rats, fetal choline administration has been shown to favorably affect the development of the 
forebrain cholinergic system (Meck et al., 1989; Williams et al., 1998; Sandstrom et al., 2002; Meck 
et al., 2003).
Two  groups  of  G93A  mice  and  non-transgenic  littermates  supplemented  with  choline  during 
gestation were used to assay,  at  125 days of  age,  ChAT levels  in spinal  cord and some brain 
regions in order to verify  whether the treatment was able to modify the adult levels of cholinergic 
activity and/or to counteract the cholinergic deficit found to be present in symptomatic G93A mice. 
As shown in Table 2, gestational choline supplementation did not result in any relevant effect on 
the decline of ChAT activity in the spinal cord and the brain regions assayed in G93A with respect 
to  non-transgenic  littermates  (compare  percent  decreases  with  those  derived  from  Fig.  1A). 
Interestingly, however, by comparing the absolute value of the catalytic activity of gestationally 
choline-supplemented mice (Table 2) with the respective values of their untreated counterparts 
(data from Figs. 1 and 3), it resulted that these values were significantly ( p < 0.001, Student’s t-test) 
higher  in  choline  supplemented  mice,  basal  ChAT  activity  resulting  increased  by  30–55% 
depending on the  region considered.  The catalytic  activity  of  AChE was  not  affected by fetal 
choline supplementation (data not shown). Survival of gestationally choline supplemented G93A 
mice was not significantly different from that of untreated animals (mean lifespan was 136 5 days 
for G93A untreated mice compared to 138 3 days for choline supplemented animals; means S.E. for 
groups of five to seven female mice). In rats, long-term administration of ALCAR has been claimed 
to be neuroprotective by positively affecting the brain cholinergic systems (Piovesan et al., 1994; 
Taglialatela  et  al.,  1994).  G93A  mice  supplemented  or  not  with  choline  during  gestation  and 
administered with ALCAR  from postnatal day 40 until death did not show any improvement of 
their survival (mean lifespan was 130 ± 6 days for ALCAR supplemented mice and 139 ± 3 days for 
choline plus ALCAR supplemented mice; means S.E. for groups of five to seven female mice).
Glutamine synthetase activity
As gliosis  has  been  repeatedly  reported  to  parallel  motor  neuron  loss  in  the  spinal  cord  of  ALS 
patients and SOD1 animal models, we also measured the activity of glutamate synthetase, an enzyme 
that is considered to be an astrocytic marker and that has been shown to increase in experimental 
models of  neurodegeneration (Virgili et al., 1992). As shown by the data presented in Table 3, we did 
not find any significant alteration of glutamine synthetase activity in the spinal cord, as well as in 
some other brain regions, of G93A mice with respect to controls, at 125 days of age.
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Fig. 1. ChATactivity in brain regions of G93A, wild-type transgenic mice and 
non-transgenic littermates at 55 and 125 days of age (A and B). Bars represent 
the mean ±  S.E. of seven to nine animals. *p < 0.05, **p < 0.01 as compared to 
both wild-type transgenic mice and non-transgenic littermates, Bonferroni’s 
test after ANOVA. (C) Composite graph showing the percent decrease of ChAT 
activity in brain regions of transgenic mice carrying the mutated SOD1 gene at 
different ages. Results are expressed as percent activity found in G93A mice 
with respect to wild-type transgenic mice of the same age. Each point is the 
mean of seven to nine animals; (*) denotes statistically significant differences of 
at least p < 0.05 (Student’s t-test).
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Fig. 2. Cholinergic neurons, revealed through ChAT immunohistochemistry, 
in the medial septum–ventral diagonal band (A and B), in the nucleus 
basalis magnocellularis (C and D) and in the striatum (E and F) of 125-day-
old G93A mice and non-transgenic littermates. Note the decreased number 
of immunopositive neurons in the basal forebrain areas of G93A mice . 
Calibration bar: 150 mm.
Table 1
Ache GAD
G93A WT SOD1 G93A WT SOD1
Cerebellum - - -
- - -
- - -
Olfactory cortex
seven to nine animals
AchE and GAD activity in various brain regions of the three groups of mice at 125 days of age
Non transgenic Non transgenic
2.39±0.37 2.44±0.22 2.9±0.14
Striatum 45.4±1.2 38.2±2.9 42.2±2
Cortex fronto-parietal 5±0.12 4.5±0.15 4.8±0.17
9±0.29 8.3±0.5 7.9±0.3 100±9 110±9 114±9
Hippocampus 7±0.17 6±0.17 6.7±0.56 56.1±3.1 56.1±2.7 53.1±1.4
     Data are expressed as mmole/g prot/h for AChE and mmole/g prot/h for GAD and are the mean ± S.E. of 
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Fig. 3. Enzyme activities in the spinal cord and brainstem of the three groups of 
mice . Bars represent the mean ± S.E. of seven to nine animals. *p < 0.05, **p < 0.01 as 
compared to both wild-type transgenic mice and non-transgenic littermates, 
Bonferroni’s test after ANOVA.
Fig. 4. Cholinergic motor neurons in the ventral horn of the spinal 
cord of G93A mice and non-transgenic littermates at 125 days of 
age . Note  the dramatic decrease  of the large cholinergic motor 
neurons in the G93A mice . Calibration bar: 50 mm.
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Fig. 6. Evaluation of nucleosomal DNA fragmentation through ELISA method in tissue extract from 
110-day-old mice. Bars are  the mean ± S.E. of three animals. ***p < 0.001 as compared to wild-type 
transgenic animals and non-transgenic littermates, Bonferroni’s test after ANOVA.
Fig. 5. Composite graph showing the percent decrease  of ChATactivity in the spinal cord 
and brain stem of transgenic mice carrying the mutated SOD1 gene at different ages. 
Results are expressed as percent activity found in G93A mice with respect to wild-type 
transgenic mice of the same age. Each point is the mean of seven to nine animals. (*) 
Denotes statistically significant difference  of at least p < 0.05 (Student’s t-test).
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Table 3
125 days
G93A WT SOD1
Cervical spinal cord
Lumbar spinal cord
Olfactory cortex
Glutamine synthetase in the spinal cord and brain regions
Non-transgenic
2.42±0.12 2.26±0.10 2.3±0.08
1.71±0.09 1.55±0.13 1.8±0.10
Brainstem 1.92±0.04 1.71±0.05 2.07±0.15
Hippocampus 1.46±0.10 1.69±0.11 1.88±0.10
2.46±0.16 2.22±0.15 2.05±0.10
Data are expressed as mmol/g prot/h and are the mean ± S.E. of seven to nine animals
G93A
(NT)
Cervical spinal cord 46.7±2.5 29** 19**
Untreated
Choline supplemented
Lumbar spinal cord 39** 32**
Untreated
Choline supplemented
Untreated 55.6±1.9 17.4** 16**
Choline supplemented
Olfactory cortex
Untreated 20** 22.5**
Choline supplemented
 (p < 0.01, Student’s t-test).
Chat activity in choline-supplemented G93A and non-transgenic littermates at 125 days of age
Non-transgenic
% ChAT decrease 
respective to NT 
(untreated)
% of ChAT decrease in 
G93A respective to NT 
(choline-supp)
65.5±2.3
86.1±1.4 (131%)º 69.7±2.3
66.4±4.5 40.7±7.4
103±3 (155%)º 69.8±2.1 (171%)
Hippocampus
45.9±2.8
88.5±2.1 74.6±2.7
88.7±3.8 70.8±12.4
133±3 (150%)º 103±2
Data are expressed as mmole/g prot/h and are the mean ± S.E. of six to nine animals.
º Denotes that the percent difference with respect to untreated animals (in brackets) is statistically significant
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Differential neuroprotecion by creatine supplementation
The dose of creatine supplementation used for present experiments was the same recently adopted 
for studies of neuroprotection in rats and mice, including G93A mice (Dedlu et. al., 2003; Klivenyi 
et al., 1999; Matthews et al., 1998;  Matthews et al., 1999). Creatine is transported to body organs, 
including the brain, where it is assumed by cells through an active membrane transport system 
(Ipsiroglu et al., 2001). Long-term (4–8 week) oral administration of creatine, resulting in average 
intake  similar  to  the  one  produced  by  our  diet,  increased  by  15–30%  total  creatine  and 
phosphocreatine  concentration  in  brain  of  rats  and  mice  [18].  Rats  fed  with  normal  or  with 
creatine-enriched  diet  did  not  show  any significant  difference  in  daily  food  intake  and  body 
weight increase. Unilateral intrastriatal injection of ibotenic acid in rats resulted in large depletion 
of  markers  for  cholinergic  and GABAergic  striatal  neurons (Fig.  7),  reflecting  the  widespread 
excitotoxic death of these neurons,  as previously shown (Ciani et al.,  2001).  Long-term feeding 
with creatine-enriched diet was remarkably neuroprotective towards the excitotoxic lesion. In the 
IBO-injected  striatum,  the  marker  for  cholinergic  neurons,  ChAT,  was  decreased  by  63%  as 
compared to the contralateral side in normally fed rats, while the decrease was only 32% in rats fed 
with creatine-enriched diet (Fig. 7A). Similarly,  the marker for GABAergic neurons,  GAD, was 
decreased by 68% in the IBO-injected striatum of normally fed rats, while it was significantly less 
reduced  (49%)  in  rats  fed  with  creatine  enriched  diet  (Fig.  7B).  Interestingly,  while  creatine 
supplementation  did  not  affect,  per  se,  the  striatal  ChAT  level,  the  GABAergic  marker  was 
significantly increased (+35%) in the saline-injected striatum of rats fed with creatine-enriched diet 
(Fig. 7B). The levels of enzymatic activities measured in saline injected striata were not different 
from those present in sham-operated animals assayed in parallel (Figs. 7A, B). In a different model 
of excitotoxicity, IBO injection in the nucleus basalis magnocellularis (NBM) with degeneration of 
cholinergic  basal  forebrain  neurons  and consequent  decrease  of  cholinergic  innervation  to  the 
cortex (Casamenti et al., 1998; Contestabile et al., 2004), dietary creatine supplementation was not 
neuroprotective, as in both groups of rats a similar decrease of ChAT activity in the ipsilateral 
cortex was recorded (Fig. 8).
In G93A SOD1 mutant mice,  the progression of the ALS-like disease can be monitored by the 
decrease of the cholinergic marker, ChAT, not only in the affected regions of the spinal cord where 
cholinergic  motor  neurons  degenerate,  but  also  in  some  forebrain  areas  receiving  cholinergic 
innervation  from  basal  forebrain  cholinergic  neurons  (Crochemore  et  al.,  2005).  Creatine 
supplementation results in increased survival of G93A mice and in delay of  some disease-related 
symptoms (Klivenyi et al., 1999; Zhang et al., 2003) and it may, therefore, favorably affect the loss 
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of the cholinergic marker. In the present experiment, 2% creatine supplementation starting at the 
age of 40 days resulted in a small, but significant, increase in the survival of transgenic mice (mean 
lifespan of normally fed G93A mice:  132.4  ±  2.6 days;  mean lifespan of creatine-supplemented 
G93A mice: 142 ± 3 days; n = 7, P < 0.05, Student’s t test). Some G93A mice were sacrificed at the 
age of 110 days, together with age-matched wild type littermates, as at this stage of progression the 
disease is already characterized by significant decrease of ChAT activity in the spinal cord, as well 
as in some forebrain areas (Crochemore et al., 2005). The levels of ChAT activity in wild type mice 
were  not  changed  by  the  different  dietary  regimen  in  any  of  the  regions  examined  and, 
accordingly,  data  from these  animals  were  pooled together.  In  the  lumbar  spinal  cord,  ChAT 
activity was similarly decreased in G93A mice, either fed with normal or creatine-supplemented 
diet, compared to wild type animals (Fig. 9A). In the olfactory cortex and the hippocampus of the 
same mice, instead, the decrease in ChAT activity present in G93A mice at 110 days of age was 
completely  counteracted by the long-term dietary supplementation with creatine (Figs.  9B,  C). 
Interestingly, also in mice, creatine supplementation increased GAD activity in the striatum, but 
not in the hippocampus of both wild type and transgenic mice (Fig. 10).
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Fig. 7. Effect of long-term creatine supplementation on neuroprotection of striatal cholinergic and GABAergic 
neurons from ibotenic acid excitotoxic insult. Bars are  the mean ±  SE of 7 animals per group. (A) ChAT 
activity in the striatum of IBO-injected rats fed with normal- or creatine-supplemented diet, compared to the 
saline-injected striatum or to the striatum of shamoperated rats. (B) GAD activity assayed in the same 
samples. **P < 0.001 vs. respective  saline-injected striata; #P < 0.01 vs. the striatum of normal diet-fed rats. 
Bonferroni’s test after ANOVA.
Fig. 8. Lack of effect of long-term creatine 
supplementation on the degeneration of the basal 
forebrain-neocortex cholinergic system. Bars are  
the mean ± SE of 7 animals per group. **P < 0.001 vs. 
corresponding samples of saline-injected rats. 
Bonferroni’s test after ANOVA.
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Fig. 9. Differential e ffect of long-term creatine 
supplementation on the cholinergic marker in the 
spinal cord and forebrain areas of G93A mice  at 
110 days of age . Bars are the mean ± SE of 7 (G93A 
mice) or 10 (wild type mice) animals per group (A) 
ChAT activity in the lumbar spinal cord of wild type 
and transgenic mice . (B) ChAT activity in the 
olfactory cortex of wild type and transgenic mice . 
(C) ChAT activity in the hippocampus of wild type 
and transgenic mice . *P < 0.05 vs. wild type mice; #P 
< 0.05 vs. creatine-supplemented G93A mice . 
Bonferroni’s test after ANOVA.
Fig. 10. Effect of long-term creatine 
supplementation on GAD activity in the striatum 
and hippocampus of wild type and G93A mice. 
Bars are the mean ± SE of 7 (G93A mice) or 5 (wild 
type mice) animals per group. *P < 0.05 vs. 
corresponding normally-fed animals. 
Bonferroni’s test after ANOVA.
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ODC/polyamine system alterations in ALS-G93A mice
ODC activity was measured in tissue extracts from cervical and lumbar tracts of the spinal cord, 
and brain stem (Fig. 11). In all cases no significant differences were found comparing G93A,wild-
type transgenic and non transgenic mice at a presymptomatic stage (55-day-old mice). By contrast, 
at  a  symptomatic  stage  (125-day-old  mice),  the  analysis  revealed  a  marked  increase  of  ODC 
activity in the spinal cord and brain stem of G93A mice, compared to both wild-type transgenic 
and non transgenic animals (Fig. 11). In  particular, ODC activity was about three times higher in 
cervical spinal cord and about four times higher in lumbar spinal cord of G93A mice. A smaller, 
but still significant, increase was detected in brain stem, where ODC activity was higher by 150–
200% in G93A mice compared to wild-type transgenic and non transgenic animals (Fig. 11). By 
contrast, the enzymatic activity did not show any significant change in the cortex and cerebellum 
of G93A mice,compared to wild-type transgenic and non transgenic animals, both at 55 and 125 
days of age (Table 4).
Tissue polyamine levels 
Figs. 12–14 show the amounts of the three main polyamines, putrescine, spermidine and spermine, 
measured in the cervical and lumbar spinal cord, as well as in the brain stem from 55-and 125-day-
old  G93A  mice  compared  to  wild-type  transgenic  mice  and   non  transgenic  littermates.  In 
agreement with alterations detected in ODC enzymatic activity, no differences were detected in 
younger animals, while levels of putrescine were consistently higher in 125-day-old G93A mice, 
compared to  wild-type transgenic  and non transgenic  animals.  In  the  cervical  spinal  cord the 
putrescine level of G93A mice was six times and 4.5 times that of wild-type transgenic and non 
transgenic animals, respectively (Fig. 12). In the lumbar spinal cord, putrescine increased about 
three times with respect to both controls (Fig. 13) and a smaller, but still significant increase was 
also  observed  in  the  brain  stem  of  G93A  mice  (Fig.  13).  As  shown  in  Figs.  12–14,  levels  of 
spermidine in both the cervical and lumbar spinal cord of G93A mice appeared higher, compared 
to the other two types of mice, but this difference was statistically significant only in the case of the 
cervical spinal cord. No significant differences were found in spermine levels in any of the regions 
examined, among the three experimental groups of animals. As shown in Table 5, no significant 
changes in the levels of any of the polyamines considered were detected among the three groups of 
experimental mice in the cortex and cerebellum,analyzed in 125-day-old animals.
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Fig. 11. ODC activity in spinal cord and brain stem 
of G93A, wild-type transgenic and non transgenic 
mice  at 55 and 125 days of age. Bars are  the mean 
± S.E.M. of seven animals. *p < 0.05, ***p < 0.001 as 
compared to non transgenic mice ; ###p < 0.001 as 
compared to wild-type transgenic mice, one way 
ANOVA with Bonferroni’s test.
Fig. 12. Polyamine content in the cervical spinal 
cord of G93A, wild-type transgenic and non 
transgenic mice  at 55 and 125 days of age. Bars 
are  the mean ± S.E.M. of five  to seven animals. **p 
< 0.01, ***p < 0.001 as compared to non transgenic 
mice ; ###p < 0.001 as compared to wild-type 
transgenic mice, one way ANOVA with 
Bonferroni’s test.
Table 4
 mice at 55 and 125 days of age
Days Days Cerebellum
NTG WT SOD1 G93A NTG WT SOD1 G93A
55 55
125 125
ODC activity in cerebral cortex and cerebellum of G93A, wild-type transgenic and non transgenic
Fronto-parietal cortex
3.09±0.51 3.27±0.24 3.48±0.41 2.59±0.35 2.41±0.28 2.37±0.27
3.41±0.39 3.86±0.22 3.56±0.16 2.22±0.28 2.37±0.28 2.29±0.29
Data, expressed as pmoles/mg protein/h, are the mean ± S.E.M. of four to six animals.
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Fig. 13. Polyamine content in the lumbar spinal 
cord of G93A, wild-type transgenic and non 
transgenic mice at 55 and 125 days of age. Bars 
are  the mean ±  S.E.M. of five to seven animals. 
***p < 0.001 as compared to non transgenic mice; 
###p < 0.001 as compared to wild-type transgenic 
mice , one way ANOVA with Bonferroni’s test.
Fig. 14. Polyamine content in the brain stem of 
G93A, wild-type transgenic and non transgenic 
mice  at 55 and 125 days of age. Bars are  the mean 
±  S.E.M. of 5–10 animals. #p < 0.05 as compared to 
wild-type transgenic mice , one way ANOVA with 
Bonferroni’s test.
Table 5
 mice at 125 days of age
Days Days Cerebellum
NTG WT SOD1 G93A NTG WT SOD1 G93A
Polyamine levels in cerebral cortex and cerebellum of G93A, wild-type transgenic and non  transgenic
Fronto-parietal cortex
Putrescine 0.042±0.007 0.022±0.003 0.049±0.008 Putrescine 0.116±0.043 0.107±0.032 0.263±0.06
Spermidine 2.389±0.097 2.069±0.104 2.304±0.129 Spermidine 6.197±0.285 5.650±0.503 6.160±0.66
Spermine 2.619±0.111 2.405±0.085 2.537±0.130 Spermine 5.154±0.181 4.910±0.426 4.820±0.46
Data, expressed as nmoles/mg protein, are the mean ± S.E.M. of six to seven animals.
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Proteomics of insoluble protein complexes
P3 fractions from mutant animal spinal cords showed strong immunoreactivity for SOD1 as shown 
by western blotting. It has previously been reported (Basso et al. 2006) that Triton extracted protein 
insoluble fractions that show strong SOD1 immunoreactivity in mutant G93A animals  are in part 
composed  of  polyubiquitinated  SOD1.  Notice  that  in  6  week-old  animals  there  are  no  high 
molecular bands when compared to 11 week-old animals:
Interestingly, these high  molecular weight bands were very strong in  the spinal cord and brain 
when compared to other tissues/organs such as muscle and liver (Fig 15A-F). The high molecular 
bands could not be detected in the whole homogenate in any of the animals (Fig. 15A) neither in 
the P3 fraction from asymptomatic animals (Fig. 15B). However they could already be detected in 
symptomatic  (Fig.  15C)  and  end-stage  (Fig.  15D-F)  animals.  Because  of  this  strong  SOD1 
immunoreactivity and high molecular bands in symptomatic animals, it was assumed that SOD1 
mediated insoluble aggregates could be present as well in this insoluble fraction (P3).
About 700-800 protein spots were detected in analytical gels by 2D-PAGE and silver staining as 
shown below (Fig.  16),  SOD1 is  circled in  red as  a  reference.  The  insoluble  protein was  also 
separated by 2D-PAGE, blotted onto nitrocellulose membrane and probed with a specific anti-
SOD1 antibody. However, because the signal spots were strong and too close, the observed signal 
was actually observed as a   blotch laying in the pH 4-7 range. Therfore we decided to further 
separate the insoluble fraction in a pH4-7 NL gradient and proceeded as before (Fig. 17). Several 
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Fig 15. Spinal cord extracts and P3 fractions probed against a specific anti-SOD1 antibody
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protein spots immunoreactive for SOD1 were found in G93A animals when compared to wild-type 
animals.
Common proteins in the insoluble fraction
A set of protein spots common to the three animal types was sequenced in order to have an idea of 
which proteins tend to be in the insoluble fraction. These proteins belonged mainly to metabolic 
pathways and cytoskeletal architecture as shown below:
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Fig. 17 2D-PAGE blotting of P3 fractions. The blotted P3 fractions were probed with a specific anti-SOD1 antibody. 
50ug of protein were loaded per 18cm IPG strips
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Some proteins present in the P3 fraction common to all 
animals
Protein Name PI Predicted 
MW kDa
Aproximate 
observed 
MW kDa
COX5A Cytochrome c oxidase polypeptide Va 6.5 16 15
COX5B COX5B_MOUSE Cytochrome c oxidase polypeptide Vv 8.8 13.7 15
CX6A1 Cytochrome c oxidase polypeptide VIa-liver 10.2 12.3 15
MBP Myelin basic protein 9.9 27.1 15
TBB3 TBB3_MOUSE Tubulin beta-3 4.9 50.4 20
TBB4 TBB4_MOUSE Tubulin beta-4 chain (20kD fragment) 4.8 49.6 20
TBB5 TBB5_MOUSE Tubulin beta-5 chain 4.8 49.6 20
VATB2 Vacuolar ATP synthase subunit B,brain isoform 5.7 56.5 50
ENOG Gamma-enolase 5.0 47.1 50
ATPB ATP synthase beta chain 5.3 56.2 50
NFL Neurofilament triplet L protein 4.6 61.5 60
Chain R 
COX
Chain R Bovine  Heart Cytochrome C oxidase 5.0 12.4 10
MYL6 Myosin light polypeptide 6 4.6 16.9 15
ATPD ATP synthase delta chain 5.0 17.6 15
hSOD1 Human Superoxide dismutase 5.7 15.9 18
ODPB Pyruvate dehydrogenase E1 component beta subunit 6.4 38.9 35
β-TUBULIN beta-tubulin 5.0 50.0 32
AINX alpha-internexin 5.2 55.7 60
NUHM NADH-ubiquinone oxidoreductase 24kDa subunit 7.0 27.3 25
VIME vimentin 5.1 53.7 42
GFAP* glial fibrillary acidic protein 5.36 49.9 variable
Successful spot sequences from MALDI-ToF
A total of 39 protein spots were identified as statistically significan differences. However only a 
total of 16 spots could be sequenced by MALDI-ToF.  In the 6 weeks age stage, 29 different protein 
spots were found to be statistically significant. Protein spots detected only in G93A animals but 
neither in non-transgenic  nor  hSOD transgenic  animals,  were  defined as  ON changes.  Upfold 
changes were defined as UP changes and downfold changes were defined as DOWN changes. The 
changes displayed were as follows: 12 ON changes (1 identity: TBB4), 7 UP changes (3 identities: 
all GFAP), 11 DOWN changes (7 identities: VATA1, VATB2, HSC70, GBB1, VDAC2x3). A total of 
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11 protein spots  were  sequenced in  this  stage.  In  the  11  week-age  stage  the  changes  were  as 
follows:  6 ON changes (4 identities: CRMP2, GFAPx3), 3 UP changes (1 identity: GFAP), 1 DOWN 
change. A total of 5 protein spots were sequenced in this stage.  A summary of the unsequenced 
protein spots is reported below:
A summary of the successfully sequenced and identified protein spots is shown below:
ratio ratio
Stage ID Name Change mut/wt mut/ntg PI MW 
kDa
Peptide 
matches
6 
weeks
TBB4 tubulin beta-4 ON 4.8 49.6 2
VATA1 vacuolar ATPase catalytic 
subunit A
DOWN 13.8 6.3 5.5 68.2 5
Q8CHX2/
HSC70
heat-shock protein 
70/ATPase H+ transporting 
V1 subunit A, isoform 1
DOWN 3.9 2.2 5.5/5.4 68.3/70
.8
1/1
VATB2 vacuolar ATPase subunit B2 DOWN 2.5 2.1 5.7 56.5 2
GBB1 guanine nucleotide-binding 
protein G(I)/G(S)/G(T) beta 
subunit 1
DOWN 2.1 2.4 5.9 37.3 5
VDAC2(1) volage-dependent anion 
channel 2
DOWN 5 9.6 7.8* 31.7 3
VDAC2(2) volage-dependent anion 
channel 2
DOWN 4 4.2 7.8* 31.7 3
GFAP glial fibrillary acidic protein varied varied varied varied varied varied
11 
weeks
CRMP2 collapsin response mediator 
protein-2
ON 6.3 62.2 4
GFAP glial fibrilary acidic protein varied varied varied varied varied varied
As reported in the table above, the only two proteins that could be detected in G93A gels but not in 
any of the control gels were TBB4 (six weeks) and CRMP2 (eleven weeks), so they were defined as 
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ON UP DOWN
3412 35 1532 35 1702 30 ON UP DOWN
874 50 1593 30 1791 25 2191 15 858 40 1341 25
899 50 1693 30 1924 75 777 40 890 40
1695 30 2733 10 1085 32
1822 25 1103 30
1879 25
1941 25
2165 23
2761 10
2845 10
6 weeks unsequenced protein spots
 kDa  kDa  kDa 11 weeks unsequenced protein spots
kDa  kDa kDa
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ON changes. All other statistically significant changes were reported as downfold changes. 2D gel 
images  and  representative  3D  images  were  created  for  the  successfully  sequenced  proteins 
comparing non-transgenic, transgenic mutant G93A hSOD1 and wild-type hSOD1 animals. The 
first 2D image shows the representative area in the gel where the spot of interest was present and 
another 2D image shows the specific protein spot. The 3D image is a 3D representation of the 2D 
image with the specific spots that gives a clearer idea of protein level differences. TBB4 at 6 weeks 
was recognized by Progenesys but was located in a very crowded area and it was not possible to 
create  good  2D  or  3D  images.  Only  those  protein  spots  that  showed  statistically  significant 
differences  in five out of  six  gels  and only protein spots  that  significantly changed in mutant 
animals when compared to the two control animals were chosen.  
VATB2  (6 weeks) showed an approximate two-time downfold (Fig. 17), VATA1 levels (6 weeks) 
showed  an  average  downfold  of  6  to  13  times  when  compared  to  controls  (Fig.  18). 
Q8CHX2/HSC70  showed an  average  downfold  between  2  and 4  times  (Fig.  18).  VDAC2 was 
present as three different spots, all with the same molecular weight but with different isoelectric 
points.  The spots had an average downfold change between 2 and 9 times when compared to 
controls (Fig.19-20). GBB1 (6 weeks) showed an average downfold of 2 times (Fig.21). GFAP was 
found at 6 and 11 weeks as different spots with different molecular weight and PI, showing both 
up and downfold changes (not shown). CRMP2 (11 weeks) in G93A animals was present as a very 
faint spot very close to other protein spots (Fig. 22). The 3D image is different from the previous 
ones because Proteomeweaver analysis software (BioRad) was used to create this representation in 
another laboratory.
Two different proteins Q8CHX2/HSC70 were actually detected in one protein spot. Both proteins 
have a very similar molecular weight and isoelectric point. 
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Fig. 18
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Fig. 19
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Fig 20
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Fig 21
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Fig 22
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Overview of the identified proteins
VATB2 and VATA1
Vacuolar ATP synthase subunit B (VATB2) also known as Vacuolar ATP synthase subunit B, brain 
isoform is a 56kDa protein that belongs to the ATPase alpha/beta chains family. It is a non-catalytic 
subunit of  the peripheral V1 complex of vacuolar ATPase (V-ATPase).  Vacuolar ATP synthase 
catalytic subunit A (VATA1) also known as Vacuolar ATP synthase catalytic subunit A, ubiquitous 
isoform is a 68kD protein that belongs to the same family as VATB2 and it is the catalytic subunit 
of  the  peripheral  V1  complex  of  vacuolar  ATPase.     ATPase  is  a  heteromultimeric  enzyme 
composed of a peripheral catalytic V1 complex (main components: subunits A, B, C, D, E, and F) 
attached to  an integral  membrane V0 proton pore  complex  (main component:  the  proteolipid 
protein).   Vacuolar ATPase is  a multisubunit  enzyme that mediates acidification of  eukaryotic 
intracellular  organelles.  V-ATPase  dependent  organelle  acidification  is  necessary  for  such 
intracellular processes as protein sorting, zymogen activation, receptor-mediated endocytosis, and 
synaptic  vesicle  proton gradient  generation.   VATB2 and VATA1 present  an  intracytoplasmic 
membrane and peripheral membrane location. 
Q8CHX2
ATPase  H+ transporting  V1  subunit  A,  isoform  1  (Q8CHX2)  also  known  as  ATPase,  H+ 
transporting, lysosomal V1 subunit A is a 68kDa protein that belongs to the ATPase alpha/beta 
chains family. It may be involved in organelle acidification.
HSC70
Heat shock cognate 71kDa protein also known as heat shock 70kDa protein 8 is, as the name states 
a 71kDa protein that belongs to the heat shock protein 70 family. It is present as two isoforms. This 
protein binds to nascent polypeptides to facilitate correct folding. It also functions as an ATPase in 
the disassembly of clathrin-coated vesicles during transport of membrane components through the 
cell  (De Luca-Flaherty et al.,  1990).   Its activity is suppressed by interacting with HSP105alpha 
(Yamagishi et al., 2004).  It has a cytoplasmic localization though it translocates rapidly from the 
cytoplasm to the nuclei, and especially to the nucleoli, upon heat shock (Tsukahara et al., 2004). 
Hsc70 has been reported in protein inclusions from sporadic ALS cases (Watanabe et al., 2001).
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VDAC2
Voltage-dependent  anion-selective  channel  protein  2  is  a  38kDa  protein  that  belongs  to  the 
eukaryotic mitochondrial porin family. It is ubiquitously expressed although it is a low-abundance 
VDAC  isoform.  It  forms  a  channel  through  the  mitochondrial  outer  membrane  which  allows 
diffusion  of  small  hydrophilic  molecules  and  adopts  an  open  conformation  at  low  or  zero 
membrane potential and a closed conformation at potentials above 30-40 mV. The open state has a 
weak anion selectivity whereas the closed state is cation-selective. VDAC2 is present as 6 different 
isoforms, all derived from alternative splicing. It  has been shown to bind the apoptotic protein 
Bak (Cheng et al., 2003). Because Bak binds and inactivates the antiapoptotic protein bcl-2 (Enyedy 
et al., 2001), VDAC2  also has an antiapoptotic function.
GBB1
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 1 also known as transducin beta 
chain 1,  is  a  37kDa protein.  Guanine nucleotide-binding proteins (G proteins)  are involved as 
modulators or transducers in various transmembrane signaling systems. G proteins are composed 
of 3 subunits, alpha, beta and gamma.The beta and gamma chains are required for the GTPase 
activity, for replacement of GDP by GTP, and for G protein-effector interaction. 
TBB4
Tubulin beta-4 chain, also known as tubulin 5 beta, is a 49kDa protein and belongs to the tubulin 
family. Tubulin is the major constituent of microtubules. It is a dimer of alpha and beta chains It 
binds  two  moles  of  GTP,  one  at  an  exchangeable  site  on  the  beta  chain  and  one  at  a  non-
exchangeable site on the alpha-chain. The highly acidic C-terminal region may bind cations such as 
calcium. 
CRMP2
Collapsin-response mediator protein-2 also known as Dihydropyrimidinase-related protein 2 is a 
62kDa protein that belongs to the dehydropyrimidinase family. It is ubiquitously expressed and 
has a  cytoplasmic localization. It has been reported to bind to tubulin and promote microtubule 
assembly   (Fukata  2002)  and to  transport  the  Sra-1/WAVE1  complex  to  axons  in  a  kinesin-1-
dependent manner, thereby regulating  axon outgrowth and formation (Kawano et al., 2005).  It 
has  also  been  linked  to  Alzheimer's  disease:  a  monoclonal  antibody  which  strongly  stains 
neurofibrillary  tangles  in  Alzheimer  disease  brains,  specifically  labels  CRMP2  when 
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phosphorylated on Ser-518, Ser-522 and Thr-509 (Gu et al., 2000). Aberrant expression of CRMP-2 
has been documented in fetal Down-syndrome brains (Weitzdoerfer et al., 2001).
GFAP
GFAP is a 50kDa type-III intermediate filament protein. It is a cell-specific marker that during the 
development  of  the  central  nervous  system,  distinguishes  astrocytes  from  other  glial  cells. 
Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous 
system (Der Perng et al., 2006). 3 isoforms have been so far reported. Isoform 3 (epsilon) interacts 
with the N-terminus of presenilin-1 (Nielsen et al.,  2002), involving this protein in Alzheimer's 
disease as well. An additional transcript variant has been described, but its full length sequence 
has not been determined. 
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Forebrain cholinergic alterations in SOD1 mutant mice
The  present  results  reveal  in  an  established  animal  model  of  human  ALS  that  the 
cholinergic  activity  of  cortical  and  hippocampal  areas  receiving  their  cholinergic 
innervations  from  the  basal  forebrain  neurons  significantly  decreases  at  symptomatic 
stages of the disease. Accordingly, at the same stages these cholinergic neurons appear 
remarkably reduced in number. These alterations temporally parallel the degeneration of 
lower motor  neurons.  Gestational  supplementation of  choline,  while  resulting in long-
term enhancement of cholinergic activity, was unable to increase the lifespan of transgenic 
mice or to counteract the cholinergic impairment in brain regions and spinal cord.
A previously unsuspected decrease of the cholinergic activity in some brain areas of G93A 
mice, namely the hippocampus, the olfactory–entorhinal cortex and, to a lower extent, the 
fronto-parietal cortex has been found in the present study. This effect is clearly linked to 
the disease progression, as it only appears at symptomatic stages, in parallel with motor 
neuron loss and ChAT decrease in the spinal cord. The effect  on forebrain cholinergic 
neurons is somehow specific, as it is not accompanied by any change in the activity of an 
unrelated neurotransmitter system such as the GABAergic one, which is also unchanged 
in  the  affected  segments  of  the  spinal  cord.  The  immunohistochemical  observations 
establish  a  clear  correlation  between  the  decreased  ChAT  activity  in  cortical  and 
hippocampal areas and the decrease in the number of basal forebrain neurons that provide 
most of the cholinergic innervations to these structures. Anterior cholinergic neurons of 
the medial septum-diagonal band, that mainly project to the hippocampus and olfactory 
areas  (Mesulam  et  al.,  1983;  Woolf,  1991)  are  drastically  decreased  in  number  at 
symptomatic stages of the disease. More posterior and lateral basal forebrain cholinergic 
neurons  of  the  nucleus  basalis  magnocellularis-substantia  innominate,  that  are  mainly 
responsible  for  the  cholinergic  innervation  to  neocortical  areas  (Mesulam  et  al.,  1983; 
Woolf, 1991) appear also reduced in number. While the loss of cholinergic neurons was 
not directly measured by counting them, the decreased ChAT activity in their terminal 
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fields of  innervations,  the cortices and hippocampus, constitutes a reliable quantitative 
evaluation of  the alterations  of  this  system with the progression of  the disease.  Other 
cholinergic  systems,  for  instance,  the  one  constituted  by  striatal  interneurons,  were 
unaffected  in  symptomatic  G93A mice  both  concerning  the  biochemical  evaluation  of 
ChATactivity  and  the  number  and  distribution  of  ChAT-immunoreactive  neurons.  A 
previous study (Azzouz et al., 1999) reported an increased mRNA ChATexpression in the 
striatum of 130-day-old G93A mice, suggesting to the authors that it could reflect some 
form of compensation for the death of spinal motor neurons. The present observations do 
not support this conclusion, as they demonstrate the invariance of the striatal cholinergic 
system at symptomatic stages of G93A mice. There are severeal reports demonstrating that 
ALS patients develop with the progression of the disease cognitive deficits and forms of 
dementia (Kew et al., 1993; Kato et al., 1994; Massman et al., 1996; Hanagasi et al., 2002). It 
could be of interest to investigate whether in human patients these cognitive dysfunctions 
are  accompanied  by  a  decreased  activity  of  the  forebrain  cholinergic  system,  whose 
alterations have been often found to be involved in cognitive deficits.  The presence, at 
symptomatic stages of the disease, of a sizeable deficit in basal forebrain system providing 
cholinergic  innervations  to  cortical  and  hippocampal  areas,  indicates  that  this  system 
undergoes regressive changes in the mouse model of ALS and suggests that the same may 
also happen in the human disease. Post mortem studies in brain areas of ALS patients are 
needed in order to verify whether this is actually the case. 
In the present study, an attempt was made to counteract the cholinergic deficits observed 
in symptomatic G93A mice through gestational supplementation of choline and/or long-
term administration of ALCAR. Fetal supplementation of choline through maternal diet in 
the rat has been shown to favorably affect the development of the forebrain cholinergic 
system, possibly by increasing the level of NGF in the target regions of these neurons and 
to improve learning and memory (Meck et al., 1989; Williams et al., 1998; Sandstrom et al., 
2002;  Meck et  al.,  2003).  ALCAR, a putative cholinergic  substance,  has been shown to 
improve memory performance in the rat after lesions and in aging condition (Piovesan et 
al.,  1994;  Taglialatela  et  al.,  1994).  In  the  present  study,  neither  gestational  choline 
supplementation,  nor  chronic  adult  ALCAR  supplementation,  nor  both  treatments 
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combined together, were able to significantly improve survival of G93A mice. However, 
gestational choline supplementation significantly increased the basal level of cholinergic 
activity in several brain and spinal cord areas, an observation that is made here for the first 
time in mice. The fact that this relevant increase of the basal cholinergic activity had no 
significant beneficial consequences on its disease-related late impairment or on survival of 
G93A  mice,  may  be  interpreted  as  an  evidence  that  the  cholinergic  deficit  is  not  the 
primary factor in the development of the disease.
However,  the  fact  that  the  expression  of  the  mutated  SOD1  specifically  results  in 
regressive  alterations  of  motor  neurons  and  of  the  cholinergic  neurons  of  the  basal 
forebrain, that have in common the relatively large size and the high content of ChAT 
protein, may not be merely circumstantial. The decrease of ChAT catalytic activity in the 
cervical and lumbar segments of the spinal cord of affected mice, that is measured here for 
the first  time in  the present  animal  model,  should theoretically  match the decrease  of 
motor neuron number previously reported at equivalent stages of the disease in the same 
animals. Based on cell count in Nissl stained sections of the lumbar spinal cord in G93A 
mice at late symptomatic stages (more than 120 days of age), a total estimate of around 
50% decrease in motor neuron number has been reported, with large (>25 mm in cell soma 
size) neurons appearing decreased by more than 90% in number (Klivenyi et al.,  1999; 
Guegan and Przedborski, 2003). At slightly earlier symptomatic stages (110–115 days of 
age), the estimate was around 40% decrease in cervical and 40–45% in lumbar spinal cord 
(Beers et al.,  2001; Li et al.,  2003). Similar estimates derive from studies on G93A mice 
exhibiting a slower disease progression, due to a reduced number of copies of the mutated 
gene,  by comparing stages of  the disease equivalent in terms of  symptomatic  features 
(Joosten et al., 2001; Sun et al., 2002; Copray et al., 2003). In evaluating the decrease of 
ChAT  catalytic  activity  in  the  spinal  cord  of  the  affected  mice,  one  should  take  into 
account the fact that the biochemical assay collectively measures the catalytic activity of 
motor neurons as well as of cholinergic interneurons of the spinal cord, that have not been 
reported to be affected by the disease. Furthermore, enzyme expression and activity may 
be  differently  regulated  in  healthy,  atrophic  and  damaged  neurons.  Data  from  post 
mortem  tissue  from  ALS  patients  suggest  that  some  of  the  affected  motor  neurons, 
86
CHAPTER 4: DISCUSSION
exhibiting  a  definite  atrophic  state,  may  still  increase  the  efficiency  of  acetylcholine 
synthesis through enhanced ChAT activity (Kato, 1989). This may contribute to the fact 
that loss of ChAT activity does not
result  so sharp when assayed in post mortem patient  spinal cord (Berger  et  al.,  1992). 
Recent  data  suggest  that  motoneurons  of  symptomatic  mice  modify  the  expression  of 
proteins  that  may  in  turn  affect  directly  or  indirectly  the  overall  cholinergic  activity 
(Copray et al., 2003). In the brain stem, the moderate decrease of ChAT activity measured 
in the present study likely reflects the fact that motor neurons of different nuclei are not 
equally affected in the disease and that anyway these cholinergic nuclei only represent a 
small fraction of the total brain stem volume (Reiner et al., 1995; Nimchinsky et al., 2000; 
Haenggeli and Kato, 2002). 
Death  of  motoneurons  in  the  spinal  cord of  ALS  patients  or  mouse  models  has  been 
considered to be essentially apoptotic and to belong to a typical programmed cell death 
mechanism by several authors, mainly on the basis of the signaling pathways found to be 
altered in the disease (Mu et al., 1996; Friedlander et al., 1997; Martin, 1999; Li et al., 2000; 
Pasinelli et al., 2000). However, studies on the morphological changes or in situ labeling 
with  methods  to  detect  DNA  fragmentation  have  not  been  conclusive  (Guegan  and 
Przedborski,  2003).  In  human  ALS,  as  well  as  in  mouse  models  of  the  disease,  some 
authors have reported evidence for nucleosomal DNA fragmentation in the spinal cord 
(Yoshiyama et al., 1994; Martin, 1999), while others have not (Migheli et al., 1994, 1999; He 
and Strong, 2000). The relatively long time course of the disease in human patients and in 
transgenic mice with low number of copies of the mutated SOD1 may render difficult to 
have a substantial number of apoptotic neurons in any single sample of the spinal cord 
(Guegan and Przedborski, 2003). In this respect, instead, mice with rapid progression of 
the disease may offer a more favorable model as the occurrence of some TUNEL-positive 
neurons can be demonstrated in the spinal cord of G93A mice at symptomatic stages of the 
disease (Kang et al., 2003).
Taking  advantage  of  a  sensitive  Elisa  method  to  detect  fragmented  DNA  in  brain 
homogenates,  that  had been previously demonstrated to be reliable  for  developmental 
programmed neuronal elimination as well  as for age-related neuronal loss (White and 
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Barone, 2001; Monti and Contestabile, 2003), the results here show that a sizeable amount 
of DNA fragmentation can be detected in samples of mutated transgenic mice spinal cord 
at  a  stage  characterized  by  substantial  motor  neuron  loss  and  ChAT  decrease.  This 
experimental evidence supports the notion that motor neuron death in ALS models is, to a 
significant extent, a programmed cell death of apoptotic type.
Reactive astrogliosis in ALS patients has been described in the spinal cord and the cortex 
from post mortem samples (Nagy et al.,  1994; Schiffer et al., 1996). In SOD1 transgenic 
mice, astrogliosis and microglial activation in the spinal cord of affected animals closely 
parallels the progressive motor neuron degeneration and is associated with up-regulation 
of neuroinflammatory markers (Levine et al., 1999; Xie et al., 2004). Being considered a 
marker of the metabolic state of astrocytes, glutamine synthetase is theoretically expected 
to be increased in cases of astrogliosis consequent to neuronal degeneration (Virgili et al., 
1992).The previous results  confirm,  instead,  that  the  absence  of  increased activity  and 
expression of the enzyme, previously reported for the lower spinal cord of G93A mice 
(Fray et al., 2001), is also a feature of the cervical spinal cord as well as of the brain stem 
and other brain regions. The apparent dissociation between gliosis and metabolic activity 
of astrocytes, may be related to the complex interplay between neurons and astrocytes in 
glutamate neurotransmitter function. Data on glial glutamate transporters in G93A mice 
are  controversial,  decrease  or  invariance  having  been  described  in  different  studies 
(Canton  et  al.,  1998;  Trotti  et  al.,  1999;  Sasaki  et  al.,  2001).  Recent  studies  have 
demonstrated multiple alterations of reactive astrocytes in the spinal cord of ALS patients, 
such as increased expression of metabotropic glutamate receptors and of neuronal nitric 
oxide synthase, that may theoretically aggravate glutamate excitotoxicity (Aronica et al., 
2001; Catania et al., 2001). Under these circumstances, the fact that glutamine synthetase is 
not increased in its activity may be favorable by not increasing the amount of glutamine, a 
quickly convertible precursor of the neurotransmitter pool of glutamate (Fonnum, 1985).
In conclusion, the present report provides new information on disease-related regressive 
changes of the forebrain cholinergic system in G93A mice, whose possible existence and 
extent is worth of being investigated in ALS patients too.
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Differential neuroprotection by creatine supplementation
The dose of creatine supplementation used for present experiments was the same recently 
adopted for studies of neuroprotection in rats and mice, including G93A mice (Dedeoglu 
et al., 2003; Klivenyi et al., 1999; Matthews et al., 1998, 1999). Creatine is transported to 
body  organs,  including  the  brain,  where  it  is  assumed  by  cells  through  an  active 
membrane  transport  system  (Ipsiroglu  et  al.,  2001).  Long-term  (4–8  week)  oral 
administration of creatine, resulting in average intake similar to the one produced by the 
diet  used  in  this  study,  increased  by  15–30%  total  creatine  and  phosphocreatine 
concentration in brain of rats and mice (Ipsiroglu et al., 2001). Rats fed with normal or with 
creatine-enriched diet did not show any significant difference in daily food intake and 
body weight increase. Unilateral intrastriatal injection of ibotenic acid in rats resulted in 
large  depletion  of  markers  for  cholinergic  and  GABAergic  striatal  neurons  (Fig.  7), 
reflecting the widespread excitotoxic death of these neurons, as previously shown (Ciani 
et  al.,  2001).  Long-term  feeding  with  creatine-enriched  diet  was  remarkably 
neuroprotective towards the excitotoxic lesion. In the IBO-injected striatum, the marker for 
cholinergic neurons, ChAT, was decreased by 63% as compared to the contralateral side in 
normally fed rats, while the decrease was only 32% in rats fed with creatine-enriched diet 
(Fig. 7A). Similarly, the marker for GABAergic neurons, GAD, was decreased by 68% in 
the  IBO-injected striatum of  normally  fed rats,  while  it  was  significantly  less  reduced 
(49%)  in  rats  fed  with  creatine  enriched  diet  (Fig.  7B).  Interestingly,  while  creatine 
supplementation did not affect, per se, the striatal ChAT level, the GABAergic marker was 
significantly  increased  (+35%)  in  the  saline-injected  striatum of  rats  fed  with  creatine-
enriched diet (Fig. 7B). The levels of enzymatic activities measured in saline injected striata 
were not different from those present in sham-operated animals assayed in parallel (Figs. 
7A,  B).  In  a  different  model  of  excitotoxicity,  IBO  injection  in  the  nucleus  basalis 
magnocellularis  (NBM)  with  degeneration  of  cholinergic  basal  forebrain  neurons  and 
consequent  decrease  of  cholinergic  innervation  to  the  cortex  (Casamenti  et  al.,  1998; 
Contestabile et al., 2004), dietary creatine supplementation was not neuroprotective, as in 
both  groups  of  rats  a  similar  decrease  of  ChAT  activity  in  the  ipsilateral  cortex  was 
recorded (Fig. 8).
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In G93A SOD1 mutant mice, the progression of the ALSlike disease can be monitored by 
the decrease of the cholinergic marker, ChAT, not only in the affected regions of the spinal 
cord  where  cholinergic  motor  neurons  degenerate,  but  also  in  some  forebrain  areas 
receiving cholinergic innervation from basal forebrain cholinergic neurons (Crochemore et 
al.,  2005).  Creatine supplementation results in increased survival of G93A mice and in 
delay of some disease-related symptoms (Klivenyi et al., 1999; Zhang et al., 2003) and it 
may,  therefore,  favorably  affect  the  loss  of  the  cholinergic  marker.  In  the  present 
experiment, 2% creatine supplementation starting at the age of 40 days resulted in a small, 
but significant, increase in the survival of transgenic mice (mean lifespan of normally fed 
G93A mice: 132.4 ± 2.6 days; mean lifespan of creatine-supplemented G93A mice: 142 ± 3 
days;  n = 7,  P < 0.05, Student’s  t  test). Some G93A mice were sacrificed at the age of 110 
days, together with age-matched wild type littermates, as at this stage of progression the 
disease is already characterized by significant decrease of ChAT activity in the spinal cord, 
as well as in some forebrain areas (Crochemore et al., 2005). The levels of ChAT activity in 
wild type mice were not changed by the different dietary regimen in any of the regions 
examined and, accordingly, data from these animals were pooled together. In the lumbar 
spinal cord, ChAT activity was similarly decreased in G93A mice, either fed with normal 
or creatine-supplemented diet, compared to wild type animals (Fig. 9A). In the olfactory 
cortex and the hippocampus of  the same mice,  instead,  the decrease in ChAT activity 
present in G93A mice at 110 days of age was completely counteracted by the long-term 
dietary supplementation with creatine (Figs. 9B, C). Interestingly, also in mice, creatine 
supplementation increased GAD activity in the striatum, but not in the hippocampus of 
both wild type and transgenic mice (Fig. 10).
With  the  present  report,  we  demonstrate  differential  response  to  dietary  creatine 
supplementation in different types of  acute excitotoxic  insults  as  well  as  in an animal 
model  of  a  human degenerative  disease.  In  our  model  of  excitotoxicity  involving  the 
degeneration of intrinsic striatal neurons, the neuroprotective effect of long-term creatine 
supplementation was similar to the one determined by different methods in similar types 
on neurodegenerative insults involving the striatum (Malcon et al., 2000; Mattews et al., 
1998;  Zhu  et  al.,  2004).  The  experimental  approach  allowed  to  evaluate  the  relative 
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damage, and the degree of protection granted by creatine, regarding different neuronal 
population of the striatal complex. The present data suggest that one of the ways through 
which creatine is beneficial  towards excitotoxic lesions,  at least regarding the striatum, 
may be related to increased inhibitory activity at synaptic  connections in the neuronal 
circuits  involved  in  the  excitotoxic  mechanism.  Theoretically,  indeed,  this  may be  the 
consequence  of  the  increased  activity  of  the  GABA  synthetic  enzyme,  GAD,  in  the 
striatum, which we have observed both in rats and mice. The  data on increased GAD 
activity  in  the  striatum  of  creatine-supplemented  rats  may  suggest  that  creatine 
supplementation has  a  role  in  favoring  recovery of  GABAergic  neurons surviving the 
lesion rather than an actual neuroprotective role. This would not explain, however, the 
similarity  of  the  results  concerning  striatal  cholinergic  neurons,  whose  neurochemical 
marker, ChAT, displays the same degree of protection of GAD, without undergoing any 
diet-related upregulation. Hypotheses regarding the mechanisms of neuroprotection from 
dietary creatine supplementation have been, so far, mainly focused on enhanced energy 
stores granted by increased phosphocreatine availability for ATP synthesis, stabilization of 
creatine  kinase,  protection  of  mitochondrial  integrity  and  direct  antioxidant  activity 
(Klivenyi et al., 1999; Lawler et al., 2002; Matthews et al., 1998; O' Gorman et al., 1997; 
Wendt et al., 2002; Wyss et al., 2000; Zhang et al., 2003; Zhu et al., 2004). These hypotheses 
are  in  agreement  with  the  well  established  role  of  energy  deficit/mitochondrial 
impairment  in  excitotoxic  neurodegeneration  (Beal  et  al.,  1993;  Bordelon  et  al.,  1997; 
Greene et al., 1993; Stout et al., 1998; Tsuji et al., 1994) (see however the negative evidence 
concerning creatine kinase in a knockout mouse model) (Klivenyi et al.,  2004), and the 
mechanisms listed above likely contribute to the neuroprotective effect of creatine. It is, 
however, difficult to explain, on the sole basis of these hypotheses, why different types of 
excitotoxic insults are ameliorated or not by creatine administration and why different 
neuronal populations respond or not to the dietary supplementation. An example of the 
first case is given by a previous report demonstrating a protective effect of creatine against 
excitotoxic lesions caused by intrastriatal infusion of NMDA, but not against kainic acid or 
AMPA, notwithstanding the similarity in the striatal lesion size (Malcon et al., 2000). The 
present results give an example of the second case, as we demonstrate here that long-term 
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creatine  supplementation  protects  striatal,  but  not  basal  forebrain,  neurons  against 
ibotenic acid excitotoxicity. These intriguing results  suggest that, in addition to a general 
role of metabolic type, creatine supplementation may have differential effects related to 
the nature, the brain topography and the connectivity of different neuron types. In this 
respect, a possible effect on GABAergic system, which is suggested by our data on GAD 
activity increase in the striatum of creatine-supplemented rats, may be relevant in order to 
investigate at the neurochemical level these possible differences. Interestingly, indeed, a 
similar increase of GAD activity was not detected in the cortex of creatine-supplemented 
rats (data not shown). A specific effect of long-term creatine supplementation on GAD 
activity,  apparently  restricted  to  the  striatum,  also  emerged from measurement  of  the 
enzymatic  activity  in  transgenic  and  wild  type  mice.  Researches  are  presently  being 
carried  on,  to  see  whether  increased  potency  of  GABA  synthesis  actually  results  in 
increased  GABA  availability  at  synaptic  sites  and  whether  similar  alterations  can  be 
detected in other brain regions. Long-term creatine administration has been demonstrated 
to delay disease symptoms and to prolong mean lifespan in the G93A mouse model of 
ALS (Klivenyi et al., 1999; Zhang et al., 2003). Concerning survival,  the results confirm 
here a small, but significant, beneficial effect of dietary creatine supplementation. A new 
observation regards a primary neurochemical marker of the disease, i.e. the decrease of 
ChAT activity related to degeneration of the cholinergic motor neurons in the spinal cord, 
as well as an accessory neurochemical marker recently discovered by us (Crochemore et 
al.,  2005), i.e.  the decrease of ChAT activity in forebrain regions that are targets of the 
cholinergic neurons of the basal forebrain. As it has recently been demonstrated that both 
these markers are significantly affected at an intermediate stage of the disease (110 days of 
age),  this  stage  was  used  to  characterize  protective  effects  of  the  creatine  creatine 
supplemented diet. By using the neurochemical parameter to evaluate the effect of choline 
supplementation, no significant alteration in the cholinergic decrement associated with the 
disease was demonstrated in the lumbar segment of the spinal cord, while the decrease of 
cholinergic activity found in the two forebrain regions examined was completely reverted 
by the dietary supplementation. Previous reports have correlated the increased survival 
granted by creatine, which may vary in its extent likely depending on subtle differences 
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among different founders of litters from the same strain ((Klivenyi et al., 1999; Zhang et 
al.,  2003)  (and  present  results),  with  protection  and  delaying  of  motor  neuron  death 
(Klivenyi et al., 1999). This was, however, demonstrated at 120 days of age in a group of 
transgenic mice whose normal lifespan reached 143 days instead of the 126 – 132 days 
documented by others, (Crochemore et al., 2005; Facchinetti et al., 1999; Zhang et al., 2003) 
(and including present results).  It may be that a more rapid progression of the disease 
renders  more  difficult  to  put  in  evidence  stages  of  partial  protection  concerning  the 
primary targets of the neurodegenerative process, i.e. the spinal cord motoneurons and 
their distinctive neurochemical marker. Alternatively, this difference could be explained 
by  the  different  way  adopted  to  monitor  spinal  motor  neuron  death,  i.e.  direct  cell 
counting vs. quantitative evaluation of the decrease of a specific neurochemical marker, as 
previous observation suggested that the matching between these two procedures is not 
absolute (Crochemore et al., 2005). The complete reversion of the cholinergic impairment 
detected in forebrain areas of G93A mice at 110 days of age (Crochemore et al., 2005), on 
the other hand, demonstrates that other neurochemical correlates of the disease can be 
ameliorated by creatine supplementation, in parallel with the prolonged lifespan. Even if 
present data do not allow us to postulate a causal relationship among the two events, it is 
of  interest the fact that also in G93A mouse model a neurochemical  parameter,  whose 
alterations characterize symptomatic stages of the disease (Crochemore et al., 2005), is kept 
at its normal levels by long-term dietary creatine supplementation. 
Taken  together,  the  present  data  emphasize  the  usefulness  of  studying  alterations  of 
neurochemical  parameters  marking  specific  neuronal  populations,  in  evaluating 
neuroprotective effects of long-term creatine supplementation in animal models of acute 
and chronic neurodegenerative diseases.
ODC/polyamine system alterations in ALS-G93A mice
Novel data about ODC/polyamine systemchanges in the spinal cord and brain regions 
from transgenic SOD1 G93A mice, an animal model for ALS are reported in this work. It 
clearly appears that there is a remarkable up-regulation of ODC enzymatic activity, only 
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occurring at a late symptomatic stage of the motor syndrome in the affected regions of the 
spinal cord and the brainstem. The increase of ODC activity is  paralleled by a similar 
increase in levels of putrescine, the immediate product of the ODC enzymatic reaction. 
While  one could expect  to  find also  increased levels  of  spermidine and spermine,  the 
higher order direct derivatives of putrescine, the present data demonstrate that this is not 
the case except for a small increase of spermidine levels in the affected spinal cord tracts, 
that  only  reaches  statistical  significance  in  the  cervical  spinal  cord.  As  previously 
described  in  rats  and  humans  (Virgili  et  al.,  2001;  Ekegren  et  al.,  2004),  the 
spermidine/spermine ratio in mice is regionally very different, being higher in the spinal 
cord and brain stem and lower in cortex and cerebellum. The fact that these ratios are 
maintained  at  both  pre-symptomatic  and  symptomatic  stages  do  not  support  the 
occurrence  of  generalized,  pathology-linked,  biochemical  alterations.  Rather,  it  is 
confirmed the major susceptibility of the ODC-putrescine step to become upregulated in 
response  to  acute  and chronic  stressful  conditions,  as  it  has  been reported  in  various 
rodent models of neurodegeneration and by our group in aged rats (Paschen, 1992; Virgili 
et al., 2001; Babu et al., 2003). However, the dysregulation of the ODC/polyamine system 
reported  here  is  not  in  agreement  with  the  result  of  a  recent  post-mortem  study  on 
patients  deceased  by  ALS  (Ekegren  et  al.,  2004).  These  authors,  indeed,  reported  no 
significant changes in polyamine levels in spinal cord tissue autopsied from ALS patients. 
These discrepancies between data from the animal model and from human post-mortem 
analysis are a critical point that deserves to be better investigated. In particular, it should 
be verified whether the conflicting results are due to different methodological procedures 
about tissue manipulation and analytical measurements or whether they reflect specific 
differences between the human disease and the animal model. The fact that only ODC up-
regulation  and  increase  of  putrescine  level  at  symptomatic  stages  of  the  disease 
progression were found and the fact  that  these  alterations  were only  restricted  to  the 
regions where motor neuron degeneration primarily occurs, can encourage to think that 
what  was  observed  is  a  specific  correlate  of  the  neurodegenerative  process.  In  this 
experimental model, the lack of increase in spermidine and spermine as a consequence of 
putrescine  accumulation  could  reflect  a  reduced  activity  of  S-adenosylmethionine 
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decarboxylase  (SAMDC),  the  other  important  rate  limiting  enzyme  in  polyamine 
biosynthesis.  A reduced SAMDC activity,  in parallel  with increased ODC activity and 
putrescine levels but in the absence of any change in spermidine and spermine levels, has 
been found after various conditions of severe neuronal stress (Paschen, 1992). However, 
these findings cannot be generalized because a marked increase of SAMDC activity has 
been reported by others in post-mortem studies of aged human brain or in brain tissue 
from patients affected by Alzheimer’s disease (Morrison et al., 1993a,b). As an alternative, 
or additional explanation for putrescine accumulation in the absence of spermidine and 
spermine  increase,  the  role  of  spermidine/spermine-N-acetyltransferase  (SSAT)  in 
polyamine homeostasis can be considered. This enzyme, known to be stimulated during 
aging and by various noxious stimuli (Baudry and Najm, 1994; Ferioli et al., 1996; Rao et 
al., 2000), is responsible for the acetylation of polyamines. Acetylated polyamines are in 
turn a substrate for polyamine oxidases (PAO), responsible for  polyamine degradation 
and for the inter-conversion of spermidine and spermine back to putrescine (Thomas and 
Thomas, 2001). Indeed, recently generated transgenic mice overexpressing SSAT showed a 
marked accumulation of putrescine in many brain areas (Pietila et al., 1997). In the absence 
of an apparent increase of the two physiologically more relevant polyamines, spermidine 
and spermine, it is interesting to address the possible role of putrescine accumulation in 
neurodegenerative  processes,  such  as  those  accompanying  ALS  and  other  motor 
disorders.  That  ODC  induction  and  putrescine  levels  elevation  could  be  involved  in 
neuron  damage  seems  to  be  suggested  by  the  close  correlation  between  putrescine 
production and neuronal injury. Moreover, it has been reported some evidence supporting 
a putative protective effect of difluoro-methylornithine (DFMO), a specific ODC inhibitor, 
in various in vivo and in vitro models of neurodegeneration (Trout et al., 1993; Babu et al., 
2003).  On  this  basis,  the  present  data  add  evidence  to  the  tight  correlation  between 
ODC/putrescine  system  induction  and neuropathology  because  a  dramatic  increase  of 
ODC activity  and  putrescine  level  was  measured  in  the  spinal  cord,  the  region  most 
affected by motor neuron degeneration, of diseased mice and a lower to not significant 
effect moving to higher CNS regions, from brain stem to cerebellum and cortex. 
A  critical  question  regarding  the  putative  involvement  of  polyamines  in 
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neurodegeneration  is  whether  changes  in  their  levels,  due  to  change  in  enzymatic 
biosynthetic activities or in other processes of their homeostatic regulation, are causative 
agents of the neurodegenerative process as originally proposed (Paschen, 1992). Recent 
results  from  ODC  or  SSAT  transgenic  mice,  rather  support  the  view  that  polyamine 
enhanced catabolism and putrescine accumulation may be neuroprotective responses to 
injury (Kauppinen and Alhonen, 1995; Kaasinen et al.,  2000).   The present data cannot 
clarify this issue but it can be of some interest the fact that alterations in ODC enzymatic 
activity and in polyamine levels are quite absent in a pre-symptomatic stage (55 days of 
age) of the G93A mice disease. By contrast, these alterations are highly detectable at an 
advanced pathological stage (125 days of age),  when a large proportion of spinal cord 
motor  neurons  have  died  (Chiu  et  al.,  1995;  Morrison  B.M.  et  al.,  1998).  To  further 
understand  the  cellular  basis  of  the  ODC/polyamine  system  response,  it  could  be 
interesting to address in future studies the issue of the involved cell types, as astroglial 
and  microglial  activation  and  proliferation  parallel  neuronal  degeneration  during  the 
disease progression. When activated, both these cell populations are thought to be able to 
exert beneficial or deleterious effects on stressed neurons by releasing a variety of trophic 
or  cytotoxic  substances  (McGeer  and  McGeer,  1995;  van  Rossum  and  Hanisch,  2004). 
Astrogliosis  and  microgliosis  are  reactive  responses,  often  associated  with 
neuroinflammatory  states,  observed  in  acute  insults  and  neurodegenerative  diseases 
(McGeer and McGeer, 1995; Eikelenboom et al., 2002). Under these conditions, it has been 
reported that ODC can be expressed in brain and retinal astrocytes (Bernstein and Muller, 
1999; Biedermann et al., 1998) and increased ODC mRNA has been measured in microglial 
cells submitted to the activatory action of endotoxins (Soulet and Rivest, 2003). Concerning 
the  G93A  mutant  ALS  mice  model,  astrogliosis  was  found  to  be  maximal  at  early 
symptomatic stages of the disease progression while it was not further increased at more 
advanced symptomatic  phases (Hall  et  al.,  1998;  Crochemore et  al.,  2005).  By contrast, 
microglial cells have been shown significantly increased also at advanced symptomatic 
stages of the disease in G93A mice and in ALS patients (Hall et al., 1998; Turner et al., 
2004). It seems then reasonable to hypothesize, in view of future studies, a possible role of 
polyamines in contrasting or sustaining neurodegeneration mediated through a regulation 
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of glial cell populations.
Proteomics of insoluble protein complexes
As described before, numerous reports have shown that protein aggregation is a hallmark 
of  several  neurodegenerative  diseases  such as Alzheimer's  disease  (Kosik  et  al.,  1984), 
Huntington's disease (Di Figlia et al.,  1997), Kennedy's disease (Merry et al.,  1998) and 
amyotrophic lateral sclerosis as well (Watanabe et al., 2001). The present project is based 
on a modified insoluble protein (P3) fraction extraction protocol from Wang et. al. (2002) 
in order to make it compatible with 2D electrophoresis. Our P3 fractions showed strong 
SOD1 immunoreactivity, just as Wang's P3 fractions (Fig. 15A-F). We hypothesized  that 
this strong SOD1 immunoreactivity, showing also high molecular weight bands (or spots 
in the case of 2D electrophoresis) was due to SOD1 mediated protein aggregates. We also 
hypothesized that by studying this insoluble fraction through 2D gel electrophoresis we 
would  be  able  to  identify  which  proteins  could  aggregate  with  SOD1.  We  could  not 
exclude however, that this insoluble fraction is also composed of proteins that normally 
aggregate even without mutant SOD1 being present.  Basso et al. (2006) have shown in a 
Triton insoluble fraction isolated from G93A mutant animal spinal cords, separated  by 2D 
electrophoresis, that part  of the SOD1 immunoreactive spots are actually  mono and oligo-
ubiquitinated SOD1. We aimed at identifying more proteins by comparing the insoluble 
fractions extracted from G93A mutant animals, wild-type and non-transgenic animals and 
we hypothesized that the observed differences in G93A animals when compared to the 
two  controls  could  be  causally  linked  to  the  presence  of  mutant  SOD1.  The  present 
proteomic  data  show that  SOD1 immunoreactive  bands  with  a  low-to-high  molecular 
weight range are present in insoluble fractions (P3) from symptomatic animals but not 
from asymptomatic animals. No high molecular bands could be detected in the spinal cord 
extract  (whole  homogenate)  either.   A  possible  explanation  for  the  absence  of  high 
molecular SOD1 immunoreactive bands in 6 week-old G93A animals could be that SOD1 
mediated aggregates have yet not started to form or they are present to a minimal amount 
that  cannot  be  detected by western  blotting  ECL whose  sensitivity  limit  is  around 10 
97
CHAPTER 4: DISCUSSION
picograms of protein (ref).  2D gel analysis shows that there are protein level differences in 
the insoluble protein fraction (P3) between mutant transgenic mice and controls even at an 
early presymptomatic  stage of the disease (6 weeks).  Interestingly,  more proteins were 
detected as statistically significant changed at 6 weeks of age that at 11 weeks of age.  
Because  SOD1  immunoreactivity  is  much  stronger  in  P3  fractions  extracted  from 
symptomatic animals and assuming that SOD1 aggregates sequester or bind tightly other 
proteins  we  expected  to  observe  more  protein  changes  in  11-week  old  animals.  An 
explanation could be that other types of protein aggregates that form in mutant G93A 
expressing  mice  are  not  directly  mediated  by  mutant  SOD1  but  already  form  in 
asymptomatic  mice (6  weeks).  It  could  also  be  possible  that  after  the presymptomatic 
stage, there is some kind of compensatory effect that changes the proteome composition of 
the  insoluble  protein  fraction  mainly  in  mice  that  express  mutant  hSOD1.  A  third 
explanation could be that SOD1 mediated protein aggregates are very resistant even to 
urea lysis and therefore a small fraction of the sequestered proteins are released during 
urea  solubilization..  In  fact,  even  after  urea  solubilization,  high  molecular  SOD1 
immunoreactive bands are still observed in P3 fractions from symptomatic animals (Fig. 
15A-F).  Some  of  these  higher  molecular  bands  can  be  explained  as  mono  and 
oligoubiquitinated  SOD1  (Basso  et  al.  2006),  but  the  presence  of   75kDa  and  higher 
molecular bands is more difficult to be explained. 
By  using  non-transgenic  and  wild-type  transgenic  animals  as  controls,  we   aimed  at 
identifying  insoluble  fraction  components  that  were  present  only  because  of 
overexpression  of  mutant  hSOD1,  ruling  out  the  effects  of  the  sole  overexpression  of 
hSOD1. 
39 protein spots were identified as statistically significant differences: 29 protein spots at 6 
weeks and 10 protein spots at 11 weeks. However only 16 protein spots were sequenced: 
11 protein spots at 6 weeks and 5 protein spots at 11 weeks. 23 protein spots could not be 
sequenced because of  limitation of MALDI-ToF's sensitivity.
The  unsequenced  spots  appeared  very  faint  on  the  analytical  gels  and  could  not  be 
sequenced from the preparative gels. Four-hundred micrograms of protein were loaded 
for every preparative gel but probably for these spots, a greater protein load was needed 
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or even pooling from several preparative gels could have aided protein spot identification. 
It is important to remember that from one spinal cord, aproximately fifty micrograms of 
insoluble protein fraction were isolated,  thus for  a preparative gel  an average of eight 
animals  were  needed.  This  was  an  important  factor,  because  the  number  of  available 
animals was limited.
ON changes actually refer to proteins that could only be detected in G93A animals, not 
meaning that they are not present in the insoluble fractions from the other animals. It is 
likely that by  loading a greater amount of protein, the ON protein spots could have been 
detected in non-transgenic and wild-type transgenic animals. 
The reason a non-linear gradient  was used for  the first  dimension is  because proteins 
separate more evenly, especially within the pH 5-7 range. This is very useful for analysis 
and sequencing purposes. The price to pay for this enhanced separation is not being able 
to determine the exact pI of  protein spots.  pH 3-10 gradients  were used to be able to 
separate  as  many  as  possible  proteins  from  the  whole  insoluble  fraction.  By  using 
narrower pH ranges (pH 4-7, pH 5-6), specific fractions could be separated much better 
but all proteins outside these pH ranges would have been lost during isoelectrofocusing 
(IEF ). It is important to notice that by using a phH 3-10 gradient, there can be resolution 
limitations, as it was the case with the identified protein spot containing both QCX8H2 
and HSC70. These two proteins posses extremely similar molecular weight and isolectric 
points. 
VATA1,  VATB2,  QCX8H2,  HSC70,  VDAC2,  GBB1,  TBB4,  CRMP2  were  the  only 
successfully  sequenced  proteins  belonging  to  statistically  significant  changes,  besides 
GFAP.  As  described  before,  VATA1  and  VATB2  are  involved  in  vesicle  trafficking, 
QCX8H2 in energy metabolism, HSC70 in stress-response and protein folding, GBB1 in 
signal  transduction,  TBB4 in cytoskeleton architecture,  VDAC2 in ion transport  and in 
apoptosis  and  CRMP2  in  axonal  growth.  HSC70  has  previously  been  reported  to  be 
localized in some protein inclusions in sporadic ALS cases (Watanabe et al., 2001). Also, it 
is  interesting  to  notice  that  CRMP2  has  been  found  in  neurofibrillary  tangles  in 
Alzheimer's disease (Gu et al., 2000)
Therefore the identified proteins belong to very different functional roles. Except for TBB4, 
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CRMP2 and GFAP,  these proteins were found only as downfold changes, that is, they are 
less present in the insoluble fraction from mutant animals when compared to controls. 
Whether this reflects  technical  limitations of  the adopted procedure or an actual effect 
related to the presence of  mutant SOD1, cannot be resolved by our present observations. 
TBB4 being part of the cytoskeleton is a very abundant protein. GFAP is very abundant 
especially  in  advanced  disease  stages  because  of  astrocyte  activation  and  gliosis. 
Interestingly GFAP was identified especially in mutant animals as different protein spots 
with different molecular weight and isolelectric point, suggesting these are actually GFAP 
fragments. It could be possible that GFAP is therefore cleaved or degraded preferentially 
in mutant animals already during the early stages of the disease. CRMP2 seems to be 
ubiquitously expressed but has an important role in axonal outgrowth.  
The  23  unsequenced spots  could  cast  more  light  into  the  mechanisms  of  this  disease, 
especially at 6 weeks, when 11 proteins were detected as ON changes but could not be 
identified.  Overall,  considering  the  unsequenced  spots,  more  protein  spots  differences 
were found at 6 weeks, a situation quite surprising and suggesting that differential protein 
expression may result from the presence of the mutated SOD1 gene without being directly 
related  to  the  disease  itself.  Overexpression  of  wild-type  hSOD1  could  also  cause 
aggregate formation and this is why by using two different controls (non-transgenic and 
wild-type  transgenic  animals)  we  aimed  at  understanding  better  the  effect  of  mutant 
SOD1 overexpression on the insoluble fraction. 
The  present  proteomic  data  need  to  be  further  validated  by  western  blotting  and 
immunohistochemistry. Probing with a specific antibody for 1D and 2D western blottings 
can further help understand how these protein levels change in insoluble fractions. It can 
also be interesting to study protein distribution and expression in whole tissue (spinal 
cord) from animals at asymptomatic, symptomatic and end-stage animals.
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